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Integration of thrombin-binding aptamers in point-of-care devices for continuous 
monitoring of thrombin in plasma 
 
Abstract of the PhD Thesis 
Thrombin is the central enzyme in the process of hemostasis, being at the cross-roads of 
coagulation and platelet reactions. Normally, in vivo concentration of thrombin is rigorously regulated; 
however, clinically impaired or unregulated thrombin generation predisposes patients either to 
hemorrhagic or thromboembolic complications, the major causes of mortally in the US and Europe. 
Monitoring thrombin in real-time is therefore needed to enable rapid and accurate determination of drug 
administration strategy for patients under vital threat.  
Aptamers, short single-stranded oligonucleotide ligands, selected for their high affinity and 
specificity, represent promising candidates as biorecognition elements for new-generation biosensors. 
Several aptamers have been developed for thrombin sensing. These aptamers are known to bind distinct 
exosites of thrombin that gives an advantage of building different assays involving simultaneous targeting 
two different binding sites. The aim of this PhD work therefore is to investigate different solutions for the 
integration of thrombin-binding aptamers in point-of-care devices for continuous monitoring of thrombin 
in plasma.  
First the kinetics of aptamer interaction with thrombin and specificity towards prothrombin and 
thrombin – inhibitor complexes was rigorously investigated using Surface Plasmon Resonance. These 
experiments unveiled the complex character of interaction of the HD1 a 15-bp aptamer with thrombin, 
confirming nonspecific interactions with prothrombin, natural inhibitors of thrombin, serum albumin and 
some of other plasma proteins, whereas another 29-bp aptamer HD22 proved to be highly affine and 
specific towards thrombin. On the other hand we explored aptamer integration options. In order to find 
optimal surface functionalization conditions for aptamers sensing, different supports such as gold, 
polystyrene, polycarbonate and appropriate protocols were used. We found that the easiest and the most 
efficient functionalization strategy is grafting thiol-modified aptamers on the gold surface. Furthermore 
to achieve nanoscale control of functional aptamer density, we showed advantage of ordered 
immobilization of already DNA-capped nanoparticles and well-characterized on the desired solid support 
through convective assembly. Aptamer-modified Gold NP-s were also used to validate thrombin detection 
principle through hydrodynamic assay involving aggregation of NPs in the presence of the thrombin. With 
this assay, we validated the principle and at the same managed to detect different concentrations of 
thrombin (5-500 nM) with good precision, study the thermal stability of the aptamers and their complex 
with thrombin and specificity of aptamers towards thrombin in buffer. In diluted plasma, however 
aggregation of nanoparticles occurred even in the absence of thrombin, suggesting the presence of 
nonspecific interactions with aptamers that cannot be controlled or neglected in aggregation assay. 
We finally proposed a novel approach to increase sensitivity and specificity for thrombin 
detection based on the engineering of aptadimer structures bearing aptamers HD1and HD22 
interconnected with a nucleic acid spacer. This spacer forms a hairpin of 4 to 9 bp, and fluorophore and 
quencher couple is embedded within hairpin. In the absence of target, the fluorophore remains quenched, 
whereas upon capturing a target, fluorescent signal is triggered. Since this strategy requires simultaneous 
targeting of both binding-sites, it provides an efficient solution for improved thrombin detection, by 
increasing specificity, selectivity and affinity, and decreasing non-specific interactions. Preliminary tests 
gave promising results in specific detection for thrombin and opened new perspectives for development 
specific aptamer-based fluosensor both for the surface and the volume measurements.  
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L’étude de différentes solutions d’intégration des aptameres dans des dispositifs de 
diagnostic type « point of care » pour le suivi en continu de la thrombine dans le 
 plasma
 
Résumé 
La thrombine est l’enzyme principale dans le processus d’hémostase, étant impliquée dans la 
coagulation et les réactions plaquettaires. Les dérèglements de la concentration de thrombine en raison 
d’un trouble clinique prédisposent les patients à des complications hémorragiques ou 
thromboemboliques qui sont une cause de mortalité majeure en Europe et aux Etats-Unis. Le suivi en 
temps réel de la thrombine dans le sang est donc nécessaire pour améliorer le traitement de patients en 
état critique. 
Les aptamères, qui sont de courts nucléotides monobrins, sélectionnés pour leur grande affinité et 
spécificité vers des cibles déterminées, semblent constituer des candidats prometteurs pour la 
reconnaissance moléculaire dans des biocapteurs de nouvelle génération. Plusieurs aptamères ont été 
développés pour la détection de la thrombine. L’objectif de ces travaux est l’étude de différentes solutions 
d’intégration des aptamères dans des dispositifs de diagnostic de type «point of care» (au chevet du 
patient) pour le suivi en continu de la thrombine dans le plasma. 
Dans un premier temps, la cinétique d’interaction des aptamères avec la thrombine et leur 
spécificité vis-à-vis de la prothrombine et des inhibiteurs de la thrombine ont été étudiés rigoureusement 
par résonance par plasmons de surface (SPR). Ces travaux ont démontré la faible spécificité de l’aptamère 
HD1, qui un nucléotide de 15 bases, vis-à-vis de la thrombine, et  ont confirmé le présence d’interactions 
non-spécifiques avec la prothrombine, les inhibiteurs naturels de la thrombine, l’albumine de bœuf et 
d’autres protéines plasmatiques. Inversement, nous avons observé une bonne affinité de l’aptamère 
HD22 avec la même liste de cible. Parallèlement, nous avons évalué des stratégies d’intégration 
d’aptamères dans des dispositifs d’analyse. Nous montrons en particulier que la technique le plus simple 
et le plus efficace de fonctionnalisations de surface par des aptamères est fondée sur le couplage de 
fonctions thiol sur des surfaces d’or. Le principe de reconnaissance a ensuite été validé par des 
expériences d’agrégation en régime hydrodynamique. Celles-ci ont montré la possibilité de détecter la 
thrombine dans des gammes de concentration de 5 à 500nM. Toutefois, dans du plasma, l’agrégation des 
nanoparticules a été observée en absence de thrombine suggérant la présence d’interactions non 
spécifiques. 
Enfin, afin d’augmenter la spécificité de la détection de la thrombine, nous avons proposé une 
nouvelle approche basée sur l’ingénierie de structures dimères interconnectant HD1 et HD22. Le lien 
entre ces deux aptamères peut se replier suivant une structure en tête d’épingle, ce qui met à proximité 
un fluorophore et son absorbeur de fluorescence. En l’absence de cible, le fluorophore est éteint en raison 
de la proximité l’absorbeur, alors qu’après capture de la cible, le signal de fluorescence est augmenté. Des 
tests préliminaires ont donné des résultats encourageants pour la détection spécifique de la thrombine, 
même dans le plasma. 
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CHAPTER 1. GENERAL INTRODUCTION 
1.1 Hemostasis, thrombosis and bleeding – all pivots around thrombin 
Hemostasis is the body's normal physiological response for the prevention and stopping of 
bleeding at a site of injury. Congenital or clinically caused abnormalities in hemostasis may lead 
to thrombosis or to hemorrhage. Thrombosis in its various manifestations together with 
embolism, accounts for significant mortality and morbidity, as well as the cost of medical care. 
Many, if not most cases of thrombosis can be avoided and almost all recurrent episodes can be 
prevented by choosing appropriate antithrombotic therapy. But if a treatment is not tailored to 
the particular needs of patient it may lead to the blood loss. The successful and prompt medical 
decision-making for appropriate drug administration strategy requires defining 
etiology/predisposing factors and the close monitoring of hemostatic state of the patient. In this 
section we will discuss about disorders resulting from the abnormalities in the hemostasis, their 
risk factors, underlying mechanisms and the central role of thrombin, dictating normal or 
pathologic outcome.  
1.1.1 Hemostasis  
Normally, blood remains in the closed high-pressure circulatory system inside the blood 
vessels. When the blood vessel or tissue gets injured and starts bleeding, body’s instinctive 
physiological response is hemostasis - quick, localized and tightly regulated process of clotting for 
stopping loss of blood to maintain the integrity of circulatory system.  
In response to injury damaged blood vessel constricts (vascular spasm) so that blood flows 
out more slowly and outside the blood vessel an accumulating pool of blood (a hematoma) 
presses against the vessel, helping prevent further bleeding.  
Almost instantly, starts as well clot formation. Exposed collagen initiates series of 
reactions for platelet activation and accumulation at the site of injury, in process called primary 
hemostasis. Von Willebrand's factor, produced by the cells of the vessel wall, acting as glue holds 
platelets to seal the break in the disrupted endothelium. As platelets accumulate at the site, they 
change shape from round to spiny, form a mesh that plugs the injury and release proteins 
entrapping more platelets and clotting proteins in the plug that becomes a blood clot. 
At the same time exposure of the blood to tissue factor induces sequential activation of 
blood clotting (coagulation) factors, called secondary hemostasis or coagulation that culminates 
into generation of thrombin. Thrombin converts fibrinogen, a blood clotting factor that is 
normally dissolved in blood, into long strands of fibrin that radiate from the clumped platelets 
and form a net that entraps more platelets and blood cells. The fibrin strands add bulk to the 
developing clot and help hold it in place to keep the vessel wall plugged. 
Primary and secondary hemostasis are related events: activated platelets release some 
clotting factors, whereas some clotting factors – thrombin, fibrinogen, play a role in platelet plug 
formation; these events occur concomitantly, and under normal conditions, regulatory 
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mechanisms contain thrombus formation temporally and spatially (Marieb and Hoehn, 2012; 
Roderique and Wynands, 1967). 
Hemostasis is a dynamic process. The reactions that result in the formation of a blood clot 
are balanced by other reactions that slow down or stop the clotting process and dissolve the clot 
in a process called fibrinolysis when the injury site is healed.  
1.1.2 Blood coagulation 
The coagulation process is the important part of hemostasis, involving a complex set of 
stepwise protease reactions that transform circulating blood into a gel.  
Several coagulation cascade models have been proposed, including the intrinsic and 
extrinsic pathway models and the more recent cell-based and tissue factor-based models.  
1.1.2.1 The Intrinsic and extrinsic pathway model 
In the 1960s the process of blood coagulation was regarded as a cascade or waterfall 
model, where one activated protein leads to the activation of an additional “downstream” protein 
(Davie and Ratnoff, 1964; Macfarlane, 1964). The coagulation reactions were divided into two 
pathways so called intrinsic and extrinsic. Both pathways fuse in a common pathway to generate 
the enzyme thrombin, which subsequently converts fibrinogen into fibrin (Fig.1.1). 
The intrinsic pathway begins with contact activation, involving coagulation factors XII 
and XI (FXII and FXI respectively), prekallikrein (PK) and high molecular weight kininogen 
(HMWK). These four contact factors do not require the presence of the calcium for their reaction 
and are all readily absorbed onto negatively charged surfaces. After complex of HMWK, PK and 
FXII is formed, FXII and prekallikrein become activated to FXIIa and kallikrein. In the presence of 
cofactor HMWK FXIIa takes part in activation of FXI, which then activates FIX in the presence of 
calcium. The process continues with formation of FVIIIa/FIXa complex which activates FX.  
FIGURE 1.1 The extrinsic and intrinsic pathways in the cascade model of coagulation. These pathways are 
assayed clinically using the prothrombin time (PT) and activated partial thromboplastin time (aPTT), 
respectively. 
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The extrinsic pathway begins with trauma to tissue, causing exposure of tissue factor 
(TF) and activation of factor VII in the presence of calcium. The complex of TF/FVIIa then 
activates FX. Thus intrinsic and extrinsic pathways converge at activation of FX. FXa with FV will 
form prothrombinase complex that converts prothrombin into thrombin, which in its turn 
converts fibrinogen into fibrin to form a clot, and also, activated by thrombin, factor XIII 
stabilizes the fibrin.  
Though these cascade models were a major advance in the field of coagulation, they stem 
from in vitro testing and thus are unable to fully explain hemostasis in vivo. The intrinsic and 
extrinsic systems could not operate in vivo as independent and redundant pathways as the models 
implied. These two branches of cascade do not have equal importance. For example deficiencies 
in HMWK, PK and FXII do not cause bleeding disorders, indicating that they are not essential to 
hemostasis. However, activation of factor X by TF-FVIIa of the extrinsic pathway cannot 
compensate for deficiencies in FVIII and FIX in patients with hemophilia (Osterud and Rapaport, 
1977). For these reasons, a model of coagulation that better paired in vivo observations was 
proposed by Hoffman (Hoffman and Monroe, 2001). 
1.1.2.2 The cell-based model of coagulation 
The revised model of blood coagulation, called cell-based model, assumes that 
coagulation is more regulated by the cellular surfaces upon which activation of the coagulation 
proteins occurs, than by the kinetics and levels of the factors themselves. TF rather than “contact” 
factors is of central importance in the initiation of coagulation. In this model, coagulation occurs 
in three semi-concurrent phases: initiation, amplification, and propagation (Fig.1.2) (Hoffman and 
Monroe, 2001, 2007; Smith, 2009). 
The initiation stage begins on the surface of TF-bearing cell (monocyte or fibroblast). Its 
exposure to circulating VII induces activation of FVII and complex formation. The complex of 
whose catalyzes the formation of activated FIX and FX. FXa activates and joins with FV to form 
the prothrombinase complex, which forms a small amount of thrombin on the TF-bearing cell 
surface. Now that amount of thrombin is enough to catalyze several additional reactions, forming 
the amplification stage of coagulation. 
During amplification stage, platelets that were recruited to the site of vascular injury 
through platelet receptors glycoprotein VI (GPVI) and glycoprotein Ib-V-IX (GP Ib-V-IX) binding 
to the exposed extracellular matrix proteins collagen and von Willebrand factor (vWF), serve as 
the next cellular surface upon which coagulation proceeds. Once activated, platelets release alpha 
granules that contain factor V. FVIII binds to platelets in complex with vWF. The small amount of 
thrombin, generated during the initiation phase on the surface of TF-bearing cells, diffuses and 
activates these platelets through the cleavage of PAR1, and catalyzes the activation of factors XI, 
V, and VIII. Upon activation of FVIII thrombin by thrombin, the bond between FVIII and vWF is 
broken, but FVIIIa remains on the platelet surface. 
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During propagation stage FIXa diffuses from TF-bearing cell to activated platelet surface 
and there interaction with cofactor FVIIIa forms the tenase complex, which in its turn activates 
FX. Freshly formed FXa on the surface of 
activated platelet combines with the platelet-
bound FVa to form the prothrombinase complex, 
which generates the “thrombin burst” necessary 
for fibrin formation. The clotting process (fibrin 
formation) occurs at the inception of the 
propagation phase, when only 5-10 nM thrombin 
has been produced. At the end of propagation 
phase thrombin concentration locally might reach 
several hundred nM (Fig.1.3) (Brummel et al., 
2002; Mann, 2003a). 
The cell-based model of coagulation hence shows us that the extrinsic and intrinsic 
pathways are not redundant. The extrinsic pathway operates on the TF-bearing cell to initiate and 
amplify coagulation. By contrast, the intrinsic pathway operates on the activated platelet surface 
to produce the burst of thrombin that causes formation and stabilization of the fibrin clot 
(Hoffman and Monroe, 2007).  
1.1.2.3 Tissue Factor- based model 
Expanding upon the cell-based model of hemostasis, recent studies proposed a new view 
of coagulation. This model primarily highlighting the role of tissue factor, hypothesizes that 
coagulation is initiated not solely by tissue factor exposed by vascular injury but also by activation 
of encrypted tissue factor by protein disulfide isomerase (PDI) (Furie and Furie, 2008).  According 
to this model, tissue factor circulates in blood in encrypted form, bound to so-called 
microparticles (MPs). These complex vesicular structures, shed from activated or apoptotic 
endothelial cells, platelets, monocytes and, in certain disease states, from granulocytes and 
erythrocytes, are less than 1000 nm in diameter and display proteins similar to those found on 
their parent cell (e.g. ultra large vWF monomers on endothelial cell-derived MPs, P-selectin on 
platelet-derived MPs, TF on monocyte-derived MPs). MP-bound tissue factor in its encrypted 
form is not capable of initiating coagulation. But when platelets exposed to area of vascular injury 
FIGURE 1.2 Thrombin concentrations at different 
stages of coagulation (reprinted from Mann, 2003a)  
FIGURE 1.3 Steps in a cell-based model of coagulation. Initiation occurs on the TF-bearing cell as activated FX 
combines with its cofactor, FVa, to activate small amounts of thrombin.  The small amount of thrombin 
generated on the TF-bearing cell amplifies the procoagulant response by activating cofactors, factor XI, and 
platelets. Finally, the large burst of thrombin required for effective hemostasis is formed on the platelet surface 
during the propagation phase. 
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become activated by collagen and express P-selectin, then the circulating microparticles bind to it 
through P-selectin glycoprotein ligand-1. Consequently encrypted tissue factor gets activated by 
PDI, which was secreted by activated platelets, and is sequestered to the area of injury, ready to 
promote coagulation (Cho et al., 2008b). 
1.1.2.4 Inhibition of coagulation 
The attenuation of the coagulation system is as important as the procoagulant process and 
involves both stoichiometric and dynamic regulators. Tissue factor pathway inhibitor (TFPI) and 
Antithrombin III (ATIII) are the main stoichiometric inhibitors of the process. TFPI, neutralizing 
tissue factor-FVIIa-FXa complex, is the principal regulator of the initiation phase of thrombin 
generation, whereas ATIII, inhibiting FIIa, FIX, FX and FXI, acts to diminish thrombin activity 
and its generation. The dynamic regulator–activated protein C (APC), depends on thrombin 
generation, as the activation of the zymogen protein C is accomplished by thrombomodulin-
bound thrombin. APC competes with FXa and FIXa for binding FVa and FVIIIa, ultimately 
proteolytically inactivating FVa and FVIIIa. Thus, its influence is mostly associated with 
quenching the propagation phase of thrombin generation (Mann et al., 2003). 
1.1.3 Fibrinolysis 
The fibrinolytic system is being initiated to disrupt fibrin clot as soon it starts being 
formed (Hoffman and Monroe, 2007). Fibrin is cleaved into soluble degradation products by 
plasmin, the protein activated from the inactive precursor plasminogen by action of urokinase–
type plasminogen activator (uPA) and tissue plasminogen activator (tPA). The release of tPA from 
endothelial cells is provoked by thrombin and venous occlusion. Degraded fibrin exposes C-
terminal lysines and, acting as cofactor, facilitates plasminogen activation. But PAs are down- 
regulated by plasminogen activator inhibitors (PAIs). Down-regulation of fibrinolysis is also 
performed by thrombin-activatable inhibitor of fibrinolysis (TAFI) that removes C-terminal 
lysines from fibrin and prevents its degradation.  
Thus, hemostasis and fibrinolysis are conjugated processes, finely tuned to balance each 
other and well regulated to confine reactions locally and temporally. Alterations of the balance, 
either due to the absence or abnormality of specific hemostatic elements, lead to thrombosis or to 
bleeding.  
1.1.4 Thrombosis 
Thrombosis is the formation of an undesired blood clot (thrombus) inside a blood vessel, 
obstructing the normal flow of blood through the circulatory system. It happens when the 
pathologic processes overwhelm the regulatory mechanisms of hemostasis, therefore the 
formation of the hemostatic plug and the thrombotic process have several characteristics in 
common. However, there are certain principal differences between the development of thrombus 
and hemostatic plug formation.  
Thrombosis is multifactorial, though abnormalities that are characteristic to thrombosis 
can be postulated in three types known as Virchow’s triad. Particularly: (I) abnormalities of 
endothelium/endocardium – “abnormal vessel wall”; (II) abnormalities of hemorheology, 
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turbulence and stasis – “abnormal blood flow”; (III) abnormalities in platelets, the coagulation 
and fibrinolytic pathways “abnormal blood constituents” (Chung and Lip, 2003).  
Thrombus formation can happen both in vein and artery and, depending on the location, 
causes, composition, risk factors and complications are different. With arterial thrombosis, blood 
vessel wall damage is required for thrombosis formation, as it initiates coagulation (López and 
Chen, 2009), but the majority of venous thrombus form without any injured epithelium 
(Martinelli et al., 2010). Thrombus is red with predominant fibrin in venous thrombosis, and 
white due to the higher proportion of platelets in the arterial thrombosis (Sobieszczyk et al., 
2002). The main complication of thrombosis - embolism, which occurs if the thrombus breaks off 
and, carried by circulation, can induce local clogging at a site distant from its point of origin, is as 
dangerous and life threatening as the unwanted blood clotting in circulatory system.  
The formation of venous thrombosis is associated with stasis and hypercoagulability. The 
most commonly occurring venous thrombosis is the deep venous thrombosis (DVT), which 
concerns the deep veins of legs or in the pelvic veins. It is associated with serious complications 
and the high risk of embolism affecting lungs - pulmonary embolism (PE). This life threatening 
combination is called venous thromboembolism (VTE) (Anderson and Spencer, 2003).  VTE can 
also lead to serious long-term complications, including post-thrombotic syndrome (PTS) and 
chronic thromboembolic pulmonary hypertension (CTPH). 
Arterial thrombosis is the formation of the thrombus within an artery mostly following 
the rupture of the atheroma, an accumulation of degenerative material of artery walls, or caused 
by atrial fibrillation.  Arterial thrombosis is mainly associated with heightened platelet reactivity 
and damage to the vessel wall. Arterial thrombosis is not only blocking blood supply to major 
organs (heart and brain) but is also a major cause of arterial. Together, these factors manifest in 
following serious problems: Stroke – disturbance in blood flow to brain caused either by 
hemorrhage or ischemia, which on its own follows from arterial thrombosis or embolism (Deb et 
al., 2010);  Patients with stroke have a relatively high risk of deep vein thrombosis (DVT) because 
of immobility and increased prothrombotic activity (Kappelle, 2011). Myocardial infarction (MI) - 
restriction of blood supply to the heart due to abstraction of the coronary artery by thrombus 
(Gawaz, 2004); When arterial flow is interrupted, tissue necrosis and gangrene are also possible 
(Ouriel, 2001). 
The risk factors for venous and arterial thrombosis are mostly distinct, though age, 
inflammation and metabolic syndrome represent shared risk factors (Martinelli et al., 2010). The 
risk of both thrombosis in patients above 40 years of age is significantly increased compared to 
younger patients, and it approximately doubles with each subsequent decade (Bick and Kaplan, 
1998). Predisposing factors for VTE are: age, pregnancy and postpartum period, obesity, 
immobility, dehydration, use of estrogen oral contraceptives, hormone replacement therapy, 
inherited and acquired hematological conditions, previous VTE and travel.  Whereas exposing 
factors for VTE include: surgery, including major trauma, multiple trauma, hip fracture, or 
lower extremity paralysis because of spinal cord injury, orthopedic surgery, and abdominal 
surgery, active cancer or cancer therapy, respiratory or heart failure, acute medical illness, venous 
compression (e.g. by tumor, hematoma, arterial abnormality), recent MI or stroke, metabolic, 
endocrine or respiratory pathologies, central venous catheterization, inflammatory bowel disease, 
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severe infection, general care including duration and type of anesthesia, pre- and post-operative 
immobilization, level of hydration and the presence of sepsis (Anderson and Spencer, 2003; 
Martinelli et al., 2010). The presence of a residual thrombus after a first episode of deep vein 
thrombosis is an independent risk factor for recurrence. A potential mechanism by which the 
residual thrombus increases the risk of recurrence is impaired by venous outflow, resulting in 
blood stasis and clot formation. Predisposing factors of arterial thrombosis include: advanced 
age, family history smoking, hypertension, diabetes, obesity, sedentary lifestyle, stress, and 
metabolic syndrome, hyperlipidemia, and blood serum lipid abnormalities (Martinelli et al., 2010). 
Both, the venous and arterial thrombosis, together with embolism represent clearly the 
most common cause of death in developed countries. Affecting up to 15 in 1000 people, about 2 
million individuals die each year from an arterial or venous thrombosis or the following 
consequences in the USA, which is 4 times as prevalent as fatality due to malignancy. The 
morbidity rate occurring due to both arterial and venous thrombotic events has the same scale as 
the mortality (Bick and Haas, 2003). Table 1.1 shows the statistics of the morbidity and mortality 
due to several major types of thrombosis in US.  
In order to avoid development or recurrence of thrombosis and its complications after 
surgeries, stroke, myocardial infarction and other exposing factors, adequate anticoagulant 
treatment and prophylaxis is required (Bick and Haas, 2003). 
Depending on the causes of the forming blood clots some patients at risk may be given 
medications that reduce the stickiness of platelets, so that they will not clump together to block a 
blood vessel. Aspirin, ticlopidine, clopidogrel, abciximab and tirofiban are examples of drugs that 
interfere with the activity of platelets. Other patients will receive an anticoagulant, a drug that 
inhibits the action of clotting factors. Commonly used anticoagulants are warfarin, heparin, 
rivaroxaben, hirudin, hirulog, fonfraparinux. Existing blood clots can be dissolved by 
thrombolytic drugs, which include streptokinase, urokinase, anistreplase etc. (Fenton et al., 1998; 
Ofosu, 2006). However, drugs that are designed to inhibit thrombosis by selectively attacking one 
single enzyme may in practice work out completely different than expected. These drugs may 
save lives, but by introducing misbalance in circulatory system, they can also put the person at 
Table 1.1Incidence of thrombosis in United States 
Disease U.S. Incidence/100 
000 
Total cases in US/ 
Year 
Deep Vein Thrombosis (DVT) 159/100 000  450 000 
Pulmonary embolus (PE) 139/100 000 355 000 
Fatal pulmonary embolus 94/100 000  240 000 
Myocardial infarction (AMI) 600/100 000  1 500 000 
Fatal Myocardial infarction 300/100 000 750 000 
Cerebrovascular thrombosis 
(CVT) 
600/100 000 1 500 000 
Fatal cerebrovascular 
thrombosis  
396/100 000 990 000 
Total thrombosis in US 1498/100 000 5 785 000 
Total Deaths in from above 
thrombosis  
790/100 000 1 990 000 
All cancer in US 1996 544/100 000 1 359 150 
Cancer deaths in US 1996 222/100 000 554 740 
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risk of severe bleeding (Levine et al., 2004). Therefore, close medical supervision and monitoring 
of patients hemostatic state is the curial part of thrombosis management (Blann et al., 2003).  
1.1.5 Bleeding  
The inability to form a proper blood clot leads to bleeding. Improper clotting can be 
caused by congenital or acquired deficiency or mutation of platelets (disorder of primary 
hemostasis) and/or coagulation factors (disorder of secondary hemostasis) (Triplett, 2000). 
Bleeding associated with coagulation abnormalities is characterized by the formation of 
large hematomas, hemarthrosis, large single ecchymosis (either spontaneous or following minor 
trauma) or prolonged bleeding following injury, trauma, surgical or dental procedures, and 
menstruation. Major bleeding occurring intracranial, intraspinal or retroperitoneal might lead to 
death and therefore require transfusion or hospital admission.  
Acquired bleeding disorders (coagulopathy) are more common in hospitalized patients 
and can be life-threatening. Causes of coagulopathic bleeding include consumption of 
coagulation factors and platelets, excessive fibrinolysis, hypothermia, and acidosis (Hoffman and 
Monroe, 2007). The hallmark of coagulopathy is microvascular bleeding, which means oozing 
from cut surfaces and minor sites of trauma, such as needle sticks. Microvascular bleeding can 
lead to massive blood loss. Acquired bleeding are often developed during medical conditions such 
as acute and chronic disseminated intravascular coagulation (DIC), anemia, cirrhosis of the liver, 
HIV, leukemia and vitamin K deficiency, or following surgical or accidental trauma, when the use 
of either fluid for volume replacement (in trauma patients), massive blood transfusion or  an 
anticoagulant therapy is administered (Hoffman and Monroe, 2007). 
Anticoagulant therapy including aspirin, heparin and warfarin is the main cause of clinical 
bleeding (Cuthbert, 1999). Therefore, because of increasing clinical use of potent antithrombotic 
drugs, perioperative bleeding is a major challenge. The risk of bleeding is related to the intensity 
and duration of an anticoagulant therapy and it can be markedly increased by combinations of 
antithrombotic drugs or during switching between different antithrombotic drugs. Although 
major hemorrhage is infrequent (up to 5% of patients receiving therapeutic doses of heparin may 
experience major bleeding episodes), management can be difficult especially with antithrombotic 
agents for which there are no specific reversal agents. Bleeding during antithrombotic therapy is 
associated with high morbidity and mortality. Especially due to increasing number of elderly 
population prevalence of thrombosis-related complications and bleeding associated with 
thrombotic treatment is also constantly rising (Schulman et al., 2008). 
1.1.6 Balancing thrombosis and bleeding risks 
In normal conditions there is a fine balance in the body ensuring that there is not too 
much blood clotting or bleeding. Given the challenge of balancing bleeding and clotting in 
patients, hemostatic management must be tailored to each patient. With every approach to 
reduce thrombosis, there is an accompanying risk of increasing bleeding complications; 
conversely reducing bleeding complications may increase thrombotic events. Hence, balancing 
both ends of the spectrum represents an essential problem. It should take into account patient's 
genetic and acquired risk factors and acute disturbances in bleeding and clotting caused by 
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surgical intervention or other predisposing and risk factors. At the same time it must consider the 
risk for development thrombotic event and bleeding relative to the risks and benefits (Makris et 
al., 2013). Individual approach relays on precise adjustment of the length and the type (dose and 
drug combination) of therapy.  
Significant advances in the management of normal hemostasis in susceptible patients 
might be achieved by introduction of novel hemostatic and antithrombotic drugs. Though it is 
challenging to make drugs that prevent thrombosis without causing a hemorrhagic diathesis and 
the therapeutic window of such agents tends to be narrow, however ideal agent would have 
specific antithrombotic activity to prevent pathological activation of hemostasis yet would 
produce negligible global anticoagulant activity so that the hemostatic system could respond 
appropriately to physiological pro-coagulant stimuli (Cuthbert, 1999).  
However therapeutic decision making, anticoagulant drug trials and subsequent tailoring 
of the treatment require monitoring of patients coagulation behavior. Observing the dynamics of 
hemostatic processes has an utmost importance to detect the propensity of patient to develop 
thrombotic or hemorrhagic disorders and to monitor the effectiveness of the combination and the 
dosage of a medication. Self-management of the dose of own anticoagulants, reducing incidence 
of bleeding and thrombosis complications, also require home monitoring. Developments of new, 
more rational antithrombotic strategies thus require tools to assess the state of patient for dose 
adjustment and safety.  
Nevertheless, the “hemostatic state of patient” bears very global meaning. There are 
various laboratory tests available to assess different profiles and parameters of the hemostasis, but 
which parameter can define the risk of thrombosis or bleeding? Both mechanisms are so 
interconnected that they must have common denominator that is a key in mechanism of 
thrombosis and hemorrhage and thus acting on it and monitoring of which will be crucial.  
Thrombin, playing important role at all stages of hemostasis and fibrinolysis has a 
potential to be considered as such denominator, as it is non-duplicated enzyme lying on the final 
common path of all coagulation and fibrinolysis reactions.  
 
1.1.7 The first law of thrombosis and hemostasis 
Prof. Hemker and his group, researching since long time connection between thrombin 
generation and the thrombotic and bleeding risks, identified thrombin generation (level) to be 
the hinge on which all the problems around thrombosis pivot on. Amount of generated thrombin 
dictates bleeding of thrombotic tendency. Based on this, he postulated following as the first law of 
thrombosis and hemostasis:  
“More thrombin means more thrombosis and less bleeding, less thrombin means less 
thrombosis but more bleeding” (Hemker et al., 2004).  
Indeed results of his extensive studies support this postulate to hold true for congenital 
and acquired tendencies to venous and arterial thrombosis, as well as for bleeding and under all 
variants of antithrombotic treatment (Al Dieri et al., 2012). 
Furthermore the clear argument in support of driving role of thrombin in thrombosis is 
the clinical effectiveness of drugs, used to treat both venous and arterial thrombosis, which either 
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inhibit prothrombin activation into thrombin, or directly inhibit thrombin or accelerate thrombin 
inhibition (Ofosu, 2006).  
In order to see in more details the importance of thrombin in various reactions will be 
described in the following paragraph.  
1.1.8 The central importance of thrombin 
Thrombin is a trypsin-like serine protease, activated by FXa or prothrombinase complex 
(FXa+FVa) from its zymogen precursor protein prothrombin as the ultimate enzyme of 
coagulation cascade (mechanism of activation is described in chapter 3).  
Thrombin exerting a multitude of highly regulated action on the blood, the vessel wall 
and large variety of cells, is involved in diverse important physiological and pathological processes 
including procoagulant, anticoagulant, inflammation and cell-signaling and-activation.  
1.1.8.1 Master enzyme of hemostasis 
Thrombin is often seen as the end-product of the coagulation cascade and as such 
responsible for the final step, the conversion of the soluble protein fibrinogen into the insoluble 
fibrin clot. However thrombin has many more important functions in whole coagulation. It takes 
part in paradoxically opposite games of procoagulant and anticoagulant pathways (Griffin, 1995).  
As procoagulant thrombin acts when it converts fibrinogen into an insoluble fibrin gel by 
ordered two step-cleavage processes, which is the non-duplicated reaction in coagulation cascade. 
The fibrin matrix is further strengthened through cross-linking reaction mediated by factor XIII, a 
transglutaminase also activated by thrombin (Dahlbäck, 2000). Into stable, cross-linked fibrin 
plug thrombin-activated platelets are recruited and aggregated (Vu et al., 1991). Thrombin mainly 
activates platelets by interacting and cleaving protease activated receptors (PARS), however there 
is also another mechanism  of thrombin mediated platelet-activation involving proteolysis of 
glycoprotein V, part of the GpIb-IX-V complex on circulating platelet surface. This in turn yields 
hyper-responsive platelets with enhanced fibrinogen binding and aggregation (Ramakrishnan et 
al., 1999).  Although the exact mechanism is still not clear, thrombin interaction with GpIbα also 
activates platelets  and GpIb-IX –thrombin complex facilitates fibrin binding to Integrin 
(Ramakrishnan et al., 2001).  
Moreover, thrombin maintains and amplifies its own production via positive feedback 
mechanism involving thrombin-activated factors V, VIII (Mann et al., 1988) and XI (Gailani and 
Broze, 1991). Factor V, when activated, associates with activated factor X and cleaves prothrombin 
to thrombin at 20 000 times higher rate. Factor VIII, when activated, associates with activated 
factor IX and activates factor X. Factor XI, when activated, activates factor IX.  Thus once the 
initial stimulus of coagulation cascade is “turned off”, it is thrombin that governs the perpetuation 
of clotting stimulus1 (Narayanan, 1999).   
To complement the role of thrombin in clot formation, thrombin also plays a part in 
inhibition of lysis of that clot. This action is carried out by thrombin-mediated activation of 
                                                        
1
 Ability of thrombin to stimulate and amplify its own production, allows initiation of undesired coagulation 
even without vascular damage, if it escapes inhibition at the injury site.  
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“thrombin-activatable fibrinolysis inhibitor" (TAFI) and stimulation plasminogen activator 
inhibitor-1 (PAI-1) synthesis (Villamediana et al., 1990). Activated TAFI inhibits fibrinolysis by 
cleavage of carboxy-terminal lysine residues on the fibrin polymers, which are needed for 
assembling of the fibrinolytic system (Tilburg et al., 2000). PAI-1 functions as the principal 
inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), the activators of 
plasminogen and hence fibrinolysis (Nilsson et al., 1985).  
Furthermore, thrombin regulates its own production by being part of an inhibitory 
system. Thrombin function as anticoagulant is achieved via binding to a vascular endothelial 
cell protein called thrombomodulin. This leads to the activation of anticoagulant protein C, 
causing inactivation of coagulation factors V and VIII and thus down-regulation of thrombin 
generation, and inhibition of thrombin's ability to form fibrin and activate factor XIII, platelets 
and coagulation feedback stimulatory proteins (Esmon, 2000).  
Interestingly, thrombin also plays a role in degradation of the fibrin clot by activating 
tissue plasminogen activator (t-PA), which in turn activates plasminogen into plasmin. Plasmin 
on one hand degrades its main target fibrin and on the other hand down-regulates thrombin 
generation by digestion of prothrombin and clotting factors V, VIII and XII (Fenton et al., 1998; 
Omar and Mann, 1987). Thrombin is a chemo-attractant for neutrophils, which take part in 
degradation of the fibrin clot (Sonne, 1988). Thrombin interaction with PAI-1 yields reciprocal 
inhibition of each partner (Ehrlich et al., 1991; Meijer et al., 1997). 
Thus, the role of thrombin as the key arbiter of complicated web of positive and negative 
feedback loops governing procoagulant and anticoagulant pathways and their balance is clearly 
impressive. Thrombin indeed deserves the title of the master enzyme of hemostasis. Thrombin, 
however, also has many biological effects that are much more complex than merely hemostatic 
ones. 
1.1.8.2 Non-hemostatic functions 
Apart from thrombin role in hemostasis, fibrinolysis and platelet activation thrombin also 
takes an important part in cell activation, modulation and signaling, and in mitogenic, 
pleiotropic, inflammatory processes through interaction with specific cell surface receptors 
(Frenkel et al., 2005). Almost every cell type tested in vitro (except erythrocytes) was responsive 
to thrombin (Fenton et al., 1998). Most of the cellular effects elicited by thrombin are mediated 
through activation and subsequent signal transduction cascades of members of the PAR family. 
Thrombin activates PAR1, PAR3 and PAR4 (Siller-Matula et al., 2011). 
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As we’ve seen above thrombin influences platelet activation in many ways. It also has 
complex effects on the endothelial cells, with the release of a variety of biologic mediators, 
including expression of ICAM-1, which promotes leukocyte adhesion on the endothelial cells 
(Rahman et al., 2001) and thromboplastin (Galdal et al., 1985). Thrombin modulates multiple 
processes in the vascular system including vascular permeability, vascular tone, inflammation and 
formation of neovessel. Thrombin interaction with PAR1 on the surface of endothelial cells, 
induces a chain of reactions causing the reversible change of endothelial cell shape thus creating 
gaps and increasing vascular permeability (Garcia et al., 1986). Thrombin-exposed endothelial 
cells reversibly lose their ability to adhere to collagen, they can migrate to a distal sites and start  
thrombin-facilitated proliferation and formation of new vessel (Maragoudakis et al., 2002). 
Thrombin also potentiates vascular endothelial growth factor (VEGF)-induced endothelial cell 
proliferation. This process is accompanied by up-regulation of the expression of VEGF receptors. 
In addition, thrombin increases the mRNA and protein levels of alphaV/beta3 integrin and it can 
bind to this receptor. This implies the role of thrombin in angiogenesis, a process that is essential 
in tumor growth and metastasis. Furthermore, thrombin indirectly up-regulates the transcription 
of VEGF by inducing the production of reactive oxygen species and the expression of the hypoxia-
inducible factor 1 (Dupuy et al., 2003). 
Thrombin also activates numerous cells involved in the inflammatory and reparative 
responses, including monocytes, T lymphocytes and mast cells. It affects leukocyte migration, 
edema formation, and other processes related to tissue repair (Rickles et al., 2003; Siller-Matula et 
al., 2011). One of the thrombin actions involves the stimulation of chemotaxis1 of white blood cells 
(neutrophils and monocytes) at the site of injury and generation and release by them chemokine  
                                                        
1
 chemo-attraction induces the objects (cells) to move down to a chemical gradient 
FIGURE 1.4 Multiple roles of thrombin. Thrombin is involved in coagulant, anticoagulant, fibrinolytic, anti-
fibrinolytic and pleiotropic processes as well as angiogenesis and gene expression.   
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and cytokine (Becker and Spencer, 1998; Frenkel et al., 2005). Moreover, thrombin plays an 
important role in cellular proliferation including smooth muscle cells, macrophages, endothelial 
cells and fibroblast. This function of thrombin causes it to be implicated in the disease process of 
atherosclerosis and the build-up of the atherosclerotic plaque which contains many macrophages 
and smooth muscle cells (Borissoff et al., 2009). 
To summarize, non-hemostatic effects being independent form hemostasis also 
complement thrombin’s importance in development of normal, hemorrhagic or thrombotic 
conditions. Thrombin interactions with various molecules and cells and consequent functions of 
thrombin demonstrate that thrombin has an impact on each and every parameter, factor 
determining course of normal hemostasis and fibrinolysis or pathological thrombosis and 
hemorrhage. Fig.1.4 summarizes most important functions of thrombin, whereas Fig.1.5 depicts 
schematically the actions of thrombin at each hemorrhage- and thrombosis-related pathologic 
process. 
Thus thrombin’s hemostatic and non-hemostatic functions prove the first part of “the first 
law of hemostasis” emphasizing the pivotal role of thrombin. 
1.1.8.3 Why does more thrombin lead to thrombosis and less thrombin to bleeding?  
In the following part, we will try to gather the evidence for answering the question, why 
and how does the amount of thrombin dictate the risk of thrombosis or bleeding and thus to 
provide the molecular proof for credibility of the first law of thrombosis.  
We’ve seen how hemostasis and fibrinolysis are interconnected with diverse positive and 
negative feedback loops, directly or indirectly influenced by thrombin. Domination of one or 
another process thus depends on developing thrombin concentration. How well thrombin is 
generated, how well it exerts its actions and how well it is inhibited-defines the extent of a 
hemostatic plug or a thrombotic or bleeding process (Hemker et al., 2004). 
FIGURE 1.5 Role of thrombin in development of hemorrhage and thrombosis. Thrombin involved in 
hemostatic and cellular interactions has impact on fibrinolysis and hemostasis as well as on vessel walls and 
blood flow. On one hand thrombin-mediated down-regulated hemostasis, increased fibrinolysis and decreased 
vascular integrity lead to hemorrhage. On the other hand, up-regulated hemostasis and down-regulated 
fibrinolysis, together or separately with alterations of vessel wall and obstructed flow (Virchow triad), cause 
thrombosis. Arrows indicate whether thrombin action (↑) up- or (↓) down- regulates or acts both ways (↕) on 
corresponding process   
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Obviously, the bleeding risk arises if at the 
site of injury not enough thrombin is 
available/generated leading to unsuccessful 
hemostasis. This can be caused by the 
malfunctioning of the clotting factors or too much 
inhibition of either thrombin or clotting factors. 
On other hand, low levels of thrombin are not 
sufficient to activate fibrinolysis inhibitor (TAFI) 
and uninhibited, accelerated fibrinolysis can lead 
to bleeding from the destabilized healing wound 
(Hemker et al., 2006). 
But there is more about low thrombin levels. In fact, thrombin is a Janus-headed allosteric 
protein, existing in anti-coagulant and procoagulant conformations (Bode, 2006; Dang et al., 
1995). Thrombin allosterity is regulated by the coordination of Na+. Na+ free thrombin, so-called 
“slow thrombin” is considered as anticoagulant, since it prefers to bind thrombomodulin. 
Thrombomodulin, on one hand, blocks thrombin’s active site preventing its action on 
procoagulant substrates and explosive generation of thrombin, and, on the other hand, 
accelerates activation of protein C, which shuts down the propagation of thrombin-generating 
cascade. Whereas Na+ bound thrombin, “fast thrombin”, upon Na+ binding undergoes allosteric 
change and gets improved affinity for procoagulant substrates and reduces affinity for protein C. 
Yet, distribution of the “slow” and “fast“ thrombins depend on thrombin level, due to the affinity 
of the Na+ which is in the range of 110 mM at 37 °C. Thus physiologic NaCl concentration of 140 
mM is not sufficient for saturation of all thrombin with Na+. At the early onset of the thrombin 
generation, thrombin concentration is low and mostly Na+-free. But in the middle of thrombin 
generation the ratio of slow/fast thrombin is about 2/3, to maintain the equilibrium between up- 
and down-regulation (Di Cera, 2007). Thus, thrombin’s character as anticoagulant or 
procoagulant depends on its structure, which in turn depends on the concentration of the 
thrombin. Studies carried out on animals, involving intravenous infusion of various thrombin 
concentrations also confirmed that slow infusion of low concentration thrombin induced 
bleeding instead of thrombosis, indicating that without damage of endothelium or alterations in 
the vessel wall, the fibrinolytic and anticoagulant properties of thrombin prevail (Siller-Matula et 
al., 2011).  
Now, there remains the question about the amount of thrombin that can be considered as 
low (anticoagulant) and high (procoagulant) level. Non-hemostatic functions of thrombin, 
described above, highlight that thrombin can function and thus be generated independently to its 
hemostatic purposes, i.e. vessel injury. And since many of these cellular processes get regulated by 
sub-nanomolar concentrations of thrombin (Vu et al., 1991), we can assume that several pM 
concentration of free non-hemostatic (not necessarily pathologic) thrombin should be circulating 
in blood. This amount of thrombin is necessary as well for keeping coagulation in state of low-
level activation but constantly poised to instantaneously respond to injury with a burst of 
thrombin generation at the site of vascular damage. This circulating thrombin level, to say so, is 
negligible to be considered as procoagulant or coagulant. The range of the “negligible” circulating 
FIGURE 1.6 Thrombin concentration during 
thrombin generation and initial points of 
detection thrombin action products. (Reprinted 
from Mann 2003) 
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15 1.1.8 The central importance of thrombin 
thrombin level obviously has a certain threshold. This threshold should be adjacent with the 
concentration initiating inhibitory pathway i.e. anticoagulation. Due to technical reasons direct 
detection of free circulating thrombin is not yet possible to determine exact ranges of “negligible” 
and “anticoagulant” levels of thrombin and hence to correlate thrombin levels to predisposition 
for development bleeding of thrombotic disorder. Though, the level of the free (uninhibited) 
thrombin that can lead to thrombotic development of scenario can be already about 5 nM. This is 
the thrombin concentration which can initiate thrombin burst. Detection level of free thrombin 
in concentration range of 5 to 20 nM in patients’ blood must indicate the high risk of thrombosis. 
And concentration above that indicates the presence of thrombosis. Thus, all cases of thrombin 
generation exceeding this negligible threshold have to be regulated to confine thrombin in time 
and space in order to keep balance in non-pathologic thrombin activities in whole organism.  
Normally thrombin, escaped inhibition by thombomodulin at the site of generation, gets 
deactivated and removed from circulation by natural inhibitors of thrombin - ATIII, HCII and 
A2M forming irreversible 1:1 complex. Nevertheless, despite rigorous regulation, the risk of 
development of pathologic outcomes due to uncontrolled free thrombin outbreak still exists. The 
main sources of impaired thrombin can be: (i) existence of the non-hemostatic trigger, which 
could act on low concentration of existing free circulating thrombin to up-regulate thrombin 
production; (ii) uninhibited thrombin escaping a site of injury; (iii) thrombin, which was 
entrapped in its active form within fibrin mesh and got released following the fibrin 
degradation by plasmin. One can imagine that the extra thrombin generated after coagulation in 
vivo can diffuse from the site of coagulation and act in a hemostatic and/or prothrombotic 
manner (Kessels et al., 1994). 
Thus description of thrombin concentration in time could be used for monitoring 
patients’ state. Ability to detect free thrombin level thus could significantly improve 
determination of risk factors for bleeding in the preoperative patients and risk factors for 
recurrent thrombosis and help managing successful therapy.  
Following section covers the current laboratory methods available to indirectly measure 
thrombin concentration.   
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1.2 Monitoring of hemostatic state 
In order to assess the hemostatic state of the 
patient for identifying hemostatic defects, diagnosing 
underlying causes, predicting and avoiding 
development of pathology, making individual 
treatment decision, evaluating the success of initial 
treatment modalities, providing guidance for 
supplemental therapeutic interventions, monitoring 
new anticoagulant therapy and epidemiology there are 
several methods and test developed for clinical use or 
in trial.  
In this section will be described some of the 
main methods available in routine clinical use and the 
test that have potential to provide detailed information 
on hemostatic state, based on indirect and direct 
assessment of thrombin generation, activity and 
inhibition.  
1.2.1 Routine blood tests  
Routine tests of blood coagulation frequently ordered to assess clotting function in 
patients are in vitro screening assays prothrombin time (PT) and activated partial thromboplastin 
time (aPTT). These tests measure clotting times (time needed to form a fibrin clot) of recalcified 
whole blood or platelet poor plasma. Assessing only the time taken to form a clot, which occurs 
when only around 5% of all physiologically relevant thrombin is formed (Hemker and Beguin, 
1995), these tests do not entirely reflect global hemostatic balance. They permit only 
identification of connectivity between plasma levels of soluble coagulation factors required for 
hemostasis and give an indication of specific deficiencies, which do not always closely correlate 
with the clinical phenotype. These screening tests are abnormal when there is a deficiency of one 
or more of the soluble coagulation factors but they do not tell us what the risk for clinical 
bleeding will be and also are insensitive to prothrombotic states. However apart from their 
application as screening assays, these methods serve as the backbone of all the specialized clot-
based assays for factor activities, for the indirect measurement of inhibitory antithrombin and 
protein C activities and also for the measurement of the effect of treatment with an anticoagulant 
drug or a combination of drugs during pathological conditions (Tripodi, 2008).  
Prothrombin Time measures the time needed to form a clot after reagent containing a 
phospholipid-protein extract of tissue (thromboplastin) and access of calcium is added to blood 
or plasma sample. Thromboplastin leads to clot formation through activation extrinsic and 
common pathways, thus allowing assessment of functionality of FVII, FV, FX and FII clotting 
factors and fibrinogen. It is used to detect inherited or acquired coagulation defects related to the 
extrinsic pathway of coagulation, to monitor warfarin therapy and to evaluate liver damage and 
vitamin K status (Kitchen and Preston, 1999). 
FIGURE 1.7 Monitoring of thrombin as the 
focal point   
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17 1.2.2 Thrombin generation assay 
Activated Partial Thromboplastin Time is the time taken to the formation of a fibrin 
clot after addition of calcium in the plasma incubated with phospholipid (cephalin) and contact 
activator (e.g. Kaolin, micronized silica or ellagic acid). In this method fibrin clotting is induced 
by activation of intrinsic pathway and therefore reflecting function of intrinsic factors such as 
FVIII, FIX, FXI, FXII, vWf, prekallikrein. The principal clinical use of aPTTs include the detection 
of hereditary or acquired deficiencies or defects of the intrinsic coagulation factors, monitoring 
heparin anticoagulant therapy, the detection of coagulation inhibitors (i.e., lupus anticoagulant), 
and to monitor coagulation factor replacement therapy (Korte et al., 2000). 
Both essays depend on detection of a fibrin clot as the endpoint. Detection of clot 
formation is performed mostly on automated instruments employing mechanical and optical 
methods. Mechanical detection comprises electro-mechanical method, based on completion of 
an electrical circuit by a fibrin strand; and electromagnetic-mechanical approach, based on an 
increase in plasma viscosity as fibrin forms. Optical detection include photo-optical method, 
which observes the phenomenon of light scattering upon fibrin strand formation and photometric 
approach based on absorbency change of monochromatic light. 
For monitoring of oral anticoagulation therapy (warfarin) there are commercial portable 
instruments already available for self-testing PT (CoaguChek® XS system), which have proven 
self-testing to be as good clinically as visiting the anticoagulation clinic and even shown that self-
testing patients have less thrombotic and hemorrhagic events than those who visit 
anticoagulation clinics as their only form of monitoring (Heneghan et al., 2012). However when 
coagulation assays are performed for other, above-described purposes, despite automation, the 
presence of highly qualified and trained medical personal is required for blood and plasma 
collection, treatment, analysis and result interpretation. While these tests have proven useful in 
identifying bleeding risk, they have limited utility when applied to the evaluation of thrombotic 
risk (Mann, 2003b).  
1.2.2 Thrombin generation assay 
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) do not 
incorporate cellular elements and provide data only on isolated components of the coagulation 
cascade. Since clotting times only represent the lag phase before thrombin generation starts, they 
not always mirror pathologies associated with bleeding or thrombosis (Hemker and Beguin, 1995). 
The extent of hemostatic-thrombotic reaction is also critically determined by the amount of 
thrombin that forms and by the time it remains active. The end result of one’s capacity to 
generate thrombin captures the interaction between proteases and their inhibitors and is 
therefore potentially more useful as a reflection of a thrombotic or hemorrhagic phenotype (van 
Veen et al., 2008).  
Thrombin formation in plasma can be measured by the thrombin generation potential in 
plasma in vitro after the activating stimulus, or by measuring the in vivo markers of thrombin 
generation, inhibition and activity. In vivo markers are discussed in the next paragraph.  
Thrombin generation assay is based on thrombin generation in recalcified plasma 
(Hemker et al., 2006) or blood (Tappenden et al., 2007) triggered by tissue factor in the presence 
of phospholipids. Generated thrombin causes the cleavage of a chromogenic (defibrinated, 
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platelet poor plasma) or fluorogenic (platelet rich plasma, whole blood) substrate of thrombin. 
Derivation of the thrombin concentration in the plasma from the rate of substrate conversion 
produces a characteristic pattern of thrombin generation in time (Baglin, 2005).  
The curve obtained is called 
thrombogram (Fig. 1.8), showing the four main 
parameters: lag time (A), time to peak (B), peak 
thrombin (C) and endogenous thrombin 
potential (area under the curve). During an 
initiation phase, or lag time, small amounts of 
thrombin are formed. This is followed by a 
propagation phase, a thrombin burst, which 
reaches its peak and afterwards declines to the 
baseline upon the activation of inhibitors 
(Hemker et al., 2004). The amount of thrombin 
formed reflects the function of the hemostatic 
system much better than the clotting time does. 
Thrombogram measures both low and high 
reactivity of the clotting system, hence thrombin generation potential may correlate more closely 
with a hyper- or hypocoagulable phenotype and is sensitive to the action of all types of 
antithrombotic drugs or a combination of pathological conditions (Berntorp and Salvagno, 2008; 
Al Dieri et al., 2012). 
Thrombin generation has been automated to run several samples together (Hemker et al., 
2002) and also miniaturized in microfluidic system, to decrease the volume of reagents and to 
investigate thrombin generation in constrained environment more alike to blood vessels (Koch et 
al., 2009). However the application of thrombin generation assays to clinical decision-making 
remains still hampered by standardization problems (Castoldi and Rosing, 2011).  
1.2.3 Markers of thrombin formation 
While routine blood tests look how fast fibrin clot is formed i.e. how well is thrombin 
activated, they don’t tell how much thrombin was in blood before coagulation and how much was 
generated. Current state of thrombin levels can be assessed indirectly by measuring the in vivo 
markers of thrombin generation, activity and inhibition in plasma. These include prothrombin 
fragment F1+2 representing a measure of thrombin generated (Pelzer et al., 1991), FPA, reflecting 
thrombin activity towards fibrin (Nossel et al., 1974) and thrombin-antithrombin complexes; 
indicating the amount of thrombin inhibited (Pelzer et al., 1988). 
Identification of these molecular markers is being done by means of, specific antibodies 
prepared against them (LIA or ELISA methods). Measured marker levels show the effect of 
coagulation factor levels on thrombin generation and function, and thus indicate ongoing 
physiological or abnormal process related to clot formation, thrombosis, vascular damage, or drug 
effect (Quinn et al., 2000).  
FIGURE 1.8 Thrombogram, showing (A) lag time 
(min); (B)Peak height (nM) (C) Endogenous thrombin 
potential(area under the curve) (D) maximal raising 
slope (nM/min) (E)time to peak (min) 
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19 1.2.3 Markers of thrombin formation 
Prothrombin fragment F1+2 or just  
F1+2 is the fragment of prothrombin formed 
during prothrombin activation by FXa in 
amounts equimolar to the thrombin generated 
with half-life of 90 min (Bauer, 1993; Pelzer et al., 
1991). Prothrombin fragment 1+2 is a quantitative 
marker to assess the degree to which the 
coagulation system has been activated. F1+2 
levels have been used to assess thrombotic risk 
and monitor the lowest dose of warfarin needed 
to prevent a thrombotic event in those patients on oral anticoagulant therapy. Elevated levels are 
observed in inherited thrombophilia (protein C deficiency, protein S deficiency, and antithrombin 
deficiency). Increased levels occur in thrombosis, pulmonary embolism, DIC, trauma, septicemia 
and complications of pregnancy. Patients on oral anticoagulant therapy have reduced levels of 
F1+2 (Pelzer et al., 1991). 
Fibrinopeptide A or FPA is a peptide of 16 amino acids obtained from cleavage of the 
two A chains of fibrinogen by thrombin, thus concentration of it is a specific index of thrombin 
action in which only active, non-inhibited thrombin plays important role. Short half-life of 3-5 
min makes FPA reliable marker for actual blood clotting activation (Nossel et al., 1974). Elevated 
FPA levels in plasma are shown to be associated with disorders such as disseminated intravascular 
coagulation, deep venous thrombosis, arterial thrombosis, coronary artery thrombosis and 
malignancy (Eisenberg et al., 1985). 
Thrombin-Antithrombin complex or TAT is complex of thrombin irreversibly inhibited 
by the main natural inhibitor of thrombin ATIII. The half-life of TAT is less than 15 min (Pelzer et 
al., 1988). Elevated concentrations of TAT are found in persons predisposed to thrombosis as well 
as in patients with: multiple trauma, liver dysfunction, septicemia, or preeclampsia (López et al., 
1999). TAT is complementary to FPA assay as they are related to different steps. TAT complexes 
indicate thrombin bound to ATIII, if all thrombin was inhibited by ATIII no FPA would be ever 
formed. 
Above described markers, formed during certain processes are then cleared from 
circulation only after definite time and thus, depending on their half-life, they represent 
cumulative, average image of thrombin generation, action or inhibition over a longer period of 
time, i.e. they do not reflect instant picture of thrombin levels. In addition, prothrombin 
activation in vivo normally increases with age in the healthy population. Therefore, the levels of 
thrombin production and action need further investigation in order to discriminate between 
pathological and hemostatic thrombin (Ofosu, 2006). 
Although these methods are used as gold standards, they are time-consuming, manually 
intensive, and not suited for the evaluation of large numbers of clinical samples and give the 
information about thrombin concentration indirectly.  
  
FIGURE 1.9 Molecular markers of thrombin 
generation, action and inhibition  
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1.2.4 Free Thrombin as the marker 
Thus, as we saw above, routine blood tests show how well fibrin clots and based on this 
information make qualitative prediction of possible risks of development hypo- or hyper-
coagulation states or indicate on already existing disorders due to congenital and acquired 
reasons. But these tests do not reflect complete hemostatic picture, they do not give quantitative 
information about instant concentrations of coagulation factors and most importantly of 
thrombin and hence they do not allow quantitative risk assessment.  
Measurement of levels of molecular markers, allows indirect assessment of picture of 
hemostatic state integrated over larger time based on thrombin generation, activity and 
inhibition occurred in the past and thus can only indicate already occurred or ongoing disorder.  
Thrombin generation assay shows how well the system can react on the trigger of the 
coagulation and lead to the thrombin generation. By the characteristic parameters of the 
thrombogram, one can detect the presence of coagulation problems, but it can’t register and 
determine whether there is free thrombin circulating in the blood in the dangerous amounts 
escaped from the site of the injury.  
Hence, a simple clinically useful test indicating coagulability is being increasingly 
recognized. Despite the challenges associated with low concentration and rapid inactivation by 
natural inhibitors, direct detection of circulating free thrombin levels, holds great promise to be 
more reliable test for the prediction of prethrombotic states. As thrombin concentration defines 
the character of thrombin functions and directly correlates with the different hemostatic states, 
monitoring dynamic of free thrombin level over time has potential to be powerful marker, more 
accurately reflecting disease-relevant intermediate phenotypes and thus representing a better 
basis for diagnostics and prophylaxis, consequently improving patient care and outcomes. 
1.2.5 Sensor for free thrombin 
Other than drawbacks of existing hemostatic monitoring methods covered above, it 
should be noted that those methods involve highly complex, costly, and time-consuming 
procedure that needs to be performed by a laboratory specialist. For some methods (PT, aPPT) 
diagnostic equipment in hospitals relies on large-scale automated instruments that are geared 
towards the efficient processing of large batches of prepared samples, whereas other depend on 
intensive manual manipulation (F1+2, TAT, FPA). Thus, these methods are not adapted for 
emergency care patient for example with serious conditions as MI or stroke, in which continuous 
protein measurements are often needed for monitoring anticoagulant or antiplatelet drugs.  
Therefore, there is a need for a method that is sufficiently inexpensive, fast, efficient, 
convenient, durable and reliable to detect marker level (thrombin) at point-of-care by untrained 
individuals, for example, at medical emergencies or in non-clinical locations (home-testing). For 
such situations, it is desirable to develop compact and autonomous chips that can measure 
marker levels in this case thrombin levels within patient blood for the treatment duration of 
several days. Point-of-care device, moreover, has to be capable of overcoming major challenges of 
thrombin detection in real conditions, which comprises the variation of thrombin concentration 
in non-thrombotic and thrombotic states over a broad range (from nM to µM ranges); and the 
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complexity of the medium (whole blood), where thrombin in complex with factors, numerous 
species of macromolecules and cells represent interfering factors hindering detection through 
sedimentation or nonspecific interaction mechanisms. 
Recent advancement and achievements in fields of biosensing, nanotechnology and 
microfluidics offer broad options to tackle those problems. Now it has become possible to treat 
the complex medium, separate its components and perform detection, in time and cost-effective 
manner, in one miniaturized device, instead of whole lab. Specificity of detection is guaranteed by 
special molecules called bio-receptors that through specific interaction called “biorecognition” 
bind their target (molecule or cell) with high affinity and specificity. Devices employing bio-
recognition to detect the target are called biosensors.  
Biosensor device comprises at least two or more of the following parts: one, as we’ve said, 
is the bio-receptor, which could specifically recognize and identify target, and the other is the 
signal transduction part, which could transform the signal of analyte into some detectable signal. 
Recognition components, typically enzymes, antibodies or nucleic acids, directly decide the 
selectivity, sensitivity, stability, as well as application prospects of biosensors. Among them, 
antibodies were regarded as almost the only choice in protein detection. Recently, a new class of 
recognition components, aptamer, has attracted tremendous attention and been supposed to be 
promising alternatives of conventional recognition elements. 
Using aptamers as the biosensing element for monitoring free thrombin is regarded to 
have a great potential. In following sections aptamers and their application for thrombin 
detection will be discussed in more details.  
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1.3 Aptamer – as a sensing element for a biosensor 
In the past two decades, high-affinity nucleic acid aptamers have been developed for a 
wide variety of molecules and complex systems such as live cells. Conceptually, aptamers are 
developed by an evolutionary process, whereby, as selection progresses, sequences with a certain 
conformation capable of binding to the target of interest emerge and dominate the pool. 
Aptamers have initially been explored for their importance in molecular medicine, but have 
enormous potential in other biotechnological fields, especially for analytical application, 
historically dominated by antibodies. In this section aptamers, their selection process, application 
in various fields will be discussed.  
 
1.3.1 What are aptamers  
Aptamers are artificial receptors, selected through a Darwinian-like evolution method to 
bind their target with high affinity and specificity. Aptamers are usually short (15-80 nt), single 
stranded nucleic acid molecules such as RNA or single-stranded DNA (ssDNA) or their unnatural 
analogues, though double-stranded DNA (dsDNA) and peptide aptamers (Hoppe-Seyler et al., 
2004) have also been reported.  
Making an historical review, the first examples of in vitro selected aptamers were small 
RNA molecules that bound to either T4 DNA polymerase(Tuerk and Gold, 1990) or organic dyes 
such as Cibacron Blue and Reactive blue (Ellington and Szostak, 1990), reported independently 
and almost simultaneously in 1990 1. These discoveries, however, were based on the advances in 
medicinal and molecular biology achieved over the preceding 30 years, out of which work of Sol 
Spiegelman represented the main breakthrough towards the discovery of aptamers (Joyce, 2007). 
In the mid-1960s Spiegelman realized that the three fundamental processes of Darwinian 
evolution – amplification, mutation, and selection – could be elevated to a chemical process and 
applied to a population of RNA molecules in vitro, thus creating first aptamer, although it was not 
referred to as such (Mills et al., 1967).  
                                                        
1
 Both groups described similar in vitro selection process almost simultaneously, Tuerk and Gold coined the 
term SELEX (Systematic Evolution of Ligands by Exponential Enrichment) for in vitro evolution process of 
aptamers, whereas Ellington and Szostak gave the name to the aptamers. 
FIGURE 1.10 Schematic illustration of tertiary structures of aptamer, allowing aptamer to adopt specific 3D 
configuration, necessary for key-lock interaction with target.  
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23 1.3.2 Aptamer selection process 
The name aptamer, originating from the Latin word “aptus” meaning “to fit” and the 
Greek word “meros” meaning “part “ or “body” (Ellington and Szostak, 1990), references the lock-
and-key relationship of aptamers with their targets. In contrast to DNA or RNA sequences, which 
bind through base-base complementarities, aptamers bind their ligands by folding into well-
defined, flexible three-dimensional structures (Fig. 1.10). Three-dimensional shapes of aptamers 
are characterized by stems, loops, bulges, hairpins, pseudoknots, triplexes, quadruplexes, g-
quartets or T-junctions and their combinations (Leontis and Westhof, 2003; Stoltenburg et al., 
2007). These conformations allow aptamers to adopt unique interfaces  and tightly interact with a 
wide variety of small and macromolecular targets through dynamic structure compatibility, 
stacking of aromatic rings, electrostatic and van der Waals interactions, and hydrogen bonding, 
or from a combination of these effects (Hermann and Patel, 2000; Westhof and Patel, 1997).   
Unique structural compatibility, allows 
aptamers to bind their cognate target with very 
high affinity and specificity. Having dissociation 
constants in range from sub-pM to µM, aptamers 
are comparable with monoclonal antibodies and 
sometimes even better (Jayasena, 1999). In terms 
of specificity, aptamers are able to distinguish 
their target between molecules having the same 
structure but  different functional groups 
(Jenison et al., 1994), enantiomers (Geiger et al., 
1996) closely related macromolecules (Srinivasan 
et al., 2004) or protein family members (Pagratis 
et al., 1997). 
As a result, since their first appearance, aptamers gained increasing attention evidenced 
by the expanding number of publications (Fig. 1.11). Consequently aptamers have been selected for 
wide array of molecular targets (Tombelli et al., 2005) ranging from  proteins (Dupont et al., 2011),  
peptides (Ye et al., 1996), nucleic acids (Noeske et al., 2007), small organic and inorganic 
molecules (Ellington and Szostak, 1990), antibiotics (Derbyshire et al., 2012), vitamins (Sussman 
et al., 2000), metal ions (Wrzesinski and Jóźwiakowski, 2008) to even whole cells (Blank et al., 
2001; Daniels et al., 2003), viruses (Pan et al., 1995; Wang et al., 2000) or microorganisms (Chang 
et al., 2013).  
1.3.2 Aptamer selection process 
Nucleic acid aptamers are screened by a process of in vitro selection and evolution 
referred as SELEX. SELEX, standing for Systematic Evolution of Ligands by EXponential 
enrichment is combinatorial chemistry technique, developed by Tuerk and Ellington in 1990 
(Ellington and Szostak, 1990; Tuerk and Gold, 1990). SELEX enables the selection of ligands from 
chemically produced oligonucleotide libraries in artificial environment theoretically for any 
molecular target without the constraints imposed by having to be selected or produced in a living 
system. With the time, the methodology of SELEX has evolved itself and various formats have 
been developed beyond the conventional SELEX (Stoltenburg et al., 2007).  
FIGURE 1.11 Aptamers in literature from 1990 to 
2014. Results obtained by searching the word 
“aptamer” in title, abstract or key words of articles 
indexed by Scopus 
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Typically, SELEX process (Fig. 1.12) starts with chemical synthesis of an ssDNA library 
consisting of about 1013 to 1015 different oligonucleotides. Each molecule in a library is a liner 
oligonucleotide with unique sequence, in which central region of randomized 15-60 nt sequence 
motifs are flanked at both ends by fixed regions containing primer sequences necessary for 
annealing primers for PCR and/or reverse transcriptase (RT)-PCR amplification. Upon 
amplification of the randomized pool, RNAs or ssDNAs are generated. This pool is incubated 
directly with a desired target. The binding complexes are subsequently partitioned from unbound 
and weakly bound oligonucleotides. Target bound oligonucleotides are eluted and further 
amplified. The new enriched pool of selected oligonucleotides is used for a binding reaction with 
the target in the next SELEX round. By iterative cycles (rounds) of selection and amplification 
under increasingly stringent conditions, the initial random oligonucleotide pool is reduced to 
relatively few sequence motifs with the highest affinity and specificity for the target. Thus this 
process drives the selection towards relatively few, but optimized structural motifs able to bind 
desired targets with high affinity in Darwinian-manner (Göringer et al., 2003). As only the 
receptor, with dissociation constant in the low nanomolar to high picomolar range is considered 
as “high affinity”, 8 to 15 rounds might be needed until a pool of aptamer candidates for the target 
is obtained (Marshall and Ellington, 2000).   
In order to avoid evolving of non-specific binders to support material (e.g. affinity 
chromatography column, magnetic beads, nitrocellulose filters etc.), negative selection processes 
comprising pre-incubation without the target is performed and nonspecifically binding sequences 
FIGURE 1.12  Scheme of in vitro selection process of aptamers through SELEX . Reprinted from (Strehlitz and 
Stoltenburg, 2009) 
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are excluded (Ellington and Szostak, 1992). Similarly, to avoid cross-reactivity and select aptamers 
only very specific to the target, a pre-incubation step termed counter-selection is carried out in 
the presence of potentially interfering molecules (Fitzwater and Polisky, 1996).  
Once target-specific oligonucleotide pool is generated, last round of SELEX is stopped just 
after the amplification step and the PCR products are cloned to get individual aptamer clones 
from the selected pool. These individual aptamers are sequenced and sequence-analyzed. The 
identification of common sequences as well as homologous regions in the pool and the 
comparative analysis of the sequences are conducted to identify consensus motif – the region 
playing the central role in the specificity of target binding (Hoinka et al., 2012). Selected aptamers 
are subsequently analyzed by affinity techniques such as SPR, ELONA, fluorescent and 
radioactive binding assays etc.  
SELEX can be conducted virtually for any target; however its success rate has been 
reported to be at about 50% (Mayer et al., 2010). Target type, size, purity, concentration, charge 
distribution represent the main constraints of the SELEX. Hence, each target requires unique 
approach to achieve appropriate selection environment (binding and elution buffers, stringency). 
Nowadays there are many different modifications of SELEX depending of the specificity of the 
targets (Stoltenburg et al., 2007). Therefore, selection process might take from weeks to months if 
completed manually. However, the automated SELEX techniques have been developed and then 
modified to be applied to the selection of aptamers on a robotic workstation, which allow 
completing approximately 12 rounds of selection in few days with reduced regents and cost (Cox 
and Ellington, 2001). 
In addition, SELEX has two main limitations: first, is that starting random libraries are 
always incomplete, given the astronomical number of possible different sequences (4n different 
sequences, where n is number of nucleotides in the sequence). Though larger library has higher 
possibility to contain aptameric sequences, analysis of such system is much more expensive and 
time consuming (Kim et al., 2007a). Secondly, unfavorable PCR amplification reactions introduce 
bias towards sequence acquisition, and consequently some sequences, even with the highest 
affinity, might be neglected and misrepresented (Hamula et al., 2006). One of the main reasons is 
crosstalk between flanking primer regions with central aptameric sequence.  
To overcome limitations of SELEX, the first experimental attempt at non-SELEX selection 
of nucleic acid aptamers, avoiding PCR amplification step was proposed by Berezovski and Krylov. 
This method involves repetitive steps of portioning by non-equilibrium capillary electrophoresis 
of equilibrium mixtures termed NECEEM. This technique allows isolation of high affinity 
aptamers in fewer rounds (Berezovski et al., 2006). Another method reported recently is DNase-
Mediated Single-Cycle Selection enables discovery of DNA Aptamers for proteins blotted on a 
membrane (Liu et al., 2012).  
Computer-assisted library screening methods, on the other hand, offer prediction of 
potential aptameric sequences allowing synthesis of library with fewer sequences but higher 
probability. For example, RNA-As-Graph-Pools (RAGPOOLS) web server offers a theoretical tool 
for RNA in vitro selection and related problems (Kim et al., 2007b); in silico selection method for 
generation RNA library based on RNA secondary and 3D structure and virtual screening of this 
library was also investigated (Chushak and Stone, 2009). 
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1.3.3 Aptamer features 
Aptamers are attractive receptors for wide range of applications due to their unique 
combinations of qualities.  
Hence, aptamers, characterized by high affinity and selectivity,  rival antibodies in all 
those  application fields in which selective recognition is required i.e. in therapeutic, diagnostic  
and sensing  applications (Jayasena, 1999). 
Aptamers, being produced through purely chemical process out of nucleic acids enjoy 
advantages of both chemicals and biological molecules (Tolle and Mayer, 2012). Cost-effective and 
relatively easy solid phase chemical synthesis of aptamers allows scalable production of aptamers 
with high reproducibility and purity from commercial sources. Therefore aptamers are less prone 
to bacterial or viral contamination and batch-to-batch variation. As for selection and production 
of aptamers, in contrast to antibodies, animal (cellular) host and initiation of immune response  
are not needed, aptamers can be selected for almost any target in non-physiological even low-
immunogenic and toxic.  
In contrast to antibodies, nucleic acid aptamers are characterized with remarkable 
stability; they resist harsh conditions, can undergo reversible chemical or temperature 
denaturation and show much longer shelf-life. Aptamers often undergo significant 
conformational changes upon target binding that can be exploited for designing various bio-
recognition-based signal transduction formats in biosensing.  
Aptamers can function both inside and outside cells, whereas antibodies usually only work 
outside cells to target secretory proteins or cell surface receptors. 
The small size and similarity to endogenous molecules makes aptamers poor antigens, but 
their half-life in vivo and ex vivo is limited by hydrolytic action of nucleases1. However this 
vulnerability can be easily opposed by chemical modification of the aptamers. Compared to other 
receptors, the simple chemical structure of aptamer makes it easily amendable to functional 
modifications which can confer higher stability and nuclease resistance and even improve the 
overall affinity for the target. Aptamer modification by the introduction of new functional groups 
brings novel structural/physical/chemical proprieties advantageous for their application in 
various fields (White et al., 2000). These modifications play important role in aptamer 
applications and hence, few of them together with the relevant use will be discussed in following 
paragraph. 
 
 
 
 
 
 
 
 
                                                        
1
 Particularly nuclease-sensitive are RNA aptamers, as the hydroxyl group at 2’-position on the ribose 
promotes phosphodiester bond hydrolysis. 
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Table 1.2 Aptamers vs. Antibodies 
Aptamers Antibodies 
Selection 
SELEX: 
In vitro  
Any target (~ 50% success) 
Any condition 
Specific site interaction  
Cellular immune response in animal host: 
In vivo 
Non-toxic, immunogenic target 
Physiologic conditions 
Non-defined site of interacting  
Production 
Chemical solid phase synthesis: 
Scalable 
Cost effective 
Reproducible 
No batch-to-batch variation 
Non-contaminated 
Easy to add functionalities 
Immune response in animal host: 
Low amount 
Expensive 
Batch-to-batch variation 
Impurities 
Difficult to add functionalities 
 
Properties 
High affinity  
High specificity 
Non-immunogenic  
Intra and extra cellular action 
Small size 
Flexible 
Functionalities 
Stability (pH, Temperature) 
Reversible denaturation 
Nuclease degradation 
Long shelf-life 
High affinity  
High specificity 
Immunogenic 
Extracellular receptors  
Large size 
Non-flexible  
Sensitive to conditions  
Irreversible denaturation 
 
 
1.3.4 Aptamer modifications – dressing up for success 
Modifications increase the versatility of aptamer functions and applications.  So far, ~100 
different modifications can be readily introduced into different parts of aptamers including the 
nucleosides, the phosphodiester backbone and the 5’ and 3’ termini a priori - within the SELEX 
process using modified nucleic acid libraries, or a posteriori - modifying a selected DNA/RNA 
aptamer through chemical synthesis or both. In the first case adopted modification has to be 
compatible with the enzymatic amplification necessary for selection, whereas in the second 
introduced functional group should be consistent with and non-compromising the aptamer-
target recognition. These modifications expand aptamer applications in therapy and diagnostics, 
detection and as tools in chemical biology (Tolle and Mayer, 2012). 
Therapeutic applications: Aptamers possess unique chemical and biochemical 
characteristics and attractive pharmacokinetic and pharmacodynamic features. The ease and cost-
effective synthesis, structural stability across a wide range of temperature and storage conditions, 
non-immunogenic, non-toxic and degradable character - all these general properties make 
aptamer interesting tools for therapeutic applications. Aptamers can be used as drugs or as a part 
of drug-delivery system (Keefe et al., 2010). Since antidotes (complementary DNA), modulating 
functional performance of aptamers, can easily be designed, aptamers are particularly safe class of 
therapeutics. Other pharmacokinetic properties such as plasma stability, rate of clearance, uptake 
and distribution can be further tuned by modifications (Healy et al., 2004).  
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To address the problem of nuclease resistance for application requiring increased aptamer 
stability (therapy and in vivo diagnosis) there are several options available: (i)  Appending 
primary amines (2’-NH2) or fluorides (2’-F) to the 2’-position of the pyrimidines or O-methyl 
groups (2’–OME) to either pyrimidines or purines (Behlke, 2008); (ii) Modification of the 
phosphodiester backbone with phosphorothioate (thioaptamers); (iii) Locking nucleosides by 
interlinking 2’-O and 4’-C a methylene group to create Locked Nucleic Acids (LNA) (Petersen and 
Wengel, 2003); (iv) Circularization or Capping the 3’-termini by various functional groups or 
inverted thymidine (3’-idT), which creates an additional 5’; (v) Use of chiral (L-aptamers) so-
called spiegelmers (Nolte et al., 1996). Single or combinatorial modification of aptamers were 
shown to not only increase aptamer half-life in serum from several minutes to several days in vivo 
but also augment their affinity and thermal stability (White et al., 2000). 
Circulation half-life, uptake and distribution can be improved by tagging aptamers at the 
termini. Due to relatively small size (10-15 kDa), aptamers can be easily cleared from human blood 
through the kidney and liver. Annealing large molecular weight Polyethylene glycol (PEG) or lipid 
tag extends circulation half-life from few minutes up to one day. Tagging with lipids and cell-
penetrating peptides may help tissue uptake of aptamers (Healy et al., 2004).  
Aptamers can also be used as delivery vehicles. Aptamers that bind to internalized cell 
surface receptors can be used for targeted drug and other cargoes delivery into cells. This is very 
useful for example in cancer chemotherapy, which aims to kill cancer cells with cytotoxic drugs 
without harming noncancerous cells.  
Drug molecules can be directly covalently linked to aptamers (Kanwar et al., 2011). 
Aptamer combinations with another aptamer, functional biomacromolecule and/or chemical 
compounds are termed as Chimeras (Burke and Willis, 1998). Aptamers anchored to cargo-
bearing liposomes through dialkylglycerol (DAG) or cholesterol functionalities have been used for 
cargo (Perche and Torchilin, 2013), whereas aptamer-nanoparticle conjugates have found 
application, for diagnosis, imaging, targeting cancer cells (Huang et al., 2005).  
Application in detection: Owning high specificity and affinity in nanomolar (0.1-100 nM) 
range, and the availability of such a large pool of aptamers makes it possible to develop novel 
bioassay tools covering areas that include diagnostics, anti-bioterrorism, and environmental and 
FIGURE 1.13 Schematic illustration of major modifications applied on aptamers to increase stability, append 
functions and properties.  Reprinted  from  (de-los-Santos-Álvarez et al., 2008) 
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food analysis. The possibility to conjugate aptamers with functional moieties extends is advantage 
in many orders. Post selection modification of aptamers at either on 3’ or 5’ with biotin, thiols, 
amines, carboxyl, phosphates, and cholesterol not only protects them from exonuclease, but also 
allows their anchoring and conjugation to enzymes or diverse supports (Tombelli et al., 2005; 
Zhou et al., 2010, 2011).  
Introducing signaling moieties such as fluorophores or chemical reactive (redox) groups 
provides possibility to combine sensing and signal transduction in one molecule. These qualities 
offer great flexibility in the design of biosensors (de-los-Santos-Álvarez et al., 2008). 
Another type of modification provides cross-linking ability by introducing 5-Br(d)U or 5- 
I(d)U during SELEX. This type of aptamers are called photoaptamers as under laser irradiation 5-
Br(d)U or 5-I(d)U can specifically cross-link with proximal amino acids having aromatic or sulfur 
groups (Bock et al., 2004). 
Especially well-suited for diagnostic purposes seem to be so called SOMAmers - “Slow Off-
rate Modified Aptamer”. SOMAmers, due to the  presence of 5-tryptaminocarbnyl-Ud 
modifications, contain additional aromatic side chains which enhance hydrophobic and pi-
stacking interactions and generate very low-off rates (Gold et al., 2012).  
1.3.5 Thrombin aptamers 
Thrombin has been one of the most studied targets for aptamer binding and there are 
various aptamers selected against thrombin.  
Following the first reports of isolation of RNA aptamers by SELEX method in 1990 
(Ellington and Szostak, 1990; Tuerk and Gold, 1990), Bock and colleagues used thrombin as the 
first protein target, that normally does not interact with nucleic acids, to select  the first single-
stranded DNA aptamer (Bock et al., 1992). Since then at least four thrombin-binding aptamers 
and their various modified versions have been identified. Selection of thrombin aptamers was 
motivated/guided by the therapeutic application as the anticoagulant and therefore only the 
aptamers showing the inhibition of fibrinogen clotting have been described and investigated 
(Macaya et al., 1995). However some thrombin aptamers also become main tools in biosensor 
development and are widely used as prove of concept. Thrombin aptamers represent about 20% 
of the 5000 papers published about the use of aptamers for analytical technologies (Deng et al., 
2014). Thrombin aptamers will be discussed below. 
1.3.5.1 HD1  
HD1 aptamer, known also as G15D, HTQ, TBA (Thrombin binding aptamer) or ARC183 
(Archemix), is a 15 base long single-stranded DNA aptamer with the sequence 5’-
GGTTGGTGTGGTTGG-3’. HD1 was isolated  the first in 1992 by Bock et al. as the first ssDNA 
aptamer against thrombin, the protein with no known nucleic acids binding properties (Bock et 
al., 1992). Since its discovery, it has been the most investigated aptamer. HD1 was also the first 
aptamers to be used for aptasensor development. 
HD1, shown to inhibit thrombin-catalyzed fibrinogen clotting in vitro and reduce arterial 
thrombus formation ex vivo, binds alpha-thrombin with nanomolar affinity primarily at highly 
basic anion-binding (fibrinogen-binding) exosite I (Bock et al., 1992; Paborsky et al., 1993), though 
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there exist some indications of interaction to exosite II as well (Padmanabhan and Tulinsky, 
1996). The structure of this aptamer and the mechanism of interaction with thrombin will be in 
more details discussed in chapter 3.  
1.3.5.2 NU172 
NU172 with sequence 5’-CGCCTAGGTTGGGTAGGGTGGTGGCG-3’ is 26-mer ssDNA 
aptamer also known an ARC2172 (HUTABARAT, 2010). It was developed as the 
optimized/alternative form of HD1 (Archemix) for improved therapeutic purposes, which is now 
under phase II clinical trial (ARCA Biopharma; Mayer et al., 2011). This aptamer is one of the latest 
thrombin aptamers and is not widely investigated. It is thought to bind exosite I of thrombin with 
nanomolar affinity, but nothing more is known.  
1.3.5.3 HD22 
HD22, also known as HTDQ, is the 29-mer ssDNA aptamer with the sequence 5'-
AGTCCGTGGTAGGGCAGGTTGGGGTGACT-3' (Tasset et al., 1997). The affinity of HD22 aptamer 
is slightly better than that of HD1. HD22 recognizes the heparin-binding exosite II of thrombin, 
inhibiting the activations of FV and FVIII and hence showing moderate effect on fibrinogen 
regulation, is not considered for therapeutic applications but together with HD1 is often used in 
sensing. The thrombin-HD22 interaction will be discussed in more details in the chapter 3.  
1.3.5.4 Thrombin RNA aptamer 
TOG25 or Toggle-25 is a thrombin-binding 25-mer RNA aptamer with sequence of 5’-
GGGAACAAAGCUGAAGUACUUACCC-3’ contains 2′fluoropyrimidine C and U nucleotides. 
TOG25 binds to thrombin near exosite II with Kd of about 3 nM, slightly modulating platelet 
activation but not affecting fibrinogen conversion (White et al., 2001). For this reason, its use as 
anticoagulant has been abandoned. Although several studies have used RNA aptamer for 
biosensing application, degradation by nuclease represents main compromising point, rendering 
this aptamer less attractive (Bompiani et al., 2012).  
1.3.5.5 Advantage of multiple binding sites and aptamers 
The existence of two anion-binding sites on the surface of thrombin and availability of 
corresponding aptamers clearly represents the important advantage for biosensor development. 
Simultaneous targeting of two sites allows increased specificity towards target and flexibility in 
terms of choosing and developing biosensing strategies. It diversifies also bio-recognition and 
signal transduction approaches. Indeed in the past decade various aptamer-based approaches for 
thrombin detection were proposed and some of the most prominent ones will be covered in the 
next section.   
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31 1.4.1 Binding assay configuration 
1.4  Aptamer –based detection of thrombin 
Aptamers clearly represent very promising biorecognition elements: high affinity and 
specify assure sensitive and precise biorecognition; small size combined with chemical 
modifications allows efficient immobilization at high density on the surface of various planar and 
nanoparticle materials, which is a crucial importance in miniaturized systems such as a bioarrays 
and biochip; nucleic acid origin grants long shelf-life and chemical and thermal stability, offering 
advantage of regeneration and reusability; inherent conformational flexibility, ability to form 
reversible complexes with various molecules together with possibility to conjugate with various 
dyes, chemical reactive groups and nanomaterials for signal generation and amplification, permit 
use of aptamers in various biorecognition and signal transductions formats (Jayasena, 1999). 
Depending on the type of transduction type, the analyte detection could be mainly performed by 
optical, or electrochemical or mass sensitive techniques.  
Thrombin, a protein with two anion-binding sites and with at least two aptamers for each 
site, opens up a large spectrum of sensing opportunities. Indeed, since the first report of optical 
aptasensor for thrombin in 1997 (Potyrailo et al., 1998), more than 1000 aptamer-based assays and 
biosensors coupled with different transduction principles have been described in the literature for 
thrombin (Deng et al., 2014). However, it should be highlighted, that thrombin was mostly used 
as a model protein to demonstrate the usefulness of several method and different formats, 
sometimes for the first time and not all of them aimed to detect thrombin as the real target in real 
conditions. 
1.4.1 Binding assay configuration 
Prior to discussing thrombin aptasensors based on various detection methods in more 
details, it should be noted that sensitivity and transduction of bio-recognition events of those 
methods depend on the design of the assay. For thrombin, having two distinct binding sites and 
several aptamers specifically recognizing each of them, there are numerous assay configurations 
designed. Majority of these designs can be classified into two categories of configuration (Fig. 
1.14): (i) single-site binding; and, (ii) dual-site binding (Song et al., 2008).  
Single-site binding, although seems to refer simple interaction (Fig. 1.14 (A)), however, 
contrary to antibodies, chemical composition of aptamers,  granting flexibility and ability to form  
complementary base-pairing and allowing incorporation of signaling moieties, offers wide range 
of detection opportunities. Apart from single affinity binding to target that can be detected with 
conventional methods such SPR or QCM, aptamers are also able to give signal output upon bio-
FIGURE 1.14 Aptamer-based detection assay formats for thrombin. (A) Single-site binding ;(B) Dual-site binding 
involving two aptamers (C)Dual-site binding involving aptamer and antibody. 
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recognition detectible with various optical and electrochemical methods. These methods take 
advantage of aptamer to take part in molecular beacons, catalytic beacons, enzymatic 
amplification reactions, interactions with nanomaterials, etc. to generate the signal (Deng et al., 
2014). 
Double-site binding also known as sandwich assays, is the approach in which the 
analyte is sandwiched by a pair of receptors, one regarded as capture probe and the other reporter 
probe (Fig.1.14 (B,C)). Capture probes are often immobilized on the surface of solid supports (e.g., 
electrodes, glass chips, nanoparticles or micro-particles), while reporter probes are often 
conjugated with signaling moieties (e.g., fluorophores, enzymes or nanoparticles (NPs)). Double-
site binding assay is not only a mean of detection but it assures increased detection specificity as 
well. As thrombin can bind distinct aptamers on two distinct binding sites without interfering 
with each other, sandwich assay is one of the most used assay formats. For thrombin the most 
sandwich format assay use HD1 and HD22 pair (Baldrich et al., 2004; Gill et al., 2006; Ikebukuro et 
al., 2004), but assays based on HD1 and antibodies (Kang et al., 2008)also have been described. 
(Ikebukuro et al. 2004, 2005; Osawa et al. 2009) (Kang et al. 2008). 
Based on the complexity of the detection, aptamer-based assays might be classified into 
homogeneous and heterogeneous assays. Homogeneous assays or so-called non separation assays 
work in a solution phase in “mix and read” format, not demanding immobilization, separation, or 
washing procedures. Therefore simultaneous target recognition and signal output are two 
essential requirements for homogeneous assays. Although such assays can potentially deliver 
simplicity to end users, especially for on-site and resource-limited applications, the disadvantage 
is lower sensitivity compared to heterogeneous assays. In heterogeneous assays, on the other 
hand, detection of bound analyte is made after time consuming incubation-washing-separation 
steps and immobilization might be required (Deng et al., 2014; Sassolas et al., 2011).   
1.4.2 Optical detection 
Aptamers have been widely used as bio-recognition elements in optical bioassays.  Optical 
approaches include analyte detection either in liquid or at the interface of solid/liquid phase 
through fluorescence, colorimetry or the alterations the optical properties (surface plasmon 
resonance (SPR), evanescent wave spectroscopy, etc.)  
1.4.2.1 Fluorescence 
Fluorescent detection is widely employed due to the easiness of aptamer labeling with 
fluorescent dyes, the availability of wide array of fluorophores and quenchers, and the consequent 
ability for real-time detection. Detection is based on a variation in fluorescence properties of a 
molecular recognition unit that occurs when it interacts with the target. Fluorescence represents 
the main detection mode described for most homogeneous aptamer-based assays, however it is 
also used in heterogeneous formats (Sassolas et al., 2011). There are several main strategies 
developed for reporting biorecognition of thrombin by aptamers using both one-site or sandwich 
formats (Song et al., 2008). 
` 
 
33 1.4.2 Optical detection 
Single-fluorophore-labeled aptamers have been used to report target–aptamer binding by 
monitoring the changes of fluorescence intensity or anisotropy resulting from the changes of the 
microenvironment or rotational motion of the fluorophore (Fig. 1.15 (A)). In the very first 
thrombin aptasensor fluorescently labeled HD1 aptamer was covalently attached to a glass 
support. Monitoring the evanescent-wave-induced fluorescence anisotropy change upon 
thrombin addition, they detected sub-nanomolar concentration of thrombin (Potyrailo et al., 
1998). Similar approach was used for detection and quantification of thrombin on-chip (McCauley 
et al., 2003). An interesting assay is based on DNA-tiles containing HD1 aptamer, enabling 
thrombin detection in sub-nanomolar concentrations (Lin et al., 2006). Aptamers were modified 
with 3-methylisoxanthopterin (3-MI) fluorophore, in a region undergoing environmental change 
during thrombin binding and yielding increase in fluorescence signal. First ELISA-like approach 
for HD1 aptamer and anti-thrombin antibody in direct and competitive experiments enabled 
sensitive thrombin in low nanomolar range (Baldrich et al., 2004). Later HD22 labeled with 
fluorescent dye (Edwards and Baeumner, 2010; Meneghello et al., 2012) or quantum dot (Tennico 
et al., 2010) was used to report the capture of sub-nanomolar concentrations thrombin by surface-
immobilized HD1 in sandwich format (Fig. 1.15 (B)).  
Taking advantage of the ligand-induced conformational changes of aptamers, a number of 
assays have been developed based on principle of fluorescence resonance energy transfer (FRET). 
One of the first attempts included aptabeacon, in which the flourophore-labled 5’ termini of HD1 
aptamer was extended by a few nucleotides complementary to those at quencher bearing 3’end in 
order to create stem-loop structure (Hamaguchi et al., 2001). Upon thrombin binding aptamer 
adopted aptameric confirmation, increasing the distance between the fluorophore and the 
quencher and therefore reducing the quenching effect and producing fluorescence (Fig. 1.15 (C)). 
This “turn-on” assay based enabled thrombin detection in range of 10-50 nM concentration. 
Contrary, fluorescence “turn-off” was used to report the detection of thrombin in sub-nanomolar 
concentration, by HD1 aptamer bearing fluorophore  at one extremity and a quencher on the 
opposite (Fig. 1.15 (D)), which upon thrombin binding would appear in close proximity to quench 
the fluorescence (Li et al., 2002). Ingenuous approach to generate fluorescence signal upon 
FIGURE 1.15 Aptamer-based fluorescence assays for thrombin detection (A) change of fluorescence anisotropy 
or intensity upon thrombin binding; (B) ELISA-type detection with fluorescently-labeled secondary aptamer; (C-
E, G) FRET turn-on and turn-off formats; (F) Fluorescence turn-on upon thrombin binding; (H) quantum dote or 
(I-K) gold nanoparticle-mediated turn-on detection of thrombin.   
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thrombin detection was the use of “structure switching signaling aptamer” (Nutiu and Li, 2003). 
The construct was composed of duplex made out unlabeled aptamer hybridized with fluorophore-
labeled ssDNA and quencher-labeled ssDNA (Fig. 1.15 (E)). Thrombin binding induced release of 
quencher-bearing ssDNA and enabling fluorescence emission. Further improved strategies were 
proposed for a simpler competitive molecular beacon that required only the complementary DNA 
to be modified with fluorescent nucleotide for “turn-on” format (Fig. 1.15 (F)) and fluorophore 
quencher couple at the extremities for ”turn-off” (Fig. 1.15 (G)) option (Li and Ho, 2008).  
Other molecular beacons based on above-described strategies were adapted to aptamers 
conjugated with quantum dots or nanoparticles. For example thrombin aptamer was labeled with 
quantum QD (Fig. 1.15 (H)), the emission of which was quenched by the quencher embedded in 
complementary DNA in the absence of thrombin and restored upon competitive DNA 
displacement by thrombin (Levy et al., 2005). Sub-nanomolar concentrations of thrombin were 
detected by the essays employing gold nanoparticles (Wang et al., 2008a). Thrombin aptamer was 
either grafted, hybridized to complementary DNA or just adsorbed on the surface of AuNP, 
leading to quenching of the fluorescence in the absence of thrombin (Fig. 1.15 (I,J,K)). 
Apart for gold nanoparticles various other nanomaterials such as carbon nanotubes (Yang 
et al., 2008), graphene (Chang et al., 2010), mesoporous carbon microparticles (Zhang et al., 
2011b), poly(m-phenylenedi-amine) rods (Zhang and Sun, 2011), and carboxylic carbon 
nanoparticles (Liu et al., 2011) possess capacity to non-covalently absorb single-stranded DNA and 
to quench fluorescence with high efficiency (Fig. 1.16). These properties underlay the assays in 
which the fluorescence of fluorophore- or quantum dot-labeled HD1 is quenched as it is adsorbed 
on the surface of one of these nanomaterials in the absence of thrombin and fluorescence is 
restored upon binding the target. (Choi et al., 2006). 
1.4.2.2 Colorimetric detection 
Colorimetric detection is the second most popular approach  homogeneous aptamer-
based assays as it offers the simplest sensing mode (Sassolas et al., 2011). Namely, the 
biorecognition is accompanied with color change, observable in visible spectrum even by necked 
eye. Assays mostly relay on: (i) aggregation of unmodified or aptamer-modified gold 
nanoparticles; (ii) aptamer-involving catalytic reactions; (iii) interactions with a cationic polymer. 
The popularity of use of gold nanoparticles for colorimetric detection relays on the 
intrinsic property of nanoparticles - the surface plasmon resonance absorption. Due to this 
phenomenon suspended nanoparticles disperse light in red spectrum, but when particles 
aggregate absorbance maximum shifts towards blue. Hence, colorimetric assays based on analyte-
induced assembly (red-to-blue color change) or disassembly (blue-to-red color change) of 
unmodified or aptamer-functionalized AuNPs can be distinguished.  
FIGURE 1.16 Fluorescence signal modulation by carbon nanotube. The fluorescence of the labeled aptamer 
quenches when it is adsorbed on the surface of a carbon nanotube. Once thrombin interacts with the aptamer, 
the folding of aptamer changes leading to fluorescence signal recovery 
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A thrombin detection approach based on interaction of unmodified AuNPs and HD22 
aptamers in the presence and absence of thrombin was described to detect thrombin 
concentration in a linear range up to 10 μM with a detection limit of 8.3 x 10-10 M (Wei et al., 
2007). In the absence of thrombin, due to electrostatic interactions unfolded aptamers adsorbed 
on the surface of unmodified AuNPs, restricting particle aggregation and stabilizing colloidal 
solution even in relatively high salt concentration. However following thrombin titration, 
aptamers changed conformation, salt screened the negative charge and led AuNPs to aggregate, 
causing a corresponding red-to-blue color change (Fig. 1.17 (A)). Similar approach also with non-
modified nanoparticles involved interaction of AuNPs with thrombin-aptamer complex in the 
presence of salt and cationic conjugated polymer (Xia et al., 2010). Aptamer adsorbed on the 
surface of AuNP and kept colloidal solution red. Though, when cationic conjugated polymer was 
added, it removed all unfolded aptamers not paired with thrombin from the surface of AuNP, 
leading to aggregation of particles (Fig. 1.17 (B)). The more thrombin was titrated the less was the 
aggregation. Another colorimetric aptasensor based on aggregation of unmodified AuNPs in the 
presence  water-soluble cationic polymer poly(diallyldimethylammonium chloride) (PDDA) 
allowed thrombin detection down to 1 pM with high selectivity in the presence of other 
interfering proteins and in human serum sample (Chen et al., 2014). HD1 aptamers adsorbed on 
the surface of AuNPs stabilized colloidal solution in the presence of PDDA, but following the 
injection of thrombin aptamers switched the structure and facilitating (PDDA)-induced AuNP 
aggregation (Fig. 1.17 (C)). Aggregation of HD1-modified AuNPs in the presence of thrombin was 
first demonstrated by Pavlov (Pavlov et al., 2004). Nanoparticles were cross-linked by thrombin 
since HD1 interacts not only with exosite I but also with exosite II of thrombin. This approach 
enabled delectation of thrombin as low as 20 nM concentration. Recently detection sensitivity 
was improved in similar approach achieving 5 pM detection limit (Peng et al., 2013). Two 
strategies, one based on aggregation of AuNP modified with two distinct thrombin aptamers (Fig. 
1.17 (D)), and another based on disassembly of HD1 aptamer-capped AuNP aggregates 
interconnected with complementary to HD1 strand (Fig. 1.17 (E)) were  investigated in the thesis 
of Yan (Yan and Zeng, 2010). In the first case thrombin, interacting with both aptamers 
simultaneously, induced aggregation in sandwich-like manner achieving 10 nM detection limit. 
Whereas in the second approach, thrombin competed for binding with HD1, displacing 
complementary strand, and led to disassembly of aggregate. Apart from liquid phase, colorimetric 
assays for thrombin have been also design for solid phase. For example, a dot-blot assay for 
FIGURE 1.17 Colorimetric AuNP–based thrombin aptasensors. Unmodified gold nanoparticles aggregate in the 
presence (A-B) or in the absence (C) of thrombin.  Aptamer-modified gold nanoparticles (D) aggregate when 
interlinked through thrombin or (E) get stabilized by the presence of thrombin.  
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thrombin detection was reported based on thrombin adsorbed nitrocellulose membrane and 
HD1-AuNPs conjugates (Wang et al., 2008b). Catalytic reduction of silver ions was used for signal 
amplification allowing thrombin detection at the range of 0.115 to 9.25 pmol in 1% plasma. Xu et 
al. reported aptamer-AuNPs as probes in aptamer-based dry-reagent strip biosensor for thrombin 
analysis in sandwich format (Xu et al., 2009). One aptamer was immobilized in test zone and 
second on the AuNP. In the presence of thrombin, sandwich was assembled on the surface of the 
test-zone giving color signal. This simple biosensor provided a linear response for thrombin over 
the concentration range of 5-100 nM, with a detection limit of 2.5 nM.  
Wide range catalytic colorimetric sensors have been reported for thrombin. Catalytic 
molecular beacons consisting of thrombin aptamer hairpin and G-quadruplex  were developed for 
colorimetric detection of thrombin oxidation of either 2,20-azinobis(3-ethylbenzthiazoline-6-sul-
fonic acid) (ABTS) (Li et al., 2008) or 3,30,5,50-tetramethylbenzidine sulfate (TMB) (Zhang et al., 
2011a).   H2O2-mediated oxidation catalyzed by DNAzyme region in the presence, in the first case, 
and the absence, in another case, hemin groups as cofactor. In the absence of target the G-
quadruplex DNAzyme catalyzed the H2O2-mediated oxidation of to generate a colorimetric signal, 
however titration of thrombin induced dissociation of the beacons, causing decrease in catalytic 
activity and color change. The product can be detected by UV–vis absorption spectrometry. Both 
assays enabled thrombin detection down to 20 nM concentration. Another approach based on 
H2O2-mediated oxidation of 3,30,5,50-tetramethylbenzidine sulfate involves platinum 
nanoparticles (PtNPs) in the presence of luminol to catalyze chemiluminescence signal (Gill et al., 
2006). Oxidation takes place upon assembly of aptamer/thrombin/aptamer-PtNP sandwich. 
Further, a peroxidase-mimicking Fe3O4 magnetic nanoparticles were used to catalyze the H2O2-
mediated oxidation of TMB for thrombin detection (Hu et al., 2013). For this purpose, Fe3O4 
nanoparticles were encapsulated within mesoporous silica and functionalized with aptamer. 
Without thrombin, H2O2 and TMB entered the silica layer and reacted with Fe3O4 nanoparticles, 
giving a strong absorbance signal. However, following the addition of thrombin, formed aptamer-
thrombin complex created a block layer outside the nonreactor, making it difficult for substrates 
to penetrate inside the nanoparticles. Characteristic absorbance signal decreased with increase of 
thrombin concentration achieving detection limit of 0.19 nM. Another aptamer-based 
colorimetric platform thrombin detection was developed, taking advantage of aptamer-
functionalized magnetic particles (MPs) for target capture, concentration and separation, and 
aptamer-conjugated gold nanoparticle (AuNP)-catalyzed color bleaching reaction of methyl 
orange (MO) to generate the colorimetric signals. This essay allowed detection of human 
thrombin with a detection limit of approximately 320 pM for naked eye observation, 30 pM with 
the help of a UV-vis instrument (Li et al., 2013).  
Metal complex [Ru(phen)2(dppz)]2+ was used in displacement assays  for the detection 
proteins including thrombin in sub-nanomolar range within buffer and serum (Jiang et al., 2004). 
This assay took advantage of the luminescence signal decrease due to the release of rutherium 
from thrombin RNA aptamer-bound state upon protein/aptamer binding. Easy and universally 
applicable colorimetric approach was described by using a cationic water-soluble polymer 
polythiophene (Ho and Leclerc, 2004). In the absence the cationic polymer binds to the 
negatively charged backbone of the aptamer. When thrombin aptamer folds into G-quadruplex 
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conformation upon thrombin binding, the polymer prefers wrapping around it, inducing 
colorimetric response, color change from red to orange, enabling detection as low as 2 x 10-15 mol 
of human thrombin. 
1.4.2.3 Other solid-phase optical methods 
Methods based on Surface Plasmon Resonance (SPR), Surface Enhances Resonance 
Scattering (SERS), wave guide resonators, enable thrombin detection through target interaction 
with surface-immobilized aptamer in one site or sandwich type format. These methods can be 
incorporated in fluidic systems for lab-on-chip applications.  
Surface plasmon resonance (SPR) spectroscopy, in combination with one-step direct 
binding, competition, and sandwiched formats, was applied to study thrombin binding to HD1 
and HD22 aptamers and showed linear increase in signal in the range 5-250 nM of thrombin 
(Tang et al., 2007). Surface plasmonic fiber devices using immobilized HD1 aptamer were 
demonstrated to detect thrombin from sub-pM to high nanomolar concentrations in one-site 
binding format (Allsop et al., 2010). Sensitivity of SPR might be further enhanced by introducing 
long-period fiber gratings (LPG) (Coelho et al., 2014). Another technique recently employed for 
the detection of protein on aptamer microarrays is Surface Plasmon Resonance Imaging, which 
has an advantage of SPR combined with micro arrays and optical detection allowing detection 
simultaneously several analytes through one site-binding or sandwich enzymatic amplification 
assay. As low as 0.5 pM thrombin was detected with RNA aptamers (Li et al., 2007). 
SERS aptasensors for thrombin detection relay on another interesting property of gold 
nanoparticles - Surface Enhanced Raman Scattering. HD1-AuNPs have been used in SERS for 
thrombin detection. Wang et al. developed a SERS sensor for thrombin recognition using Au NPs 
labeled with aptamer and Raman reporters (rhodamine 6G) (Wang et al., 2007). Biorecognition of 
as low as 0.5 nM thrombin concentration was achieved by assembly of gold substrate-
HD1/thrombin/HD22-AuNPs sandwich construct, which gave enhanced signal in the presence of 
silver particles. Recently, Cho et al. reported a surface enhanced resonance Raman scattering  
(SERRS) sensing mechanism based on thrombin induced displacement of Raman probe 
(methylene blue) modified HD1 from Au NPs (Cho et al., 2008a). The SERS signal decreased with 
increasing thrombin concentration over the range of 0.1 nM to 1 μM, with an LOD of 0.1 nM. In 
addition, the sensor allowed detection of 1 nM thrombin in the presence of 10% fetal calf serum. 
An optical microsphere resonator biosensor using immobilized HD1 aptamer to capture 
thrombin enabled detection of thrombin in one-site binding assay from 10 nM up to 5 μM 
concentration (Zhu et al., 2006). Recently micro ring resonator was shown to detect the capture 
of 0.5 nM thrombin by surface immobilized HD1 aptamer (Byeon and Bailey, 2011). Thrombin in 
the concentration range of 0.5–75 nM was detected using resonant mirror method (IAsys 
instrument (Neosensors Ltd., UK)) (Strehlitz et al., 2008). Thrombin sensing was realized in one-
site binding assay by HD1 aptamer bound to the surface of the cuvette.   
1.4.3 Electrochemical detection  
Electrochemical detection is of particular interest as it is simple, highly sensitive, 
compatible with novel microfabrication technologies and relatively low-cost. Electrochemical 
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detection concerns the recognition of a binding complex on conductive surfaces that induces to 
variations in the current, potential, resistance or capacitance of the solution-electrode interface, 
due to chemical reactions or redox indicators. These methods, including (volt)amperometric, 
impedimetric, potentiometric transducers or a combination require aptamer immobilization on 
the surface and in some approaches conjugation with enzymes, redox moieties or nanoparticles 
(Deng et al., 2014; Song et al., 2008). In general aptamers are immobilized on gold electrodes but 
the use of various nanomaterials and conductive films such as nanotubes (Porfireva et al., 2010), 
MWCNTs (Kara et al., 2010), Graphene-nanoparticles (Jiang et al., 2012), PAMAM dendrimers 
(Zhang et al., 2009), pyrolized surfaces (Lee et al., 2008), nano-Au/thionine multilayer film (Yuan 
et al., 2010) enhance the sensitivity of electrochemical detection for 2-3 orders, enabling sensing of 
thrombin in several pM concentration. Electrochemical signals are typically generated through 
three main mechanisms: (i) label-free (ii) with conjugated catalytic labels and (iii) altering the 
proximity of electrochemical labels to the electrodes (Song et al., 2008). 
For label-free detection, impedance is one of the most commonly reported transduction 
techniques for electrochemical aptasensors, as detection can be achieved simply following target 
binding, which changes the impedance. The transduction principle is mainly based on monitoring 
the electron-transfer of the electrochemical redox marker [Fe(CN)6]3-/4- , whose access to the 
surface and therefore electron transfer is impeded or enhanced, depending on the specific 
experimental set-up (Fig. 1.18 (A)). Detection of low nanomolar concentration of thrombin were 
reported in various studies (Cai et al., 2006; Castillo et al., 2012; Radi et al., 2005). The sensitivity 
of this format can be further enhanced for example by denaturing captured thrombin upon 
addition of  guanidine hydrochloride that causes and increases blocking effect against electron 
transfer, achieving detection limit of 10 fM (Xu et al., 2006). Similar detection limit was achieved 
using neutralizer displacement strategy (Das et al., 2012). A thrombin aptamer was tethered to the 
surface of an electrode and was hybridized with a neutralizer, composed of peptide DNA (PNA) 
and cationic amino acids. Upon binding to thrombin, the aptamer changed its structure and 
released the neutralizer, turning on the electrochemical signal (Fig. 1.18 (B)).   
FIGURE 1.18 Aptamer-based electrochemical assays for thrombin detection. The presence of thrombin 
sterically (A) shields or (B) enables electron transfer to electrode; (C) Secondary reporting aptamer, upon 
binding to captured thrombin in the sandwich format, catalyzes the chemical reaction; Thrombin binding turns 
(D) off or (E-F) on the electron transfer from the aptamer-bound electrochemical label.   
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The use of catalytic labels, including redox enzymes and nanoparticles, for thrombin 
detection, often requires a sandwich assay format to produce thrombin-specific signals. The first 
example of an electrochemical aptasensor was reported by Ikebukuro et al. who reported used a 
sandwich format to detect thrombin by chronoamperometry (Ikebukuro et al., 2004, 2005). HD1 
aptamer was immobilized a gold electrode to capture thrombin to which further HD29 aptamer 
bearing either enzyme–glucose dehydrogenase (GDHPc) or pyrroquinoline quinone glucose 
dehydrogenase ((PQQ)GDH) was bound. Electrical current change upon addition and 
consequent degradation of glucose correlated to the captured thrombin concentration, achieving 
a detection limit of 1 μM for GDHPc and 10 nM in the case of (PQQ)GDH. Similar approach, again 
sandwich format, employed HD22 aptamer now linked to horseradish peroxidase (HRP) as a 
catalytic label.  The HRP catalyzed the relay-mediated reduction of H2O2 (Fig. 1.18 (C)) , measured 
by amperometric signal allowed detection of thrombin of 80 nM (Mir et al., 2006). Recently, 0.1 
nM detection limit was achieved through DPV monitoring of enzymatic ascorbic acid oxidation 
by alkaline phosphatase, conjugated to HD22 reported aptamer via streptavidin-biotin linkage 
(Xu et al., 2013). Other option to improve the sensitivity is use of various nanomaterials have as 
more efficient catalytic labels. For example, use of PtNPs instead of enzymes to catalyze H2O2, 
allowed amplified detection of thrombin with detection limit of 1 nM (Polsky et al., 2006). 
Application of AuNPs, QDs and graphene oxides for amplified signals of voltammetric and 
impedimetric aptasensors achieving thrombin detection at sub-pM levels have been also 
described (Bai et al., 2012; Deng et al., 2009; He et al., 2007; Numnuam et al., 2008).  
Another type of electrochemical approaches takes advantage of aptamer flexibility and 
justified conformational changes that aptamers undergo upon binding to thrombin and involve 
signal transduction through alteration of electrochemical label positions. Electrochemical labels, 
such as ferrocene, methylene blue (MB) or methylene green (MG) are either attached at the end 
of the aptameric sequences or electrostatically confined to the aptamers backbone in various one-
site binding homogeneous assay formats (Evtugyn et al., 2008; Hianik et al., 2005; Radi and 
O’Sullivan, 2006). For example, a “switch-off” thrombin aptasensor was constructed by  
immobilizing a methylene blue labeled HD22 aptamer (Xiao et al., 2005a). In the absence of 
thrombin, the flexible conformation of the aptamer chain allowed electrical communication 
between MB and the electrode, generating a voltammetric response. But, upon binding to 
thrombin, aptamer assembled into a G-quadruplex structure, distancing and shielding methylene 
blue from electron-transfer communication with the electrode (Fig. 1.18 (D)). This assay enabled 
thrombin detection with limit of 20 nM. Another assay now in “switch-0n” format was reported 
(Sánchez et al., 2006). Thrombin aptamer folding into a G-quadruplex structure upon thrombin 
binding was exploited to bring in the proximity of the electrode ferrocene label, which was 
located too far from the electrode to facilitate the electron transfer in the absence of target (Fig. 
1.18 (E)). This assay allowed specific thrombin detection in the range of 1-30 nM. Similar “switch-
on” mechanism with LOD of 11 nM, was reported by Bang, who used a thrombin aptabeacon 
immobilized over the electrode surface with MB indicator, which was released upon binding with 
thrombin when the stem loop was opened, leading change position of redox label from the 
surface (Bang et al., 2005). Another "signal-on" mechanism with detection limit of 3 nM was 
achieved by electrode-immobilized HD1 that was hybridized with complementary probe labeled 
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with MB at the extremity (Xiao et al., 2005b). Upon thrombin injection aptamer dehybridized its 
complementary strand, granting flexibility to it and enabling interaction with methylene blue 
label and the electrode (Fig. 1.18 (F)). Based on the principle that molecular conductivity of DNA 
double helices depend on their conformational state, Huang and co-workers (Huang et al., 2008) 
developed an aptasensor for thrombin by incorporating a thrombin aptamer into a double-helical 
conduction path, formed by introducing three-way junction. Ferrocene electrochemical label was 
conjugated to the strand encompassing an aptamer sequence. The three-way junction structure 
prevented conduction between ferrocene and the electrode in the absence of thrombin, whereas 
after titration of thrombin altered conformation of junction, switched on conductivity and led to 
increased signal, allowing detection of picomolar concentration of thrombin in various samples, 
including diluted serum. 
1.4.4 Mass sensitive detection of thrombin 
Mass sensitive detection methods offer label-free detection of the target measuring mass 
change on the sensor surface. The main mass-sensitive aptasensors include acoustic wave-based 
sensors such as quartz crystal microbalance and Love-wave devices. These methods allow real-
time and flow through measurements, however the detection sensitivity is not as high as for 
above-described optical and electrochemical methods. 
The quartz crystal microbalance (QCM)-based piezoelectric biosensors register the 
changes in frequency of a quartz crystal resonator as a result variation of mass per unit area due 
to bioselective adsorption. In the first experiment with QCM method the capture of thrombin by 
immobilized HD1 aptamer, allowed detection of thrombin in the re range of 1-150 nM with nM 
sensitivity (Hianik et al., 2005). The sensitivity in the similar range was achieved with HD1 
immobilized piezoelectric sensor also for serum samples spiked with thrombin (Bini et al., 2007). 
The sensitivity of QCM for the detection of thrombin by HD1 aptamer was further improved using 
homogeneous sandwich approach with the same aptamer-conjugated gold nanoparticles (Pavlov 
et al., 2004). Due to the larger mass of the gold nanoparticles, the change in oscillation frequency 
was significantly larger than in previous case.  Similar approach, but now with heterogeneous 
sandwich format, in which gold-nanoparticle bound HD22 was allowed to interact with 
thrombin-HD1 complex on the surface of the crystal microbalance with dissipation monitoring 
(QCM-D). Conjugated nanoparticles enhanced not only the frequency change but also dissipation 
signals allowing thrombin detection in range of 10-150 nM (Chen et al., 2010).  
Love-wave sensors is a type of surface acoustic wave (SAW) sensor in which 
mechanically generated shear horizontal acoustic wave is guided in a layer on the surface of the 
sensor.  Love-wave sensors exhibit the highest sensitivity in mass sensitive methods working in 
aqueous solution. Microfluidic Love-sensor chips coated with HD1 aptamer (Schlensog et al., 
2004) or thrombin RNA aptamer (Gronewold et al., 2005) enabled thrombin detection in the 
range of 0.05-5 μM, which shows comparable sensitivity to QCM, however further improvements 
in sensitivity are still necessary to compete with other label-free techniques. Sandwich format 
with use of nanoparticle-conjugated secondary aptamer could be used to enhance the sensitivity. 
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1.4.5 Thrombin detection in real samples 
Here, we highlight two heterogeneous thrombin-detection approaches that could be used 
for thrombin detection as the clinical marker within serum.  
The first strategy is enzymatic electrochemical assay using sandwich approach to capture 
the target (Centi et al., 2007). Thrombin was first captured by HD1-coated magnetic beads, 
allowing magnetic separation for removing supernatant and washing steps. Thrombin-bound 
beads were then incubated with biotin-labeled HD22 solution, to assemble the ternary (HD1-
throbin-HD22) complex. Now this complex was allowed to conjugate with streptavidin-alkaline 
phosphatase through biotin label of HD22. After washing and re-suspension beads were 
transferred onto the surface of the screen-printed strip electrode. The localization of the beads 
was assured by the magnetic block placed on the bottom of the working electrode. Upon addition 
of enzymatic substrate (α-naphthyl phosphate) DPV signal was measured, allowing thrombin 
detection in concentration range of 0.1-100 nM. 
The second approach enabled thrombin detection directly blood sample via enzymatic 
cleavage of thrombin fluorogenic substrate (Müller et al., 2011). Blood sample was collected in 
tubes with anticoagulant citrate buffer and reversible thrombin active-site inhibitor argatroban to 
avoid coagulation and undesired inhibition of thrombin by endogenous inhibitors. Blood sample 
was transferred in microtiter modules containing immobilized HD1-HD22 dimer aptamer. After 
capturing thrombin by aptamer dimer wells were washed to remove plasma remains and 
reversibly bound argatroban. Subsequently, a thrombin-specific peptide substrate bearing a 
fluorogenic probe (H-D-CHA-Ala-Arg-AMC, 4) was added for quantitative determination of the 
captured active thrombin. This method achieved 1 pM detection limit. This approach is the first 
and only commercial aptamer-based thrombin quantification assay existing on the market 
(Oligobind, Sekiui Diagnostics).  
Despite their ingenious designs, both strategies, described in this section, require 
incubation, washing steps, and time for enzymatic reaction are therefore time-consuming and 
incompatible with real-time, continuous monitoring of thrombin concentration. 
1.4.6 Conclusions 
Thrombin-aptamer couple is mostly used as a model to demonstrate achievement in bio -
detection and sensing technology in general. Diversity and achieved detection range of the 
aptamer-base strategies for thrombin quantification is indeed fascinating, demonstrating that 
thrombin aptamers coupled with various materials and techniques are readily able to detect 
thrombin from low pM to several μM concentration. However mostly these assays use thrombin 
as a model for the proof of principle and neglect selectivity, specificity, sensitivity and accuracy of 
assay in real samples - parameters extremely important for using devise in clinical applications. 
Some assays are incompatibles with miniaturization, require laborious involvement of trained lab 
workers or time-consuming. Thus, the aim of developing the real-time aptasensor for detection of 
free circulating thrombin has not been yet achieved.  
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1.5 Objectives of the thesis 
As demonstrated, on one hand, there is a medical problem - the need of real-time 
monitoring of free circulating thrombin for improving patient care, avoiding development 
thromboembolic and hemorrhagic complications; and, on the other hand, there is a aptamer-
based nano(bio)technological field, that could respond to the above medical challenge. However, 
the fact that till now, despite such a vivid interest towards development of thrombin aptasensors, 
the goal of continuous free thrombin detection has not been yet achieved, indicates the 
complexity of the problem - thrombin detection in real conditions. To make technology meet 
these challenges and deliver the suitable product, together with the complicated sensor 
integration-related questions, some basic points, namely specificity and affinity of thrombin 
aptamers in real conditions, have to be made clear and considered when designing an aptasensor.  
Thus, the aim of this thesis is to investigate different solutions for the integration of 
thrombin-binding aptamers in point-of-care devices for continuous monitoring of thrombin in 
real-like environment. Namely we intend to take advantage of possibility to target two different 
binding sites of thrombin by HD1 or NU172 and HD22 and to explore the ways of their 
implementation in optical detection of thrombin.  
The likelihood of success in designing such sensor depends on how well the thrombin-
aptamer interaction is understood. On one hand, an assay design and consequently time needed 
for single measurement and sensitivity depend largely on kinetic parameters of thrombin-
aptamer binding reactions. On the other hand, sensor specificity depends of aptamer selectivity in 
real-like biological condition. For this reason, as the first objective we decided to evaluate 
thrombin aptamers by investigating aptamer interaction with thrombin and possible interfering 
species in simplified and complex mediums. Characterization of the thrombin-aptamer 
interaction by SPR method is described in the third chapter.  
Aptamer immobilization, as the necessary part of most sensors, especially reusable ones, 
represents as well one of the main challenges, since immobilization strategy strongly influences 
sensitivity, specificity, functionality and therefore reproducibility of the sensor. In addition 
sensitivity and detection regime is strongly influenced by the grafting density of the sensing 
element. The question regarding the optimal choice of aptamer immobilization strategy on the 
planar and nanomaterial surfaces is addressed in the fourth chapter. Aptamer-grafting strategies 
are evaluated according to complexity of immobilization and characterization procedures, 
aptamer grafting density and functionality. The fifth chapter concerns the controlled arrangement 
of aptamer-modified gold nanoparticles on the surface for the multi-optional sensing and signal 
transduction applications.  
The sixth chapter concerns the aggregation of aptamer-modified gold NP-s, as the 
approach for thrombin sensing and characterizing of aptamer functionality. 
Finally, the seventh chapter describes our intention of providing an efficient 
homogeneous sensing approach for improved thrombin detection in complex matrixes, by 
simultaneously increasing specificity, selectivity and affinity, and decreasing non-specific 
interactions. This format could be implemented for reusable thrombin detection in liquid phase 
or at the interface of the solid support.   
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CHAPTER 2. MATERIALS AND METHODS 
 
In this chapter are listed all the chemicals, reagents, computational methods and 
instruments used for the research described in the following chapters of this thesis. The 
theoretical background of the main experimental techniques employed in these studies is covered 
as well.  
2.1 Reagents and chemicals 
2.1.1 Chemicals 
NaCl, KCl, KH2PO4, K2HPO4, Na2HPO4, NaH2PO4, MgCl2, CaCl2, , Tris, HEPES, 
TEMED, DTT, EDAC, NHS, Gly, MES, Tween 20, Triton X-100, SDS, Ethanol, DMSO, HCl, H2SO4, 
HF, acetic acid, H2O2, Bromphenol blue all molecular biology grade, were purchased from Sigma-
Aldrich (France).  
2.1.2 Proteins:  
Purified human α-Thrombin (MW 36000 g/mol) (1500-3500 NIH units/mg), Heparin 
Cofactor II (MW 65600 g/mol) and α2-Macroglobulin (725ooo g/mol) from human plasma were 
obtained from Sigma-Aldrich (Schelldorf, Germany). Prothrombin (MW 72ooo g/mol), 
Antithrombin III (58,200 g/mol), FXa (44000g/mol) and were from STAGO (France). Molecular 
biology grade BSA (66500 g/mol) was purchased from New England BioLabs (USA). Unstained 
protein ladder for SDS PAGE with broad range standards (MW 6,500–200,000 g/mol) was 
obtained from BioRad (France). All lyophilized proteins were reconstituted in deionized ultrapure 
water following manufacturer’s instructions. Stock solutions were stored in small aliquots in 
freezer at temperature of -20 °C. For the experiment the aliquot was thawed at ambient 
temperature, ultrasonicated for few seconds and kept on ice to maintain their activity. The 
concentration of Thrombin and Antithombin III was determined by UV absorbance at 280 nm 
using molar extinction coefficients of 67000 L mol-1 cm-1 (Fenton et al., 1977) and 38000 L mol-1 
cm-1 respectively (Nordenman et al., 1977).  
Murine plasma was generously provided by Sanofi-Aventis R&D department Toulouse, 
France (Dr. Laurence Millet). 
2.1.3 Substrates and inhibitors: 
Reversible direct thrombin inhibitor Argatroban monohydrate (MW 508,635 g/mol) was 
obtained from Sigma. Direct FXa inhibitor Rivaroxaban (MW 435.882 g/mol) was supplied by 
Bayer Healthcare (Wuppertal, Germany). Thrombin chromogenic substrate S-2238 (H-D-Phe-Pip-
Arg-pNA-2HCl) (MW 625.6 g/mol) was purchased from Сhromogenix (Milan, Italy). Highly 
concentrated stock solutions (1 mM) were prepared by dissolving Thrombin and FXa inhibitors and 
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chromogenic substrate in 10% DMSO and distilled water mixture.  Stock solutions were stored at 
+4°C up to 6 month.  
2.1.4 Single stranded DNA:  
All single-stranded DNA sequences given in Table 2.1 were custom-synthetized by 
Eurogentec (Belgium). All sequences bearing biotin, thiol or amine groups at the 5’ terminus 
between the functional group and aptameric sequence 20 thymine spacer for flexibility was 
included. DNA samples were received in dry format. 0.5 mM concentration stock solutions in 
water were prepared and kept in aliquots at – 20 °C.  
2.1.5 Nanoparticles 
Carboxyl modified fluorescent beads of 100 nm diameter, with fluorescence maximum at 
532 nm wavelength were obtained from Banglabs. Colloidal solutions of gold nanoparticles 20 and 
80 nm size were obtained from BBInternational (United Kingdom).  
 
Table 2.1 ssDNA sequences 
Name Sequence  Application 
HD1ref 5’-biotion-20xT-GTT-TGT-TGT-TTG-TTG-3’ SPR 
HD1 5’-biotion-20xT-GGT-TGG-TGT-GGT-TGG-3’ 
HD2ref 5’-biotion-20xT-GAC-TGC-GTT-GCA-GGA-CGG-TTG-TTT-GAG-TC-3’ 
HD2 5’-biotion-20xT-AGT-CCG-TGG-TAG-GGC-AGG-TTG-GGG-TGA-CT-3’ 
NU172ref 5’-biotion-20xT-CGC-CAA-GGA-AGT-GAA-GAG-AGG-AGG-CG 
NU172 5’-biotion-20xT-CGC-CTA-GGT-TGG-GTA-GGG-TGG-TGG-CG 
HD1thiol 5’-SH-20xT-GGT-TGG-TGT-GGT-TGG-3’ Gold 
surface and 
AuNPs 
HD1’thiol 5’-SH-20xT-CCA-ACC-ACA-CCA-ACC-3’ 
HD2 thiol 5’-SH-20xT-AGT-CCG-TGG-TAG-GGC-AGG-TTG-GGG-TGA-CT-3’ 
Nu172 thiol 5’-SH-20xT-CGC-CTA-GGT-TGG-GTA-GGG-TGG-TGG-CG-3’ 
cssHD1 5’-CCA-ACC-ACA-CCA-ACC-3’ 
HD1 Alex532 5’- SH-20xT-GGT-TGG-TGT-GGT-TGG-Alex532-3’ 
HD1 
rhodG6 
5’-GGT-TGG-TGT-GGT-TGG-rhodG6-3’ 
HD1 amine 5’-NH3-20xT-GGT-TGG-TGT-GGT-TGG-3’ Polymer 
surface and 
particles 
HD22 
Amine 
5’-NH3-20xT-AGT-CCG-TGG-TAG-GGC-AGG-TTG-GGG-TGA-CT-3’ 
A amine 5’-NH3-20xT-GAC-TAC-TAC-TGA-CTA-CTG-3’ 
B amine 5’-NH3-20xT-CAG-TAG-TCA-GTA-GTA-GTC-3’ 
S1 5’–GGTTGGTGTGGTTGG-TTTT*T*ATTCGCGAAGAA*T*AAATTTT-
AGTCCGTGGTAGGGCAGGTTGGGGTGACT -3’ 
Aptadimer 
S2 5’- GGTTGGTGTGGTTGG -
TTTTTTTTCA*T*AAGATTTTTTTTTTTTTTTTC*T*TATGTTTTTTTT-
AGTCCGTGGTAGGGCAGGTTGGGGTGACT-3’ 
` 
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2.1.6 Buffers 
All the reagents for buffers were of analytical grade and obtained from Sigma. After 
preparation buffers were kept at +4 °C up to 1 month.  Prior to use, all buffers were filtered in 0.22 
µM filter and degased first by ultra-sonication and then by incubation under vacuum for 10 mins. 
The following buffers and solutions were used for different experiments: 
SPR experiment:  
- Immobilization buffer for biotinylated aptamers: HBS-EP from GE-Healthcare 
containing 10 mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% Surfactant P2;  
- Running buffer: phosphate buffered saline (PBS) pH 7.4 containing 10mM Phosphate, 
145 mM NaCl, 5 mM KCl , 1 mM MgCl2 and 1 mM CaCl2 as running buffer; NSBr –
nonspecific binding reducer- from GE Healthcare was added to running buffet for 
reduction nonspecific binding in some experiments with plasma; 
- Surface regeneration solutions: 2 M KCl and/or 1 M NaCl with 50 mM NaOH. 
SDS PAGE separation: 
- Loading buffer containing 2% w/v SDS, 2 mM DTT, 4% glycerol, 40 mM Tris-HCl, pH 
6.8, 0.01% w/v Bromophenolblue; 
- Running buffer composed of 25 mM Tris-HCl, 200 mM Glycine, 0.1% w/v SDS;  
- Stacking  gel with 0.125 M Tris-HCl pH 6.8, 0.1% w/v SDS, 3% w/v acrylamide,0.025% 
TEMED and AP;  
- Separating gel containing 0.375 M Tris-HCl pH 8.8, 0.1% w/v SDS, 10% w/v acrylamide, 
0.025% TEMED and AP; 
- Staining solution composed of 0.1% Coomassie Brilliant Blue R-250 in 40% alcohol, 
10% acetic acid;  
- Destaining water solution of 50% alcohol and 10% acetic acid. 
Chromogenic substrate cleavage assay: 
- Activation buffer: PBS-BSA of pH7.5  containing 10 mM Phosphate, 145 mM NaCl, 5 
mM KCl , 1 mM MgCl2, 1 mM CaCl2 and 0.1% BSA. 
Functionalization of Gold surface: 
- Thiol deprotection solution: 0.18 nM PB at pH 7.4 with 0.1 M DTT; 
- Grafting buffer: 0.01 nM PB at pH 7.4, 0.7 M NaCl and only for AuNPs 0.1% Tween 20; 
- Aggregation assay buffer: PBS pH 7.4 containing 10 mM Phosphate, 145 mM NaCl, 5 
mM KCl , 1 mM MgCl2 and 1 mM CaCl2. 
Functionalization of PS nanoparticles: 
- Particle washing buffer: 50 mM MES buffer of pH 4.5; 
- Coupling buffer: 500 μL 50 mM MES buffer of pH 6.2, containing 10 mM EDAC and 100 
mM NHS; 
- Capping buffer: 10 mM glycine buffer of pH 6; 
- Storing and aggregation buffer: PBS pH 7.4 containing 10 mM Phosphate, 145 mM 
NaCl, 5 mM KCl , 1 mM MgCl2 and 1 mM CaCl2. 
Aptadimer Fluorescence: PBS pH 7.4 containing 10 mM Phosphate, 145 mM NaCl, 5 mM 
KCl , 1 mM MgCl2 and 1 mM CaCl2 as running buffer.  
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2.2 Computational resources 
2.2.1  Molecular structures 
Molecular models of aptamers and proteins were reconstructed form crystallographic and 
NMR data obtained from Protein Data Bank (www.RSCB.org). We used following molecular 
structures: 
 
 
 
2.2.2 Visualization softwares 
For visualization molecular models in 3D and measuring the intermolecular distances we 
used PyMole molecular graphics system software (www.pymole.org, Schrodinger). 
For prediction of secondary structure of ssDNA, calculation melting temperatures, 
molecular weight, extinction coefficients online resources of Mfold (http://mfold.rna.albany.edu/) 
and oligoanalyzer (https://eu.idtdna.com/calc/analyzer) were used.  
For image analysis Image J software was used (http://imagej.nih.gov/). 
  
Table 2.2 Molecular structures used to build the molecular models 
Molecule Structure name Source 
Thrombin 3U69 (Figueiredo et al., 2012) 
Thrombin HD1 4DII (Russo Krauss et al., 2012) 
Thrombin HD22 4I7Y (Russo Krauss et al., 2013) 
Thrombin-HCII 1JMO (Baglin et al., 2002) 
Thrombin-ATIII 1TB6 (Li et al., 2004) 
Alpha-2-
macroglobulin 
4ACQ (Marrero et al., 2012) 
Prothrombin 
fragment1 
2PF2 (Soriano-Garcia et al., 1991) 
Prethrombin2 1HAG (Vijayalakshmi et al., 1994) 
Meizothrombin desF1 1AOH (Martin et al., 1997) 
` 
 
59 2.3.1 Surface plasmon resonance 
2.3  Experimental methods and instruments  
2.3.1 Surface plasmon resonance 
Surface plasmon resonance method is the bio-analytical technique that relies on an 
optical phenomenon of resonance of surface plasmons on the interface of the two optical 
mediums. It occurs when p-polarized light at a certain wavelength and angle is reflected off a thin 
metal film (a thin gold film coated on the sensor chip) under the condition of total internal 
reflection (TIR). The light excites surface plasmons in the metal at a certain incident angle, called 
resonance angle. Plasmons generate an evanescent wave in the metal film that extends hundreds 
of nanometers from the surface into the medium above. The excited surface plasmons are very 
sensitive to the refractive index change at the surface of the thin metal film. Thus when the 
refractive index of the surface changes the angle of incident light at which the resonance occurs 
also changes.  
In SPR biosensors, this refractive index change is brought about by binding of analyte in 
solution to ligand immobilized on the sensor surface. Tracking the change in the incident angle 
required for SPR allows one to monitor biomolecular interactions in real-time. Recent reviews 
(Daghestani and Day, 2010; Pattnaik, 2005) and dedicated webpage (Marquart and SPR-Pages, 
2014) offer an broader overview of SPR theory and different SPR configurations. 
The change of the incident angle required for SPR is defined as SPR signal in the unit of 
response unit (RU). Plotting the SPR signal over time during the interaction between an analyte 
and a ligand, results in a sensorgram - a visual representation of the interaction over time (Fig. 2.1 
(B)). When analyte is flowed over the sensor chip and starts association with the immobilized 
ligand SPR response increases until binding equilibrium is established and sensogram reaches 
plateau (Fig. 2.1 (A)). As soon as the analyte solution is replaced with buffer, formed analyte-
ligand complex dissociates and then the SPR response decreases (Fig. 2.1 (C)). Fitting the 
sensorgram data to a binding model allows for the calculation of the association (ka) and 
dissociation (kd) rate constants and determination of the binding affinity. Thus, SPR can provide 
a wide variety of important information on biomolecular interactions such as the specificity, 
affinity, qualitative ranking, kinetics, and thermodynamics of binding. In more details, the 
FIGURE 2.1  (A) The principle of the SPR sensor: binding of the analyte to the immobilized ligand induces 
changes in intensity of the light, reflected form the surface. (B ) The change between resonance angles 
represents the response to analyte binding called sensogram. (C) Response of sensogram increases during 
analyte-ligand association is constant at steady state and decreases in during complex dissociation. 
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calculation of kinetic constants with homogeneous and heterogeneous analyte models is 
discussed in chapter 3.  
In our studies SPR measurements were performed to characterize interaction between 
the thrombin aptamers and thrombin; and to investigate behavior of thrombin aptamers in the 
presence of nonspecific proteins. Measurements were carried out mostly on Biacore 3000 and 
Biacore T200 (GE Healthcare) machines using streptavidin-coated SA sensor chip for respective 
instruments (GE-Healthcare). The response signal provided by the SPR instrument is a direct 
measure of resonant angle. 1000 RU corresponds approximately to a surface concentration of 1 
ng/mm2 for an average protein ligand. 
The microfluidic pathways of both Biacore 
instruments contain a single sensor surface overlaid 
by four flow cells (Fig. 2.2) that allows using one or 
two flow cells functionalized with reference 
sequences as a true reference during a single sample 
injection (Biacore Handbook).  
 
2.3.2 Dynamic light scattering  
Dynamic light scattering (DLS) also referred as Quasi-Elastic Light Scattering (QELS) is a 
non-invasive, well-established technique for measuring the size and size distribution of 
molecules, micelles and particles typically in the submicron region dispersed in liquid.  
When the monochromatic laser light hits the particles or molecules in the suspension, 
due to their Brownian motion light gets scattered at different intensities. This scattered light then 
undergoes either constructive or destructive interference by the surrounding particles, and within 
this intensity fluctuation information about the time scale of movement of the scatterers is 
contained. The dynamic intensity data is then collected using an autocorrelator to determine the 
size distribution of particles or molecules in a sample. Autocorrelation analyzes the degree of 
similarity of signal intensity over a period of time. The rate of decay for the correlation function 
occurs in milliseconds and depends on the particle size. Smaller particles move more quickly 
through solution than larger particles. This means that the intensity signal for smaller particles 
should fluctuate more rapidly than for larger particles and as a result the correlation decreases at 
a faster rate as seen in the figure 2.3 (A,B).  
(A) 
(B) 
 
FIGURE 2.2 Flow cells on the SPR sensor chip 
functionalized with reference and aptameric 
sequences 
FIGURE 2.3  
(A) Intensity fluctuations 
of light scattered from 
larger and smaller 
particles. (B) Decay of 
correlation functions in 
case of small and large 
particles is compared to 
perfect correlation.  
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For a monodisperse particle system experiencing Brownian motion the correlation 
function G(t) decays exponentially with decay constant Γ: 
𝐺(𝑡) = 𝑒−𝛤𝑡 ( 2.1) 
The exponential decay is related to the velocity of Brownian motion of the particles, 
specifically to the diffusion coefficient D. 
𝛤 = 𝑞2𝐷 ( 2.2) 
Where q is the wave vector which depends on the 𝜆 wave length of the incident laser light, 
𝑛0 the optical index and 𝜃 the angle between the detector and the sample cell. 
𝑞 =
4𝜋𝑛0
𝜆
sin
𝜃
2
 ( 2.3) 
Hence the particle size can be calculated using the Stokes-Einstein relationship. 
𝐷 =
𝑘𝑇
6𝑟𝜋𝜂
 ( 2.4) 
Where k is Boltzmann constant, T is absolute temperature, 𝜂 is the viscosity of the 
solution and r is the hydrodynamic radius of the particle. 
In our study, DLS method was used to investigate the size of nanoparticles before and 
after DNA-functionalization steps. With periodical DLS measurement the hydrodynamic radius of 
the particles was monitored to observe the kinetics of the particle aggregation. DLS 
measurements were performed on Zetasizer Nano (Malvern Instruments). Samples placed in 100 
µL volume disposable plastic cuvettes were illuminated with 4mW HeNe laser (632 nm) and the 
scattered light was monitored with a detector positioned at the scattering angle of 173°. 
Instrument also allowed controlling the temperature of the sample through temperature-
controlled jacket for cuvette. The same instrument allowed measurement of the Zeta potential of 
the nanoparticles.  
2.3.3 Zeta potential 
Zeta potential is a measure of the 
magnitude of the electrostatic or charge repulsion 
or attraction between particles, and is one of the 
fundamental parameters known to affect stability. 
In solution the presence of the net charge on the 
surface of a particle affects the distribution of 
surrounding ions, causing accumulation of the 
counter-ions (Fig. 2.4). The region over which this 
influence extends is called the electrical double-
layer, composed of two separate areas. The area 
where ions attach strongly to the particle is called 
the Stern layer which is followed by the outer 
diffusive layer. When the particle starts moving 
under the influence of gravity or applied voltage, 
ions within the Stern layer and for some extent from diffusive layer will move with the particle. 
That “boundary” surface beyond which ions from diffusive layer do not move with particles is 
FIGURE 2.4 Schematic representation of the 
distribution of ions around a charged particle in 
solution. 
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called hydrodynamic shear of the slipping plane. The electrostatic potential that exists on the 
slipping surface is the zeta potential. When zeta potential of particles has large negative or 
positive values (40-60 mV), then particles repel each other 
and the suspension will be stable. 
To measure the zeta potential, typically electric 
field is applied to suspension (Fig. 2.5). Charged particles 
are attracted to the oppositely charged electrodes. From 
electrophoretic mobility (𝑈𝐸) of the particles, zeta 
potential (Z) can be determined through Henry equation: 
𝑈𝐸 = 2𝜀𝑍𝑓(𝐾𝑎)/3𝜂 ( 2.5) 
Where 𝜀 is a dielectric constant of medium, 𝜂 is 
viscosity and 𝑓(𝐾𝑎) is Henry’s function, with Ka being the ratio of particle radius to the double 
layer thickness (the Debye length). For systems with particles larger than 200 nm into high ionic 
strength solution, the zeta potential is calculated according to the Smoluchowski model, where 
and 𝑓(𝐾𝑎) = 1.5. For smaller particles with non-polar media Huckel approximation is used with 
𝑓(𝐾𝑎) = 1.  
In our study zeta potential measurements were performed on Zetasizer Nano in order 
characterize gold and polymer particle stability in water and buffer and the surface charge 
difference before and after functionalization steps.  
2.3.4 UV-Vis spectroscopy 
Ultraviolet–visible or just UV-Vis spectroscopy1 refers 
to absorption spectroscopy or reflectance spectroscopy 
that uses light the in the visible and adjacent, near-UV or 
near-infrared ranges. In UV-Vis region of the electromagnetic 
spectrum, molecules undergo electronic transitions from the 
ground state to the excited state. UV-Vis absorption 
spectroscopy observes transition of π-electrons or non-
bonding electrons from the ground state to higher anti-
bonding molecular orbitals (Fig. 2.6). The absorption or 
reflectance in the visible range directly affects the perceived 
color of the chemicals involved. 
Out of various applications UV-Vis spectroscopy is 
routinely used in analytical chemistry for the quantitative 
determination of different analytes in solution. Beer-Lambert 
Law establishes the connection between the absorbance (𝐴𝜆) of a chromophore at a given 
wavelength (𝜆) and its concentration (𝑐): the higher the concentration of the molecule, the 
greater its absorbance.  
                                                        
1
 Spectroscopy is general is the study of the interaction between matter and radiated energy. Spectroscopic 
data is represented as a plot of the response of interest as a function of wavelength or frequency, called a spectrum.  
FIGURE 2.5  Cuvette with electrodes for 
measuring Zeta potential. 
FIGURE 2.6 Possible electron jumps 
upon light absorption. Black arrows 
show energetically possible electron 
transitions by light in UV-Visible 
range. Red arrow show transitions 
requiring larger energy than UV-
Visible light can provide. 
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𝐴𝜆 = 𝑙𝑜𝑔10 (
𝐼0
𝐼
) = 𝜀𝜆𝑐𝐿 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     ( 2.6) 
𝐼0 is the intensity of the incident light at a given wavelength, 𝐼 is the transmitted 
intensity, 𝐿 is the path length through the sample, and 𝜀𝜆 is molar absorptivity or extinction 
coefficient of chemical species, representing fundamental molecular property in a given 
wavelength, solvent, at a particular temperature and pressure. To determine the concentration, 
ideally, wavelength corresponding to maximum absorbance is selected (Fig. 2.7). 
𝑐 =
𝐴𝜆𝑚𝑎𝑥
𝜀𝜆𝑚𝑎𝑥𝐿
 ( 2.7) 
For example the concentration of peptides and proteins is determined by measuring 
absorbance at the wavelength of 280 nm, whereas characteristic absorbance maximum for DNA is 
at 260 nm (Fig. 2.7 (B)). 
We used to UV-Vis absorption spectroscopy not only to measure the concentration but 
also to evaluate the size of gold nanoparticles in solution, since the maximum of the absorption 
depends on the size of the colloidal particles.  
By time-dependent measurements of UV-Vis absorption, we monitored the kinetics of the 
chromogenic substrate cleavage by thrombin. 
UV absorbance measurements in our case were performed with: (i) Nanodrop 2000C 
(Thermo Scientific), enabling measurement absorbance of a single sample both in cuvette and as 
μL volume drop (Fig.2.8 (A)); and (ii) Tecan Infinite® 200 PRO (Tecan, Switzerland), enabling 
reading absorbance of 96-well plates over time with regulated temperature (Fig. 2.8 (B)). 
(A) (B) 
 
FIGURE 2.8 UV-Vis Spectrophotometer (A)Nanodrop 2000C and (B) Tecan 200 PRO 
FIGURE 2.7 (A) When light passing through the sample gets absorbed, transmitted intensity 
is lower than the that of incident light. (B) Absorbance of increasing concentration of the 
DNA. Absorbance maximum is observed at 260 nm wavelength. The larger the concentration 
of the DNA in the sample the higher is absorbance 
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2.3.5 Fluorescence spectroscopy  
Fluorescence spectroscopy 
also known as spectrofluorometry is a 
type of electromagnetic spectroscopy 
which analyzes fluorescence i.e. the 
emission of the light from a substance 
that has absorbed light. Similar to 
UV-Vis absorption, fluorescence is 
based on the transition of outer 
electrons upon irradiation with 
ultraviolet and visible light. While 
absorption measures transitions from 
the ground state to the excited state, 
fluorescence deals with transitions 
from the excited state to the ground state. Thus the fluorophore is first excited, by absorbing a 
photon, from its ground electronic state to one of the various vibrational states in the excited 
electronic state, and then it relaxes to its ground state by emitting a photon (Fig.2.9 (A)). In most 
cases, the emitted light has a longer wavelength, and therefore lower energy, than the absorbed 
radiation (Fig. 2.9 (B)). 
Most fluorimeters have dual monochromators and a continuous excitation light source to 
record both an excitation spectrum and a fluorescence spectrum. In order to avoid interference 
with transmitted excitation light the fluorescence is mostly measured at a 90° angle relative to 
the excitation light. When measuring fluorescence spectra, the wavelength of the excitation light 
is kept constant, preferably at a wavelength of high absorption, and the emission monochromator 
scans the spectrum. For measuring excitation spectra, the wavelength passing though the 
emission filter or monochromator is kept constant and the excitation monochromator is 
scanning.  
The excitation spectrum generally is identical to the absorption spectrum as the 
fluorescence intensity is proportional to the absorption. But, unlike to UV/visible spectroscopy, 
attained fluorescence spectra are not “standard”, they depend on the device, i.e. there is inter-
device variation in the fluorescence intensity. 
For fluorescence measurements in our case were used: (i) Xenius XC (Safas, Monaco) 
and (ii) thermal cycler MyCycler (Biorad) allowing simultaneous measurement of several samples 
in multi-well plastic plate; and (iii) custom-maid fluorimeter from the imaging platform of IPBS-
CNRS and (iv) FLS980 fluorimeter (Edinburgh instruments) for the single sample measurement in 
quartz cuvette with high sensitivity. 
  
FIGURE 2.9  (A) Jablonski diagram of electronic levels. Purple 
arrow shows the transition from ground to excited state, green 
arrow demonstrates internal conversion and red arrow shows 
fluorescence emission. (B) Absorption (red) and emission (blue) 
spectrum of a fluorophore Alexa 532 . 
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2.3.6 FRET 
Fluorescence or Förster energy transfer (FRET) is a non-radiative mechanism of energy 
transfer between a donor fluorophore and acceptor molecule. The acceptor can be another 
fluorophore or a non-fluorescent molecule (Didenko, 2001). Through long–range dipole-dipole 
interactions an energetically excited donor, induces the raise of the energy state of the electron to 
higher vibrational levels in a nearby acceptor. As a result of resonant coupling, fluorescence of the 
donor decreases or quenches (Fig.2.10). Transferred energy can be emitted as red-shifted 
fluorescence if the acceptor is a fluorophore or as heat. Requirement for FRET pair is that the 
fluorescence emission spectrum of the donor must overlap the absorption spectrum of the 
acceptor.  
 
 
FIGURE 2.11 Spectral overlap of donor fluorescence 
spectra and acceptor absorbance spectra  
 
The effective energy transfer is dependent on the distance between the donor and the 
acceptor molecules R and the Förster Radius R0.  
𝐸 =
𝑅𝑜
6
(𝑅𝑜
6 + 𝑅6)
 Eq.  2.8 
Ro describes the distance between the donor and acceptor at which 50% of the excited 
state energy is transferred from the donor to the acceptor. Förster Radius depends on the 
quantum yield of the donor in the absence of the acceptor (𝑄0), the refractive index of a liquid 
medium (n), the relative orientation of the transition dipoles (𝑘2), and the spectral overlap 
integral (J) (Fig. 2.11).  
𝑅𝑜
6 = 8.8 × 10−28 × (𝑘2𝑛−4𝑄0𝐽) Eq.  2.9 
How to calculate the Ro for particular donor-acceptor couple is described here (Linnet, 
2012). Typically R0 is between 40 Å to 70 Å. The most sensitive range of the distance between the 
fluorophores R is 0.7–1.4 R0, corresponding to 90–10% FRET efficiency.  
Dependency of FRET efficiency on orientation and distance of the donor/acceptor couple 
can be exploited for the design of biosensors. FRET biosensors have been engineered to detect a 
broad range of molecular events such as, conformational changes upon protein - binding 
interactions.  
FIGURE 2.10 Jablonski diagram of FRET 
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2.3.7 The setup of convective assembly  
Experiments of convective assembly of nanoparticle were performed on the platform, 
developed at LAAS by Mike Genevieve during his PhD work. The setup is schematically shown on 
figure 2.12 and more detailed description is available in the thesis (Geneviève, 2009). 
The central part of the instrument is the motorized translation stage (7) on top which a 
beforehand cleansed and treated solid substrate (3) is fixed. Drop (1) of colloidal solution (50 uL) 
is between moving substrate and a glass slide fixed (2) above at a distance of 0.5-1 mm from the 
surface. Moving of solid support with optimal velocity induces dragging of the meniscus, formed 
on the interface of air/liquid, and thus spreads colloid solution over the surface as a thin film. 
In order to control the evaporation rate, a solid substrate is fixed on top of the copper 
plate (4) under which a Peltier element (5) is located. The Peltier is regulated with the circulating 
liquid (6) passing through the radiator (12), the temperature of which is adjusted with manual 
regulator (13).  It gives possibility to set an experimental temperature from +5 °C to 55 °C with 
accuracy of ±0.002 °C and stability of   ±0.004 °C.  
The entire setup of sample holder with temperature controller is mounted on motorized 
stage (7). Various adjustable handles (screws) (8,9,19) allow precise positioning of sample 
FIGURE 2.12 Experimental platform for convective assembly. Drop of colloid (1), glass slide (2), solid support (3), 
copper platform (4), Peltier element (5), cooler (6), motorized stage (7), adjustment handles (8,9) positioning 
platforms (10,11), radiator (12), temperature regulator (13), glass slide holder(14), platform (15), anti-vibration 
table (16), pneumonic feet (17) Thermometer and hygrometer (18), optical microscope coupled with CCD camera 
(19) 
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platform. Movement of the stage is controlled with software, allowing displacement with 
velocities in a range of 0.1-1000 um/s. The second stage (stationary) is responsible for fine-tuning 
the glass slide and its holder (14) at desired distance and angle from substrate surface 
To avoid and exclude the influence of external vibrations and noise on the experiment, the 
instrument is placed on the special anti-vibration table for optics (16), standing on pneumatic feet 
(17).  
An optical microscope coupled with CCD camera (19) is set on top of the sample to 
provide direct observation of the assembly process. Humidity and room temperature (18) are 
measured in the course of the deposition as the external and important parameters of the 
experiment.  
 
2.3.8 Measurement of Contact angle 
We accessed the surface tension of a liquid by measuring the contact angle between a 
liquid and a surface with Digidrop.  
We used an optical instrument based on reflected microscopy with computer-assisted 
shape recognition. A drop of liquid deposited on a desired support, is detected by CCD camera 
and the treated by software (Fig. 2.13 (A)). If the angle is large then the surface is hydrophobic 
(Fig. 2.13 (B)), if the angel is small then the surface is hydrophilic (Fig. 2.13 (C)). This method 
allows measuring a contact angle with accuracy of 0.1°. 
  
FIGURE 2.13 (A) schematic illustration of the setup for contact angle measurements. Images of 
the water drop on hydrophobic (B) and hydrophilic surfaces (C).  
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2.3.9 Scanning Electron Microscopy 
A scanning electron microscope (SEM) is a type of 
electron microscope that gives the information about surface 
topography and composition of the sample by scanning the 
sample with the focused beam of electrons. Specific detectors 
record backscattered electrons, secondary electrons and X-rays 
reemitted upon electron-matter interaction. The backscattered 
electrons reveal the topography of the sample surface with the 
resolution 1 to 20 nm, the secondary electrons give the chemical 
contrast, whereas X-rays bear the information about the 
chemical composition. Magnification in a SEM can be 
controlled over a range of up to 6 orders of magnitude from 
about 10 to 500,000 times. 
In a typical SEM, an electron beam is thermionically 
emitted from an electron gun fitted with a tungsten filament 
cathode. Electrons are accelerated with electric field to energy 
level of 0.1-30 keV and focused by passing through magnetic 
lenses, before they interact with a sample to be studied (Fig. 
2.14). Samples generally are mounted rigidly on a specimen holder called inside a vacuum 
chamber. For the most instruments, specimens must be electrically conductive, at least at the 
surface, and electrically grounded to prevent the accumulation of electrostatic charge at the 
surface (AMMRF).  
In our studies all SEM imaging of convectively assembled particles were performed with 
the field Emission Scanning Electron Microscope Hitachi-S4800. This instrument with maximal 
resolution of 1nm equipped with both secondary electron and backscattering electron detectors. 
The samples were on silicon wafer, which represents a conducting surface.  
 
  
FIGURE 2.14 Illustration of the 
SEM instrument 
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CHAPTER 3. THROMBIN INTERACTION WITH APTAMERS  
3.1 Introduction  
Biomolecular recognition is central to biosensing (Chambers et al., 2008), since it governs  
specificity, sensitivity and time of analyte detection. These three parameters represent the most 
important requirements of biosensor (Foulds and Lowe, 1985). Therefore during sensor 
development the first and the most important step is to understand well the process and 
mechanism how the sensing element, in our case aptamer, recognizes and interacts with its 
molecular target - thrombin.  
Indeed thrombin aptamers HD1 and HD22 have been the most studied aptamers as they 
not only satisfy aptameric requirements (affinity and specificity) but also show their effect on 
modulation of coagulation process (Bock et al., 1992; Kretz et al., 2006; Tasset et al., 1997). These 
qualities make them interesting candidates both as the anticoagulant for therapeutic applications, 
and as sensing elements, in affinity biosensing. Truly, over the past two decades, significant 
research effort has explored the properties and emerging applications of these aptamer resulting 
in more than 1000 publications (Deng et al., 2014). However, thrombin-aptamer couple is mostly 
used as a model system to demonstrate achievement in bio -detection and sensing technology in 
general. Such approaches do not require comprehension the problematics of thrombin detection 
in reality and consequently they do not push the existing boundaries of understanding thrombin 
–aptamer interactions. The complexity of thrombin detection in real environment remains 
underestimated and therefore under-investigated Hence when it comes to an actual problem of 
developing aptamer–based sensor for substantial purposes i.e. thrombin detection in real-like 
conditions, we are still confronted with unanswered questions of feasibility of such sensor. 
In this chapter we desire to identify the key points of the thrombin-aptamer interactions, 
which are essential for sensor development but remain still untacked, and to try finding 
exhaustive answers about specificity and sensitivity of thrombin detection in real-like 
environment.  
To understand the complexity of the problem, first, let us have an overview what is known 
about the molecular structure of thrombin, its activation and interactions with substrates and 
aptamers. 
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3.1.1 Activation of prothrombin into thrombin 
Thrombin in is the activated form of zymogen prothrombin. Mature prothrombin is 
glycoprotein with 579 amino acids and arranged in four domains: Gla domain, two adjacent 
Kringle domains and catalytic domain with A and B chains (Fig. 3.1). Prothrombin is 
proteolytically activated to by factor Xa or by the prothrombinase complex consisting of factor 
Xa and Va. Prothrombin is cleaved, first at R320 (located between the A and B chains) to 
generate meizothrombin and then at R271 (located between the A chain and Kringle 2) to 
generate thrombin and fragment F1+2. Although kinetically less favored, an alternative activation 
pathway is also possible (Lane et al., 2005). 
As a result of activation α-thrombin represents only the half of the prothrombin molecule 
(36 kDa and 72 kDa respectively) since it lost the domains important for initial recognition 
interactions and was left with two polypeptide chains A and B. This loss permits exposure of 
cryptic functional regions, which were well hidden within prothrombin and now play crucial role 
for extending the range and specificity of thrombin’s actions (Crawley et al., 2007). 
3.1.2 Thrombin structure and interactions 
As we showed in the first chapter thrombin is involved in more than dozen paradoxically 
opposite reactions. These multiple interactions, in which thrombin participates, raise the 
question of how it knows which substrate it should interact with and cleave. The question how 
thrombin realizes recognition and interaction with these multiple biomolecules, can be addressed 
only by considering how the activity of thrombin is controlled by its structure.  
Thus, thrombin is composed of two polypeptide chains A and B. The light chain A 
consisting of 36 residues is linked by a single disulfide bond to the heavy chain B with 259 
residues that contains three intra-chain disulfide bonds (Siller-Matula et al., 2011). The B chain is 
FIGURE 3.1. Activation of prothrombin. Molecular model reconstructed by superposition of crystal structures 
of prothrombin fragment1 (2PF2), prethrombin2 (1HAG), Meizothrombin desF1(1AOH). Upon prothrombin 
cleavage at Arg271 prothrombin Fragment 1.2 is realized and cleavage at Arg320 creates mature thrombin. 
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shaped like a sponge, with deep crevices and large protuberances on its water-accessible surface, 
hosting the entrance to the active site and all functional epitopes of the enzyme. The active-site, 
containing serine residue S195 involved in the nucleophilic attack of the target peptide bond, is 
located in a deep canyon formed by the flanking hydrophobic 60-insertion and hydrophilic γ-
loops (Di Cera, 2003).  
 
 
  
The wealth of thrombin interactions depends on a rich repertoire of mechanisms 
underlying substrate recognition (Di Cera, 2003). For establishing these interactions thrombin 
also has two anion-binding exosites (I and II), made up of clusters of surface- exposed basic 
residues. These charged patches interact with negatively-charged regions of thrombin cofactors 
and substrates. Occupancy of exosites I and II may induce allosteric changes to the active site to 
promote catalysis (Bode, 2006). 
Exosite I is located “east” of the active site (Fig 3.2). It contains hydrophobic patches 
and charged residues K36, H71, R73, R75, Y76, R77a, and K109/110 and acts as steering for active 
site substrates such as fibrinogen, fibrin, PAR-1, PAR-3, PAR-4, thrombomodulin, heparin cofactor 
II, factors V, VIII, XI and XIII (Fig. 3.3).  
Exosite II is positioned “west” of the active site (Fig 3.2). It is also centered on charged 
residues R93, K236, K240, R101, and R233, but unlike exosite I, exosite II has no hydrophobic 
patches on its surface. Exosite II is the local for docking antithrombin III, PAR-1, factors V, VIII 
and XI, protein C and TAFI (Fig. 3.3) through interaction with polyanionic ligands 
glycosaminoglycan cofactors and carbohydrates such as heparin, GpIbα and chondroitin sulphate 
(CS) (Bode, 2006).  
Another important loop contains a site for Na+ binding The binding of a sodium ion 
modulates thrombin allosterically and regulates procoagulant and anticoagulant activities (Di 
Cera, 2003). 
FIGURE 3.3  Schematic interaction of thrombin 
(represented as large ellipsoid) and its different 
surface regions binding substrates, inhibitors, 
carbohydrates and cofactors. Adapted from (Bode, 
2006).  
FIGURE 3.2 Solid Connolly surface representation 
of human α-thrombin in covalent complex with 
PPACK. Thrombin is colored according to the 
electrostatic surface potential (red:negative; blue: 
positive). Reprinted from (Bode, 2006). 
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3.1.3 Binding of thrombin aptamers to thrombin 
3.1.3.1 Molecular structure ofHD1 
HD1 aptamer is known to interact with exosite I of thrombin. Despite ambiguities in 
previous X-ray and NMR models (Macaya et al., 1995; Padmanabhan and Tulinsky, 1996 of HD1, 
recent study finally confirmed that HD1 folds into a stable unimolecular antiparallel quadruplex 
structure containing two G-quartets spaced by two TT loops and a TGT referred as chair-like 
structure(Russo Krauss et al., 2012). In the structure of HD1, G1, G6, G10 and G15 form the top 
layer of G-tetrad; G2, G5, G11 and G14 form the second layer. Potassium ion fits the cavity between 
the two G-tetrad planes of HD1 properly and coordinately interacts with eight oxygen atoms in G-
quadruplex. K+ cations stabilize quadruplex conformation of HD1 and improve the thermal 
stability (Kankia and Marky, 2001).  
HD1 interacts with thrombin exosite I through 
TT loops acting as a pincer-like system (Fig. 3.4). T4 
and T13 are mainly involved in polar interactions 
whereas T3 and T12 form hydrophobic contacts. The 
amino residues His71, Arg75, Tyr76, Arg77, Asn78, 
Ile79, Tyr117 in the exosite I of thrombin are involved 
in the interaction with HD1. Since the aptamer 
sequence is palindromic, two almost identical binding 
regimes where observed, they differ from each other by 
180° rotation with respect to thrombin, the only 
significant difference is confined to the orientation of 
the TGT loop Russo Krauss et al., 2012). 
In addition, there is also an evidence that TGT 
loop might interact with certain amino residues of exosite II (Padmanabhan and Tulinsky, 1996; 
Pagano et al., 2008; Russo Krauss et al., 2011)  
3.1.3.2 Molecular structure of HD22 
The structure of aptamer HD22 was solved only recently with a 2.4 Å resolution (Russo 
Krauss et al., 2013). Unlike HD1, HD22 has a duplex/G-quadruplex mixed structure (Fig. 3.4). The 
nucleotides 1-3 and 25-27 with an additional C4-G23 form a duplex motif, and the sequence 
ranging from G5 to G20 folds into a G-quadruplex structure with four connection loops: T9-A10, 
T18-T19, G13-C14-A15 and an one-nucleotide loop (T6). In G-quadruplex motif, two G-tetrad 
planes are formed by G5-G7-G12-G16 and G8-G11-G17-G20. There is a 90-degree turn between the 
G-quadruplex and duplex motifs (Russo Krauss et al., 2013).  
HD22 interacts with the exosite II of thrombin via the nucleotides G23, T24, G25, A26, C27 
in the duplex and T9, T18, T19, G20 in G-quadruplex. On thrombin side, the residues Tyr89, His91, 
Pro92, Arg93, Tyr94, Asn95, Trp96, Arg97, Arg126, Leu130, Arg165, Lys169, His230, Arg233, Trp237, 
Val241 and Phe245 take part in the interaction. Since the exosite II is positively charged, motifs of 
exosite II create ion pairs with the HD22 backbone, mostly in the duplex region. Formed complex 
is stabilized by hydrophobic interactions observed in the G-quadruplex region (T9, T18 and T10). 
FIGURE 3.4 Molecular structures of thrombin 
complex with HD1 (4DII) and HD22 (4I7Y) 
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3.1.4 Kinetic parameters of thrombin-aptamer interactions 
Several fundamental studies were carried out to get an answer about the affinity of 
aptamers to thrombin with different surface and volume-based techniques such as SPR, QCM 
summarized it the table 3.1 and 3.2 respectively for HD1 and HD22.The variation between reported 
values is significant not only for inter methods but also intra. Obviously, it is difficult to say which 
of these values are true for that particular conditions in which we would like to work. 
  
Table 3.1 Reaction and affinity constants of HD1 aptamer interaction with  thrombin 
known from the literature determined with various methods 
Complex Method kon 
10
6 
M-1s-1 
koff 
10
-3 
s-1 
Kd 
10
-9 
M 
Source 
 
HD1-
Thrombin 
exosite 1 
SPR 1.3 1.80 1.38 (Davis, 1994) 
0.290 1.80 6.2 (Davis 1994) 
0.19  3.83 20.2 (Hasegawa et al., 2008) 
0.66 4.7 7.1 (Müller et al., 2008) 
0.52 89 171 (Lin et al., 2011) 
0.023 9.54 421 (Pinto, 2012) 
- - 102.6 (Pasternak et al., 2011) 
RIfS 0.075 3.38 45.4 (Goji and Matsui, 2011) 
IAsys - - 11.06 (Strehlitz et al., 2008) 
labeling - - 10-25 (Macaya et al. 1995) 
fluorescence - - 34 (Kretz et al., 2006) 
 
 
Table 3.2 Reaction and affinity constants of HD22 aptamer interaction with thrombin 
known from the literature determined with various methods 
Complex Method kon 
10
6 
M-1s-1 
koff 
10
-3 
s-1 
Kd 
10
-9 
M 
Source 
 
HD22-
thrombin 
exosite2 
SPR 0.44 1.54 3.5 (Hasegawa et al., 2008) 
0.35 0.82 2.4 (Müller et al., 2008) 
0.58 2.86 4.91 (Pinto, 2012) 
0.84 92 110 (Lin et al., 2011) 
QCM 97 86000 88 (Hianik et al., 2007) 
ITC - - 94 (Nallagatla et al., 2009) 
fluorescence - - 29 (Kretz et al., 2006) 
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3.1.5 “Million-dollar questions“ 
Based on what is known, below are listed the key questions, on our opinion, requiring to 
be answered, before considering construction of aptamer-based thrombin sensor. 
3.1.5.1 Sensitivity 
Sensitivity of detection depends great deal on the properties of molecular interaction 
between thrombin and aptamer. Namely it depends not only on affinity, but also on rate contents, 
characterizing how quickly complex is formed and how strong is the interaction. As we saw in 
previous paragraph, only the range of the thrombin-aptamer affinity constant is known. But what 
are the rate-constants in the experimental conditions that we intend to use? Even more 
interesting, is to know interaction character of aptamers with thrombin not only in simplified 
condition, but also in real-like environment. 
3.1.5.2 Specificity 
On one hand, sensing elements, aptamers, when selected by SELEX, are the most specific 
and affine of all the other nucleotide strands in the library, meaning that they bind their target 
the best. Therefore they should guarantee selective and sensitive detection of the target. However 
in real conditions like a plasma or blood, in the presence of my many other biomolecules, initial 
target may not be the only fitting partner for aptamer and in this case specificity of detection is 
compromised. Cross-reactivity with other targets might often be one of the biggest drawbacks. 
Thus the behavior of the aptamers in the real-like conditions, need to be investigated.  
On the other hand, target, depending of the function, might be interacting with wide 
array of molecules that can also complicate accurate detection. In this respect, thrombin is indeed 
a very tricky target. Thrombin is the multidomain protease, generated by proteolyctical activation 
of coenzyme prothrombin, to which it bares structural similarities. Thrombin is actively involved 
in diverse physiological processes and therefore it recognizes and interacts with multiple 
substrates (Di Cera, 2003). Therefore specify of the detection is highly depended on behavior of 
aptamers. 
The first most important question concerns interaction of aptamers with prothrombin, 
the precursor of thrombin that is present in the blood with micromolar concentration. It is 
known, to be recognized by HD1, and interaction is characterized with affinity comparable to 
thrombin (Kretz et al., 2006; Müller et al., 2008). But only little is known for prothrombin 
interaction with HD22. Even more, it is interesting whether there is the difference in the 
signatures of thrombin and prothrombin binding to HD1.  
Thrombin, regulating numerous reactions is on its own regulated by inhibitors, hence 
when considering real environment we have to take in account that thrombin might be in 
complex with the regulated or regulating molecules. Therefore the second question concerns the 
ability of aptamers to discriminate between free and thrombin complexes. Of particular interests 
are thrombin complexes with its natural inhibitors ATIII, HCII and A2M, since ultimately all 
thrombin gets irreversibly inhibited and cleared form the circulation by them (Siller-Matula et al., 
2011). 
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3.1.6 Objectives of this study 
Thus, in this work we want to address these above-mentioned questions and answer them 
with surface plasmon resonance method. SPR method is not only sensitive method, which gives 
us possibility to simultaneously measure association and dissociation rate constants and thus 
access the affinity, but it also represents an example of the surface based affinity sensors, that can 
give us insight of strong and weak points of using such method when designing a sensor.  
The aim is to start with the simple conditions, i.e. to perform kinetic experiments of 
thrombin and prothrombin interactions with aptamers; then characterize interaction of aptamers 
with thrombin-inhibitor complexes and nonspecific proteins; and finally go towards more 
complex case where thrombin instead of buffer will be in diluted plasma. This approach is 
expected to elucidate which reactions and at which step could be limiting thrombin detection by 
the aptamers. 
We also want to investigate aptamer NU172, that, similarly to HD1 is known to interact 
with the exosite I with nan0molar affinity (Mayer et al., 2011), however characterization of 
association and dissociation rate constants neither for thrombin nor prothrombin hasn’t been 
reported.  
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3.2 Experimental 
3.2.1  SPR experiments 
3.2.1.1 Immobilization of thrombin-binding aptamers on the surface of SPR sensor chip 
For the aptamer immobilization, a single step attachment approach was chosen. For this 
reason aptamers had biotin-modified 5’ end and sensor chip SA was functionalized with 
streptavidin. To avoid steric hindrances, aptamers contained a 20-Thymine spacer between the 
biotinylated end and the aptameric sequences.  
The sensor chip allowed working with four flow-cells, i.e. we could use four patches for 
aptamer immobilization. On the first two patches we immobilized one of the aptamers and 
corresponding scrambled aptamer sequence1. Another aptamer and its scrambled sequence were 
immobilized on the remaining patches. Each DNA was immobilized at a separate step. It should 
be noted, that in all measurements HD1 and HD22 where examined together on the same sensor 
chip, whereas for NU172 similar experiments were performed on the separate sensor surface, 
having also HD22 immobilized to ensure the similarity between the experiments  
Before immobilization of biotinylated aptamers on SA senor chip, the surface of the chip 
was primed with HBS-EP buffer and rinsed by 3 consecutive 1 minute-long injections of 1 M NaCl 
and 50 mM NaOH solution at rate of 30 µl/min.  
For kinetic analysis low surface density of a ligand has crucial importance. In 
general, for kinetic measurements, when the analyte is injected, a total analyte response of 
maximal 100 RU is desired. The amount of ligand (in response units) to be immobilized, 
corresponding to desired maximal response, can be calculated by following relationship: 
𝑅𝑙𝑖𝑔𝑎𝑛𝑑 =
𝑅𝑚𝑎𝑥 × 𝑀𝑟𝑙𝑖𝑔𝑎𝑛𝑑
𝑀𝑟𝑎𝑛𝑎𝑙𝑦𝑡𝑒 × 𝑉𝑎𝑙𝑒𝑛𝑐𝑦𝑙𝑖𝑔𝑎𝑛𝑑
 (𝑅. 𝑈. ) (3.1) 
Of course, there is the linear relation between response and amount of ligand 
immobilized to the sensor surface and the theoretical number of ligand sites after immobilization 
can be calculated with following equation: 
𝑙𝑖𝑔𝑎𝑛𝑑𝑠𝑖𝑡𝑒𝑠 =
𝑅𝑙𝑖𝑔𝑎𝑛𝑑
𝑀𝑟𝑙𝑖𝑔𝑎𝑛𝑑 × 𝑉𝑎𝑙𝑒𝑛𝑐𝑦𝑙𝑖𝑔𝑎𝑛𝑑
 (𝑝𝑚𝑜𝑙 × 𝑚𝑚2) (3.2) 
Thus, for the kinetic experiments, over the clean sensor chip surface solution of 10 nM 
aptamer in HBS-EP buffer was flown at a rate of 30 µl/min. A 12 sec long ligand injection was 
sufficient to obtain immobilization level of 40±5 RU.  
In the case of interaction analysis, where the obtained result has more qualitative 
(yes/no) character, higher surface density of ligand is better. For this reason, aptamer solution 
was injected longer (about 2 minutes) until 500±50 RU response was achieved.  
  
                                                        
1
 Scrambled aptamers were used as the reference for nonspecific interactions, the impact of which was then 
subtracted from the response of the corresponding aptamers. Scrambled aptamers have the same length as the 
corresponding aptamers but their sequence is highly altered. (See chapter 2 for the sequences).  
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3.2.1.2 Protein interaction with aptamers 
In typical SPR experiments proteins (thrombin, prothrombin, BSA, and 100 fold diluted 
plasma) in PBS running buffer were injected into the system allowing interaction with surface-
immobilized aptamers for 3 minutes at a constant flow rate of 30 µl/min and constant 
temperature of 25 °C. Association phase was followed with running buffer injection for 120-180 
seconds to allow complex dissociation. After each injection, surface was regenerated with 30 sec 
pulse of 2 M KCl and let stabilize for 120 seconds. Kinetic experiments were made in duplicate. 
In order to get insight into the kinetics of thrombin interaction with the aptamers set 
of physiologically relevant concentrations of proteins ranging from 0.78 nM to 50 nM was used. In 
the case of prothrombin, two kinetic experiments in the same concentration range as for 
thrombin were performed in the presence and absence of argatroban - thrombin active site 
blocking agent. As argatroban is a reversible thrombin inhibitor, final concentration of 50 µM was 
used to keep the active site of thrombin continuously blocked.  
Whether or not the presence of thrombin can be detected in abundance of 
prothrombin, was investigated by injecting mixture of various proportions of thrombin and 
prothrombin keeping total protein concentration equal to 50 nM (50 nM thrombin, 40/10 
thrombin/prothrombin, 30/20 thrombin/prothrombin, 20/30 thrombin/prothrombin, 10/40 
thrombin/prothrombin, 50 nM prothrombin ). 
To verify aptamer specificity kinetic experiments were also performed with 12.5 nM- 3.2 
µM BSA, the most abundant plasma protein, and thrombin complexes with its natural inhibitors 
ATIII, HCII and A2M in various stoichiometric ratios (thrombin concentration 12.5 nM, inhibitor 
concentration 12.5, 50, 200, 800 nM). 
Behavior of thrombin natural inhibitors ATIII and HCII in the presence of aptamer 
bound thrombin was studied by injecting (coinject mode) increasing (12,5; 50; 200; 800; 1500 nM ) 
concentrations of inhibitors right after association phase of thrombin in mass transport limited 
conditions, (with high surface density of aptamers 500±50 RU) 
Aptamer specificity towards thrombin in real-like conditions was investigated by 
injecting thrombin concentrations in 100 and 10 times diluted murine plasma. Murine plasma 
prior to use was centrifuged at 14000 rpm for 5 minutes; supernatant was collected and filtered in 
0.22 µM filter. Plasma then was diluted either 10 or 100 times in PBS containing 0, 1 or 10 mg/mL 
nonspecific binding reducer (NSBr). 
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3.2.2 SDS PAGE separation 
In order to elucidate the composition of prothrombin sample, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) was carried out according to the method of 
Laemmli (Laemmli, 1970). Briefly, in assembled glass cassette for electrophoresis freshly prepared 
separating gel was poured and let to reticulate for 20-30 minutes. Over the separating gel well-
forming comb was placed and fresh stacking gel was injected. Stacking gel was allowed to gelate 
for 30 minutes. Meanwhile, 20 µL prothrombin of 8 µM concentration was mixed with loading 
buffer and incubated for 5 minutes in boiling water bath to facilitate protein denaturation. 
Protein sample was loaded into solidified acrylamide wells. Molecular weight size marker of 
known molecular weight was placed in a separate lane in the gel. Acrylamide cassette was placed 
in electrode chamber with and all together in the tank with Tris running buffer. 100 V of 20 mA 
constant current was applied to separate proteins for 2 hours until bromophenol blue marker 
reached bottom of the gel. After the completion of the electrophoresis, the gel was fixed with 10% 
trichloroacetic acid for 5 minutes. For visualization of the separated proteins gel was incubated 
with staining solution of CBB till the appearance of clear bands on the gel (1 hour). Gel was 
diffusion-destained by repeated washing in destaining solution. Intensity of SDS bands was 
analyzed with image J software. 
3.2.3 Chromogenic substrate cleavage assay 
The presence of thrombin and its activity can be monitored by hydrolysis of chromogenic 
substrate that upon cleavage starts to absorb the light. In all of our experiments kinetics of 
cleavage of 83 µM concentration chromogenic substrate S2238 was monitored by measuring 
absorbance at 405 nm. Samples of 100 µL final volumes were prepared in duplicates and placed in 
96 plates for absorbance measurement. Thrombin and FXa where pipetted the last in order to 
avoid missing the begging of the activation. All assays were performed with PBS-BSA activation 
buffer at 20°C, cleavage kinetics was recorded up to 1 hour. 
We compared kinetics of chromogenic substrate hydrolysis of samples with various 
thrombin concentrations (1.3, 4.5, 13, 45, 130 nM) with the 200 nM prothrombin sample in order to 
verify the presence of thrombin in prothrombin sample.  
In order to follow prothrombin activation into thrombin by FXa and to evaluate effect of 
aptamer the presence on prothrombin activation as well, we let 2.5, 5, 25 and 50 nM FXa to 
interact with 100 nM prothrombin in the presence and absence of 0.5, 1 and 2 µM HD1 or HD22.  
To observe the inhibition of prothrombin activation by of FXa at different time points 1 
µM of direct FXa inhibitor rivaroxaben was added after each 5 minutes to the samples containing 
100 nM prothrombin and 50 nM FXa. 
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3.3 Data analysis of SPR kinetic experiments:  
Before analysis of a kinetic data, signals from the reference flow cells and blank sample 
were subtracted from the signal of sample cell, to remove impact of all the nonspecific 
interactions.  
In order to access affinity and reaction contacts of thrombin or prothrombin interaction 
with aptamers, date were globally fitted with nonlinear least square method with floating 
parameters (Rmax, ka, kd) using integrated rate equations either for one-to-one interaction or more 
complex, heterogeneous analyte models derived below.  
3.3.1 One-to-one binding 
The most commonly used and the simplest model for description interaction of 
immobilized ligand and injected analyte is the Langmuir model (3.3), applicable in the vast 
majority of cases. It assumes that one monovalent and homogenous analyte (A) interacts with 
homogenous ligand (L) and that all binding events are independent. Formed complex (LA) 
follows pseudo-first order kinetics, assuming that reaction is not mass transport limited. 
(o’shannessy 1993).  
𝐴 +  𝐿   
𝑘𝑎
⇄
𝑘𝑑
   𝐴𝐿 (3.3) 
The association constant ka represents the rate of the complex formation, while 
dissociation constant kd is the rate of complex decay. The rate equation describing AL complex 
formation at time t, may be written as: 
𝑑[𝐴𝐿]
𝑑𝑡
= 𝑘𝑎[𝐴][𝐿] − 𝑘𝑑[𝐴𝐿] (3.4) 
Taking in account that ligand concentration is solution stays constant,  [𝐴]𝑡 = 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 
and with reaction time ligand concentration changes[𝐿]𝑡 = [𝐿]𝑚𝑎𝑥 − [𝐴𝐿]𝑡, then 
𝑑[𝐴𝐿]
𝑑𝑡
= 𝑘𝑎[𝐴]([𝐿]𝑚𝑎𝑥 − [𝐴𝐿]𝑡) − 𝑘𝑑[𝐴𝐿] 
(3.5) 
 
Term [𝐿]𝑚𝑎𝑥 corresponds to maximum concentration of the ligand. The observed SPR 
signal R is proportional to formed complex, and the maximum signal Rmax will be proportional to 
the maximum ligand concentration of the surface. Therefore eqution (3.5) becomes: 
𝑑𝑅
𝑑𝑡
= 𝑘𝑎[𝐴]([𝑅]𝑚𝑎𝑥 − 𝑅) − 𝑘𝑑𝑅 (3.6) 
It is convenient to analyze date in terms of integrated form of rate equation (3.6, since it 
directly derives ka and kd 
𝑅𝑡 =
[𝐴]𝑅𝑚𝑎𝑥𝑘𝑎
[𝐴]𝑘𝑎 + 𝑘𝑑
(1 −
1
𝑒([𝐴}𝑘𝑎+𝑘𝑑)𝑡
) (3.7) 
This equation assumes that Rt=0= 0, however if the baseline is not zero baseline correction 
can be achieved either by subtracting the response before the injection of the analyte, or by 
adding additional fitting parameter Ri that is equivalent value of the signal at the point of analyte 
injection. Ri also accounts also for any change in response due to the refractive index change upon 
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binding of analyte. Equation (3.7) gives advantage to derive ka and kd from single binding 
experiment.  
When the analyte solution has traversed the flow cell and the buffer is injected instead, 
equations (3.6) and (3.7) will have following expressions:  
𝑑𝑅
𝑑𝑡
= −𝑘𝑑𝑅 (3.8) 
𝑅𝑡 = 𝑅𝑎𝑒
−𝑘𝑑𝑡 (3.9) 
The integrated rate equation of the dissociation process shows that rate of complex 
dissociation follows simple exponential decay. Ra is the signal level at the end of association 
phase. If even after complete dissociation of the complex the response is not equal to zero, 
correction of the baseline might be achieved by adding again new fitting parameter R (t→∞), 
representing response after infinite time 
3.3.2 Heterogeneous analyte model 
This model describes more complex interaction, when the immobilized ligand is 
interacting with bivalent or several species of analytes and the binding events are independent.  
In the case of bivalent analyte, assuming that binding sites are not equivalent and have 
distinct association and dissociation rate constants and  that only one site of the analyte interacts 
with the ligand at a time, integrated rate equations of association dissociation phases can be 
expressed by the equations (3.8) and ( 3.9): 
𝑅𝑡 =
[𝐴]𝑅𝑚𝑎𝑥1𝑘𝑎1
[𝐴]𝑘𝑎1 + 𝑘𝑑1
(1 −
1
𝑒([𝐴}𝑘𝑎1+𝑘𝑑1)𝑡
) +
[𝐴]𝑅𝑚𝑎𝑥2𝑘𝑎2
[𝐴]𝑘𝑎2 + 𝑘𝑑2
(1 −
1
𝑒([𝐴}𝑘𝑎2+𝑘𝑑2)𝑡
) (3.10) 
𝑅𝑡 = 𝑅𝑎1𝑒
−𝑘𝑑1𝑡 + 𝑅𝑎2𝑒
−𝑘𝑑2𝑡 (3.11) 
Where ka1 and kd1 are reaction constants describing interaction of site of the analyte and 
the ligand with the maximal response of Rmax1 and ka2 and kd2 are describing interaction of the 
second site with maximal response of Rmax2. Ra1 and Ra2 represent corresponding amplitudes of 
dissociation. Concentration of the analyte [A] is the same for both sites.  
When the system of the analyte contains two different species of various concentrations 
[A1] and [A2], in this case integrated rate equation for association and dissociation phases will 
look like equations (3.12) and (3.11) respectively.  
𝑅𝑡 =
[𝐴1]𝑅𝑚𝑎𝑥1𝑘𝑎1
[𝐴1]𝑘𝑎1 + 𝑘𝑑1
(1 −
1
𝑒([𝐴1}𝑘𝑎1+𝑘𝑑1)𝑡
) +
[𝐴2]𝑅𝑚𝑎𝑥2𝑘𝑎2
[𝐴2]𝑘𝑎2 + 𝑘𝑑2
(1 −
1
𝑒([𝐴2}𝑘𝑎2+𝑘𝑑2)𝑡
) (3.12) 
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3.4  Results: Interaction of HD1, HD22 and NU172 aptamers with thrombin 
and prothrombin 
Aptamers are selected for their high affinity towards desired targets. However, the affinity 
constant represents the ratio of association rate constant ka and dissociation rate constant kd, thus 
similar affinities can be a result of different kinetics. For sensor development along with the high 
affinity it is also extremely important to know kinetic parameters that reveal valuable information 
how rapidly a complex is formed and how rapidly it falls apart. Knowledge of underlying kinetic 
parameters is therefore relevant for better understanding of the molecular basis of complex 
formation and stability. Surface plasmon resonance enables to follow binding interactions in real 
time and determine kinetic parameters. We performed kinetic experiments of HD1, HD22 and NU 
172 aptamer interaction both with thrombin and its precursor protein prothrombin.  
3.4.1 Flow rate optimization for non-mass transport limited kinetics 
In order to determine kinetic constants of reaction precisely, all the factors affecting their 
determination should be limited and therefore proper experimental design is critical. In all 
surface-based analysis methods one of the most important phenomenon influencing apparent 
constants of binding reaction of analyte to surface-bound ligand is the mass transport. Mass 
transport limitation emerges when the transport of an analyte molecule from bulk solution to the 
sensor surface, where it binds an immobilized ligand, is much slower than the association of 
ligand and analyte itself. This effect leads to partial or no kinetic information in the binding data. 
Under laminar flow conditions used in Biacore, the rate of transport of the analyte to the surface 
is proportional to the cube root of the flow rate, and is also influenced by the dimensions of the 
flow cell, the diffusion properties of the analyte and the ligand density on surface.  
In order to diminish mass transport effect, only two experimental conditions can be 
adjusted. First, during the ligand immobilization the surface density has to be low and, second, 
during the kinetic experiment the flow rate of analyte solution has to be high enough. In all our 
kinetic experiments the level of the ligand immobilization was equal to about 40 RU, which 
FIGURE 3.5 Determination an optimal flow rate for kinetic experiments. 12.5 nM thrombin was flown over 
HD1 (A) and HD22 (B) aptamers at 5 ,10, 30 and 60 μL/min injection rates 
(A) (B) 
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taking in account molecular weights of ligand and analyte, represents sufficiently low density 
required for precise measurements (eq. 3.1 and 3.2). For the purpose of selection of an appropriate 
flow rate, it was necessary to perform injection of fixed concentration of thrombin with different 
flow rate. For this reason 12,5 nM thrombin was injected over the surface functionalized with HD1 
and HD22 for 3 minutes with 5, 10, 30 and 60µL/min flow rates (Fig. 3.5FIGURE 3.5). 
The response of thrombin interaction with aptamers differed significantly at low flow 
rates of 5 μL/min and 10 μL/min, meaning, that at this rates association kinetics was influenced by 
mass transport. With increase of the injection rate, interaction response stabilized and didn’t 
show significant change between 30 and 60 μL/min. We assumed that already at 30 μL/min flow 
rate thrombin-aptamer interaction is not mass transport limited and thereafter all experiments 
where performed at this rate.  
3.4.2 Kinetics of thrombin interaction with HD1, HD22 and NU172 
To observe binding kinetics of α-thrombin and immobilized HD1, HD22, NU172 aptamers 
and determine governing reaction constants, various concentrations of thrombin ranging from 
0.78 nM to 50 nM were injected for 180 seconds with the flow rate of 30 um/min. Following 
suggestions of SPR instrument manufacturer, thrombin concentrations were obtained by 2 fold 
serial dilutions of the highest concentration of 50 nM, so that a concentration range of about 0.1-
10 times expected KD was covered.  
Significant response signal was observed even at thrombin concentration as low as 0.78 
nM (Fig. 3.6). The highest response was observed for thrombin interaction with HD1 aptamer, 
then for HD22 and the smallest for the NU1721.  
In order to calculate reaction constants, sensograms of thrombin binding to aptamers 
were initially described with the simplest 1:1 interaction model (eq. 3.7), assuming that HD1 and 
NU172 interact with exosite 1 and HD22 binds to exosite2 of Thrombin.  
For HD22 1:1 interaction model described the association and dissociation reactions pretty 
well (Fig. 3.7 (C)) and corresponding reactions constants ka and kd and consequently Kd were 
deduced easily (Table 3.3).  
However in the case of HD1 and NU172 aptamers (Fig. 3.7 (A) and (B) respective), known 
to recognize fibrinogen binding exosite I of thrombin, fitting one-to-one binding model failed to 
describe entire kinetics (mostly dissociation part), indicating that thrombin interaction with these 
aptamers has more complicated character than it is assumed widely.  
                                                        
1We should note that the kinetics for NU172 was performed as the separate experiment with different type of 
SA sensor chip having HD22 immobilized as the control. The response of the control kinetic experiment of 
thrombin interaction with HD22 (not shown here) was similar to the experiment shown here but with smaller Rmax 
up to 5-6 RU. Namely, the maximal response for the 25 nM Thrombin in one case was 40 RU and in another was 34 
RU. This small difference could be explained with inter experimental and inter surface variation. Nevertheless 
maximal response for NU172 was smaller than corresponding response for HD22. 
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Complexity of this interaction might be hidden in the ability of these aptamers to 
recognize not only exosite I but also heparin binding exosite II. This hypothesis in the case of HD1 
has solid arguments. Some of the very first NMR and X-ray studies suggested that one molecule of 
HD1 aptamer could simultaneously bind two different molecules of thrombin with distinct 
manner (Padmanabhan and Tulinsky, 1996). Indeed this was confirmed with the most recent  
NMR study showed that HD1 binds thrombin exosite I with pincer-like conformation of TT-loops1, 
in addition, TGT loop being exposed towards solvent can interact with heparin-binding site  of 
another Thrombin (Russo Krauss et al., 2011, 2012). This means that apart from binding exosite I, 
HD1 might have some affinity towards thrombin exosite II, which could be reflected in the 
sensogram.  
As for the aptamer NU172, nothing is known about its structure and mechanism of 
binding to thrombin apart, that it interacts with exosite I, since with this binding, it inhibits 
generation of fibrin and modulates coagulation(Mayer et al., 2011). However, for both aptamers 
HD1 and NU172 there is the further evidence of interaction with more than one sites of thrombin. 
Namely, thrombin-induced aggregation gold nanoparticles (results chapter 6) functionalized 
either with HD1 or NU172, suggests that one thrombin molecule is capable of interacting 
simultaneously with two aptamers of the same type. Notably, no aggregation is observed for 
HD22-functionlized gold nanoparticles. Thus, this gives us right to consider thrombin as a 
bivalent analyte for HD1 or NU172.  
Assuming bivalent character of the thrombin towards HD1 and NU172 and supposing that 
one thrombin molecule can interact only with one site of aptamer at a time i.e. binding events are 
independent (one thrombin cannot be captured by two aptamers simultaneously), heterogeneous 
analyte binding model (Eq. 3.9 and 3.10) was fitted to kinetic data (Fig. 3.7). This model seems to 
describe interaction much better than the initial 1:1 model. We obtained reaction and affinity 
constants for two sites (Table 3.5).  
                                                        
1
   (Russo Krauss et al. 2012) also showed that due to the symmetry with the helix axis there are two binding modes of 
TT-loops differing only by a 180 rotation about the helix axis when compared with thrombin exosite I. These modes are 
practically equivalent, the only difference is the orientation of the TGT loop. We don’t consider existence of these two modes in 
SPR data analysis.   
FIGURE 3.6 Determination of dissociation constants by surface plasmon resonance. Interaction kinetics of the 
DNA aptamer HD1 (A), NU172 (B) and HD22 (C) with increasing concentrations  from 0.78 to 50 nM of α-
Thrombin.  Red lines represent the fitting of 1:1 binding model. 
(A) (B) (C) 
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Data analysis revealed that aptamer NU172 has several fold higher affinity towards exosite 
I (0.4 nM) than HD1 (1.2 nM), due to the higher association constant (7.8 x 106 M-1s-1 and 2.1 x 106 
M-1s-1 respectively for NU172 and HD1) even though the half-life of thrombin-aptamer complex is 
slightly larger for HD1 (277 sec) than for NU172 (225 sec).  
As for the affinity for the exosite II 1, as expected, HD22 has the best and the highest 
affinity (3.2 nM), followed by the HD1 (17.4 nM) and NU172 (47 nM). Interestingly, association 
constants for all of these three aptamers are very close (1.9 x 106 M-1s-1, 1.1 x 106 M-1s-1 and 1.1 x 10
6 M-
1s-1 respectively for HD1, NU172 and HD22), but the main difference is in the stability of the 
complexes, HD1 and NU172 dissociate very rapidly compared to HD22. This proves our hypothesis 
that HD1 and NU172 interact with exosite II, but this binding is weaker than interactions of HD22 
with exosite II and HD1 and NU172 with exosite I. Nevertheless, we shouldn’t forget that, by 
definition, aptamers may have affinities as low as low-micromolar, thus giving to HD1 and NU172 
full authority to be called - ”aptamers for both binding sites of thrombin”.  
 
                                                        
1Based on the experimental results of gold nanoparticle aggregation, presented in chapter 6, we can 
confidently tell that HD1 and NU172 bind to two (not more) distinct sites of thrombin: one is exosite I and the 
second site is exosite II. 
Table 3.3 Reaction  and affinity constants of thrombin interaction with HD1, NU172 and HD22 
aptamers. 
aptamer Fitting model Binding 
site 
ka 
10
6 
M-1s-1 
kd 
10
-3 
s-1 
Kd 
10
-9 
M 
Residence 
time s 
HD1 1:1 Exosite1 2.36±0.12 5.03±0.28 2.14±0.23 137.8 
Heterogeneous 
analyte 
Exosite1 2.12±0.10 2.52 ±.0.28 1.19±0.15 277.2 
Exosite2 1.91±0.31 32.60±4.90 17.4±3.60 21.3 
NU172 1:1 Exosite1 7.75±0.08 3.86±0.16 0.50±0.02 179 
 Heterogeneous 
analyte 
Exosite1 
Exosite2 
8.12±0.10 
1.10±0.06 
3.06±0.11 
51.7±5.10 
0.38±0.02 
46.9±6.50 
225.3 
13.4 
HD22 1:1 Exosite2 1.02±0.10 3.20±0.13 3.16±0.34 216.6 
FIGURE 3.7 Determination of dissociation constants by surface plasmon resonance. Interaction kinetics of the 
DNA aptamer HD1 (A) and NU172 (B) with increasing concentrations from 0.78 to 50 nM of α-Thrombin. Date 
was fitted with heterogeneous analyte model 
(A) (B) 
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3.4.3 Kinetics of prothrombin interaction with HD1 and HD22 
Prothrombin is the precursor zymogen of thrombin. Activation of prothrombin into 
thrombin occurs in two-step, through cleavage at Arg271 and Arg320 (Wood et al., 2011). After 
cleavages Gla and Kringle domains of Prothrombin are removed and remaining A and B chains 
form the activated thrombin (Fig. 3.1) that represents only the half of the prothrombin molecule 
(36 kDa and 72 kDa respectively). On the prothrombin molecule active cleft and anion-binding 
sites are either premature or hidden. The anion-binding exosite I is located on the surface of 
prothrombin and accessible for interaction, but it is characterized with low affinity to the ligands 
and is therefore called proexositeI. Only after proteolytic cleavage and thrombin formation 
affinity for its ligands increases, meaning that during activation exosite I undergoes allosteric 
changes (Bukys et al., 2006). On the other hand anion-binding exosite II is well hidden inside 
prothrombin and becomes well-exposed only after cleavage of Arg271 on the surface of thrombin 
or prethrombin2 (Kretz et al., 2006). Studies showed clear evidence that HD1 is interacting with 
exosite1 (Kretz et al., 2006) with comparable to thrombin affinity (Müller et al., 2008) but yet, 
whether kinetic parameter of binding reaction are the same and whether there is the mean to 
distinguish thrombin from prothrombin upon binding that remains unanswered.  
First, we tried to answer this question by performing the similar kinetic analysis for 
prothrombin to what was done in the case of thrombin, by injecting prothrombin concentrations 
from 0.78 nM to 50 nM over HD1 and HD22 aptamer-covered surface. The results turned out to be 
surprising (Fig. 3.8). We let prothrombin to interact with both HD1 and HD22 aptamers, 
expecting binding only with HD1, however signal of interaction with HD22 was unexpectedly very 
high (Fig, 3.8 (B)). Yet it couldn’t be attributed to nonspecific interactions. In addition, observed 
signal for both aptamers was different from the response seen for just thrombin, characterized 
with fast association and dissociation. The only explanation for this effect was the presence of 
thrombin and/or other intermediate species between thrombin and prothrombin bearing exosite 
II exposed for specific interactions (Fig. 3.9).  
  
FIGURE 3.8 Sensograms of HD1 (A) and HD22 (B) aptamer interaction with increasing concentrations of 
prothrombin, ranging from 0.78 to 50 nM.  
(B) (A) 
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3.4.4 Investigation of integrity and purity of prothrombin 
To verify purity of the sample, we carried out SDS PAGE separation of prothrombin 
sample. Moreover to see whether there was thrombin in stock solution, chromogenic substrate 
activation assay was performed with several known concentrations of thrombin and 200 nM 
prothrombin.  
Indeed, SDS PAGE separation results (Fig.3.9) confirmed that in prothrombin sample 
apart from prothrombin were also present other intermediate species, such as meizothrombin, 
prethorombin1 and/or1 meizothrombin desF1 (52 kDa), α-thrombin and/or prethrombin 2 (36 
kDa) and prothrombin fragment F1.2 (31 kDa). The main components of the sample were 
prothrombin 60% followed with about 30% of prethrombin and/or meizothrombin.  
Chromogenic substrate cleavage assay, on the other hand, showed that in prothrombin 
stock solution there was only minute concentration (much less than 1 nM) of thrombin that 
induced insignificant cleavage of chromogenic substrate compared to 1 nM thrombin (Fig. 3.10). 
Since the prothrombin was of good quality in stock solution, it means that degradation 
occurred during the sample preparation or in the course of the experiment. From the 
literature it known that if there is some minute concentration of thrombin, it can initiate cleavage 
of prothrombin and thus autocatalyze its own production. Meizothormbin or meizothrombin 
desF1 and thrombin are capable of cutting Arg155 and thus transforming prothrombin into 
prethrombin1, meizothormbin into meizothrombin desF1, α-thrombin is further able to cut 
Arg288 to produce β- and γ- thrombins (Fischer et al., 1996).  
                                                        
1
 The difference between prethrombin and meizothrombin, prethrombin1 and meizothrombin desF1 as well 
as prethrombin2 and thrombin couples is only in absence of the cleavage at Arg320 in first of them. Since by SDS 
PAGE we now can distinguish molecules only by molecular weight, but we are not able to say which conformations 
are present is the investigated sample.   
FIGURE 3.9 SDS PAGE separation of prothrombin sample showing that sample along with the prothrombin 
contains species of three different molecular weights that might correspond to prothrombin cleavage products 
such as meizothrombin,  prethorombin1 and/or meizothrombin desF1, α-thrombin and/or prethrombin 2 and 
prothrombin fragment F1.2. 
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3.4.5 Kinetics of prothrombin interaction with aptamers in the presence of Argatrobane 
Knowing about the instability of prothrombin in the presence of thrombin, we decided to 
add high concentration (50 µM) argatroban, the small molecule reversibly inhibiting thrombin 
active site, directly to the running buffer. The presence of high concentration argatroban 
guaranteed that thrombin would have been almost always inhibited from interaction with non-
activated prothrombin. 
New set of experiments were performed with the same concentrations of prothrombin but 
in the excess of the argatroban for HD1, HD22 and NU172. In such conditions binding of 
prothrombin was exclusively observed with HD1, NU172. From Fig. 3.11 It is clear that signal for 
HD1 and NU172 is neither artefact nor effect of 
local refractive index change, since if it was the 
case, we would have had the same bulk effect 
for HD22 as well. But as we see the injection of 
similar sample did not induce any change in 
refractive index in the case of HD22. Thus our 
supposition on effect of autoactivation was 
confirmed. 
Kinetics of interaction of prothrombin 
with HD1 was different than that with 
thrombin. The response intensity was much 
higher (more than twice) for prothrombin than 
for the same concentration thrombin. Before 
going into quantitative analysis, the 
observation of sensogram (Fig.3.11) of HD1 
interaction with prothrombin shows very fast 
association dynamics that never reaches equilibrium. The dissociation phase has also very stiff 
descend but is not reaching zero. This suggests that observed signal represents the sum of two or 
several interactions, one part of which is characterized with very high on- and off- rate (reaching 
the limit of the instrument sensitivity) and another with comparably lower on- and off- rate. 
 
 
 
FIGURE 3.10 Kinetics of cleavage of chromogenic substrate S2238 by 1.5, 4.5, 15 and 45 nM thrombin (A)and 
200 nM prothrombin (A-B) 
FIGURE 3.11 Overlaid sensograms of aptamer HD1, 
NU172 and HD22 interaction with 50 nM Prothrombin 
incubated with 1µM argatroban 
(A) (B) 
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Meaning that, despite of inactivation of thrombin active site, prothrombin sample still contained 
some other species. Since binding of thrombin to aptamer HD1, as shown above, is not 
characterized, with such an aggressive signature, these extremely fast on and off rates can be 
attributed to prothrombin (and other intermediate species). Overall, by the shape of the 
sensogram, it can be attributed to the class of difficult-to-interpret interactions (Rich and Myszka, 
2008). 
For NU172 as well, the signal of interaction with prothrombin was different from the 
response of binding to thrombin. The intensity of the response was several times higher than in 
the case of thrombin. However association and dissociation phases were slower and less 
combative than for HD1. During the association phase stable equilibrium was reached and by 
dissociation phase signal tended to return to initial baseline. 
Fitting the kinetic data, at first, was performed manually with 1:1 interaction model, 
assuming that sample contained only prothrombin. In the case of HD1 we neglected the absence 
of equilibrium signal and added bulk effect for dissociation phase in order to compensate the 
signal of slow dissociation which followed the drastic complex decay (Fig. 3.12 (A)). For NU172 
only the effect of bulk was added.   
As we see from the Fig.3.12 (A) obtained fitting curve for HD1 doesn’t comprise slow 
association segment, which in the 1:1 binding case should have been flat, describing signal 
saturation at equilibrium. For NU172 fit is much better (Fig. 3.12 (B)). Calculated reaction 
constants are given in the table 3.4.  
Despite of very quick association (ka=2.6x10
6 
M-1s-1), dissociation rate is also very elevated 
for HD1 leading to very short half-life of HD1-prothrombin complex (10 s) and dissociation 
constant of 37 nM. In the case of NU172 association is also pretty fast (ka=4.6x10
6 
M-1s-1) but 
dissociation is slower than for HD1, so it comes out to have better complex stability (47 sec) and 
one order of magnitude improved affinity (3.3 nM) towards prothrombin. Again it has to be 
brought to attention that experiments for HD1 and NU172 were performed separately on different 
surfaces and the quality/density of the immobilized aptamers is thus different, giving distinct 
Rmax values, which influences the shape of the sensogram. 
  
FIGURE 3.12 Sensograms of HD1(A), NU172 (B) and HD22 (C) aptamer interaction with increasing 
concentrations of prothrombin incubated with 1 µM argatroban. Red line represents fitting of the 1:1 binding 
model 
(B) (A) (C) 
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Obviously, the complex character of prothrombin interaction with HD1 cannot be 
described adequately by the 1:1 binding model; however it gives an idea about the range of the 
governing reaction constants. Furthermore use of more sophisticated models doesn’t guarantee 
finding the exact one, correctly representing the case.  
Indeed, we performed additional data fitting with BIAevaluation software for 
sensograms only representing interaction of 6.25 nM and 50 nM prothrombin with HD1. We used 
several built-in models like “interaction with drifting baseline”, “mass transport” (fitting not 
shown here) with adjustment of different parameters, but none of them gave neither good fit nor 
sane parameters. At last, the satisfying fit was achieved once we used heterogeneous analyte 
model, where we assumed that prothrombin sample had similar composition as shown on the 
SDS-page results. Namely, it was composed of 40% protein with molecular weight 52 kDa 
(prethrombin/meizothormbin desF1) and 60% protein with M.W. 72 kDa (prothrombin). 
Obtained fitting curves described both the fast and slow association and dissociation. By the 
results of the model, the larger molecule, 
prothrombin, has to be the one which associates 
with high on-rate (ka=2.44 x 10
6 M-1s-1) and 
dissociates super rapidly, staying in complex 
with HD1 only for 6 seconds. On the other hand, 
molecule with 52 kDa molecular weight (either 
prethrombin1 or meizothrombin desF1), is the 
one, involved in slower interactions with 
relatively low on-rate ka=1.1 x 10
5 M-1s-1 but with 
extremely long residence time (1350 sec) 
resulting in 4.6 nM affinity. If we compare 
results obtained using one-to-one and 
heterogeneous analyte model for prothrombin 
we get very similar association rate constants 
and range of affinity. Interestingly, fitting 
similar model and conditions didn’t give 
realistic results for NU172. 
   
Table 3.4 Reaction and affinity constants of prothrombin interaction with HD1, NU172 
and HD22 aptamers. 
Aptamer Fitting 
model 
Binding 
molecule 
ka 
10
6 
M-1s-1 
kd 
10
-3 
s-1 
Kd 
10
-9 
M 
Residence 
time 
s 
HD1 1:1 Prothrombin 2.61±0.12 96.8±8.61 37.2±3.26 9.6 
Two 
analytes 
Prothrombin 
Prethrombin1 
2.44±0.06 
0.11±0.03 
115±10.02 
0.51±0.05 
47.2±3.51 
4.85±0.41 
6 
1351 
NU172 1:1 Prothrombin 4.56±0.47 14.9±0.27 3.26±0.33 46.4 
HD22 1:1 prothrombin - - - - 
FIGURE 3.13.Sensograms of interaction of 6.25 nM 
and 50 nM prothrombin interaction with HD1. 
Black line represents the fitting of the 
heterogeneous analyte model assuming that sample 
is composed of 60% 72 kDa protein and 40% 52 kDa 
protein. Fitting was made by BIAevaluation 
software   
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3.4.6 Following prothrombin activation with aptamers 
As we saw above the character of interaction of aptamers is different for thrombin and 
prothrombin. However in real plasma samples concentration of prothrombin is usually up to 0.1 
mg/mL (1.4 μM) (Butenas et al., 1999) that is much higher (with order of 103) than the 
concentration of possible circulating free thrombin ((Mann et al., 2003)). It is interesting and, 
even more, necessary to know whether we can be able to distinguish the contribution of 
thrombin from prothrombin when they are present simultaneously in the sample for example 
during thrombin generation process.  
In the blood, thrombin is generated from the zymogen prothrombin by the 
prothrombinase complex, composed of the trypsin-like protease factor Xa, the cofactor factor Va, 
phospholipid membranes and Ca2+(Davie et al., 1991). FXa on its own is also able to cleave 
prothrombin but with 100 fold lower rate than prothrombinase. In the lab, we can follow the 
thrombin generation, catalyzed by prothrombinase complex or only by FXa, through monitoring 
hydrolysis of chromogenic or fluorogenic substrate. Upon activation of thrombin more and more 
substrate gets cleaved inducing characteristic absorption or/and fluorescence. We are interested 
to know whether we can follow similar process with surface based affinity sensor, in general, and 
by SPR, in this particular case. 
3.4.6.1 Optimal FXa concentration 
Before observing thrombin generation SPR we need to understand the process of 
thrombin generation and adjust parameters for consequent experimental design. For this reason 
we performed several thrombin generation assays by FXa and monitored it with cleavage of 
chromogenic substrate S2238.  
The first experiment was performed to see how much time it takes to activate 100nM 
Prothrombin by different concentrations of FXa (2, 5, 10, 50 nM). We wanted select an optimal 
concentration of FXa to carry out further experiments, so that they would be slow enough to 
observe all the stages of thrombin activation but on the same time wouldn’t take more than 1 
hour, to avoid degradation of the sample (Fig. 3.14 (A)). We observed that 50 nM FXa takes up to 
30 minutes to fully activate all the thrombin, which was optimal for our further experiments, 
whereas lower concentrations took much longer time.   
FIGURE 3.14 kinetics of chromogenic substrate cleavage by thrombin activated form100 nM prothrombin in the 
presence 2, 5, 25 and 50 nM FXa.(A), or 50 nM FXa and 50, 100, 200 nM HD1 (B) or HD22(C) 
(A) (B) (C) 
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3.4.6.2 Effect of aptamer presence on prothrombin activation with FXa 
Very important is as well to evaluate whether the presence of aptamers can alter the 
cleavage of the prothrombin by FXa. For this reason during the thrombin generation experiment 
various concentrations (50, 100 and 200 nM) of aptamer HD1 and HD22 were carried out. As we 
see form the Fig. 3.14 (B) and (C), the curves of the chromogenic substrate cleavage in the 
presence of aptamers were almost identical to the one without aptamers. Meaning that, the 
presence of HD1 and HD22 in these concentrations doesn’t influence neither the interaction of 
prothrombin with FXa nor the interaction between thrombin and S2238. 
3.4.6.3 Designing thrombin generation experiment for SPR 
Once we found the optimal concentration of FXa and clarified that aptamers do not affect 
thrombin generation, we can start designing SPR experiment for real-time monitoring thrombin 
generation process. Of course when we say “to follow the prothrombin conversion process with 
SPR”, we think of injecting aliquots of the same sample at different time points to see the change 
between characteristic sensograms rather than observing single long sensogram. To obtain 
instant picture of the process we need to hold the activation process, i.e. stop the activity of FXa 
at desired time points. This can be achieved by adding to the system high concentration (1 μM) of 
FXa inhibitor rivaroxaban at appropriate moment (Fig. 3.15). 
To visualize our idea, i.e. show the effect of FXa inhibition at different time points, we 
again performed classical thrombin generation assay. We pipetted same sample containing 
prothrombin and S2238 in 8 different wells. FXa was injected into all wells, except the first well, 
where along with FXa we put also 
rivaroxaban at the same time, and 
started absorbance acquisition. After 
five minutes rivaroxaben was injected 
in the second well continuing recording 
of absorbance, after next 5 minutes 
rivaroxaben was injected in the third 
well and so on, we injected FXa 
inhibitor in following wells one buy one 
after each 5 minutes delay. The last well 
we kept uninhibited by rivaroxaben.  
Fig.3.14. illustrates the outcome 
of this experiment. As we see (as it was 
expected) the rate of thrombin generation is the highest at the begging of experiment, where the 
concentration of prothrombin is the highest as well, and drops with the increase of the thrombin 
concentration (Fig. 3.16 (A)). Meaning that concentration of thrombin is not directly proportional 
to the time passed and when we perform SPR experiment we don’t know the exact composition of 
sample (thrombin/prothrombin ratio) unless we carry out additional calculations to determine 
actual concentration of thrombin.  
FIGURE 3.15 Kinetics of chromogenic substrate cleavage by 
thrombin activated from 100 nM Prothrombin with 50 nM FXa. 
Activity of FXa was inhibited by rivaroxaben each 5 minutes.   
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Thus, instead of stopping prothrombin activation after each 5 minutes or at the times 
where the calculated ratio of thrombin and prothrombin is desired and , it is much easier and 
convenient to make a sample with predefined composition of thrombin and prothrombin 
(Fig.3.16 (B)). This approach allows performing SPR experiment avoiding the presence of FXa and 
rivaroxaben, compounds that could complicate the system. 
 
3.4.6.4 SPR experiment of thrombin-binding-aptamer interaction with the mixture of prothrombin 
and thrombin 
To mimic real activation process, samples of different prothrombin/ thrombin 
composition were made, so that the total concentration of protein was fixed to be. We started 
with 100% prothrombin and gradually decreased content by 20 percent increasing at the same the 
concentration of thrombin (Fig. 3.16 (B)). These samples were used to carry out kinetic 
experiments on SPR for HD1, HD22 and NU172 (Fig. 3.17). 
For HD1 and NU 172 the highest signal was observed for the sample with 100% 
prothrombin and then with 100% thrombin. The difference between these two samples was 
evident: remarkably quick association and dissociation was observed for prothrombin sample 
compared to only thrombin (Fig. 3.17 (A) and (C)). 
In the case of HD22, the signal from 100% prothrombin was the least observed. The 
intensity of the signal increased with the augmentation of thrombin percentage in the sample. For 
FIGURE 3.17 Sensograms of HD1 (A), HD22 (B) and NU172 (C) aptamer interaction with samples of various 
thrombin and prothrombin composition 
(C) (B) (A) 
FIGURE 3.16  Schematic illustration of sample composition during thrombin generation assay (A) and in the 
samples used to perform SPR experiment with thrombin and prothrombin mixture (B) 
(A) (B) 
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HD1 and NU172 all the rest of samples gave almost the same signature, making it impossible to 
guess the composition of the sample only by looking at sensograms.  
Since an observed SPR signal represents integrated response of analyte binding, by 
differentiating the signal by time we can obtain the rate or binding at every time point. This 
action is called derivative method. Derivative methods have been widely used in analytical 
spectroscopy as qualitative fingerprinting technique to accentuate small structural differences 
between nearly identical spectra and to enhance the resolution of overlapping spectral bands. We 
applied this approach to try to interpret overlapping sensograms of HD1. Since in affinity 
biosensors the most important part of interaction is signature of association, we took closer look 
to the beginning (first 30 seconds) of sensogram derivatives.  
Figure 3.18 illustrates results of differentiation of the SPR response by time. In the case of 
HD1 there is clear difference between thrombin and prothrombin derivatives. Prothrombin 
associates to HD1 quicker than thrombin and that’s why we can see the higher peak of the 
derivative emerging the soonest for the prothrombin (Fig. 3.18 (A)). With decrease of the 
percentage of prothrombin composition in the sample peak becomes lower, wider and smaller. 
For HD22 due to the absence of the interaction with prothrombin, the highest peak is 
observed for the 50 nM thrombin (Fig. 3.18 (B)). Intensity of characteristic peak decreases with 
diminution of thrombin content in the sample.  
Interaction of aptamer NU172 has very similar association patterns with both thrombin 
and prothrombin and therefore it is difficult to see clear difference in the derivatives during the 
association phase (Fig. 3.18 (C)). 
This simplified experiment showed that if we have tried to follow thrombin generation 
from prothrombin point by point, yes, we would indeed be able to see a transformation of the SPR 
signal following the thrombin activation but only in the case of HD1 and HD22. For HD1 the 
maximum (equilibrium state) response would decrease with augmentation of the activated 
thrombin, and in the case of HD22 the maximum of the signal would increase with the thrombin 
generation. Of course, HD22 is the best option for this purpose.  
  
FIGURE 3.18  The first derivatives of SPR response during association phase for various composition 
thrombin/prothrombin mixtures to HD1 (A), HD22 (B) and NU172 (C) aptamers. 
(A) (B) (C) 
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3.4.7 Conclusions for thrombin and prothrombin interaction with aptamers 
With SPR method we studied interaction of HD1, HD22 and NU172 aptamers with both 
thrombin and prothrombin to understand interaction kinetics between target and the proteins 
and performed interesting experiment with thrombin and prothrombin mixture to simulate 
prothrombin conversion into thrombin. We showed that all three aptamers have very high 
affinity in low nan0molar range for thrombin and suggested that HD1 and NU172 apart from 
binding to exosite I may also bind to exosite II with slightly less but nanomolar affinity. Only 
HD22 is selective between thrombin and prothrombin, whereas HD1 and NU172 interact with 
prothrombin with affinity one order of magnitude lower than for thrombin. Interaction of HD1 
has very specific signature that makes possible to distinguish interaction of thrombin binding 
form prothrombin.  
From point of view of therapeutic application, where the main interest is the effect of 
inhibition of binding different molecules to thrombin binding sites, of course, obtained results 
once again show that high affinity of aptamers towards thrombin makes them very good 
candidate as modulators of coagulation.  Whereas from the point of view of application of 
aptamers as sensing elements in biosensor development, where the specificity (selectivity) is as 
important as sensitivity (affinity), HD1 and NU172 arise more questions concerning specificity. 
Namely, if they interact with two distinct epitopes of thrombin with such high affinities, will they 
be able to discriminate thrombin between other serine proteases (coagulation factors) in 
coagulation cascade, since they bare structural similarities? In general, will these aptamers be 
specific at all in plasma? Some of these questions will be discussed below. 
  
` 
 
97 3.5.1 Antihrombin III 
3.5 Results of aptamer interaction with Thrombin-inhibitor complexes 
Thrombin as the key protease in coagulation is regulating various reactions, but on its 
own it is also tightly regulated. The regulation of thrombin is mainly achieved with stoichiometric 
and irreversible inhibition of the thrombin active site by natural plasma inhibitors Antithrombin 
III, Heparin cofactor II and Alpha-2-macroglobulin. Inhibited thrombin complexes are then 
cleared from the blood circulation system in liver. Whether aptamers can interact with inhibitor-
thrombin complex or affect complex formation was examined with SPR method. 
 
3.5.1 Antihrombin III 
ATIII is the major natural inhibitor of 
thrombin present in blood plasma at the 
concentration of 2.5 µM. (Conard et al., 1983). It is 
shown to accounts for 60% of plasma 
anticoagulant activity (Walker and Royston, 
2002). ATIII forms 1-to-1 complex with thrombin 
inhibiting active site with kon=1.23x10
4 M-1s-1. 
Inhibition of thrombin increases 10000 fold in the 
presence of glycosaminoglycans, for example in 
the presence of heparin kon=1.19x10
8 M-1s-1 (Myles 
et al., 1998). As it is shown Fig. 3.19and known 
form literature (Li et al., 2004; Myles et al., 1998), 
in the absence of glycosaminoglycans, ATIII 
doesn’t require contact with neither of anion 
binding sites for binding to thrombin active site 
(Fig. 3.19) (Gronewold et al., 2005). However, 
whether thrombin-ATIII complex can bind to 
aptamers, hasn’t been studied.  
3.5.1.1 Interaction of Thrombin-ATIII complex with immobilized HD1 and HD22 aptamers 
In order to investigate interaction of thrombin aptamers with thrombin-ATIII complex, 
thrombin (12.5 nM) incubated for 30 minutes at room temperature with various concentrations 
(12.5, 50, 200, 800 nM) of ATIII was flowed over the immobilized aptamers HD1, HD22 and Nu172 
(Fig. 3.20).  
At the stoichiometric concentration of ATIII, SPR response comparable to 12.5 nM 
thrombin was observed, suggesting that either ATIII-thrombin complex interacts with the 
aptamers the same way as with just thrombin or, at low concentration such as 12.5 nM, ATIII 
cannot inhibit all the thrombin in 30 minutes due to the low kon, and therefore the signal 
represents the interaction of uninhibited thrombin with aptamers (Fig. 3.20 green curves). If we 
take in account the value of kon and perform numerical simulations (Fig. 3.21 (A)), we obtain 
curves of thrombin-ATIII complex formation over time. Figure 3.21 (B) shows that when 
FIGURE 3.19 Molecular model of Interaction of 
HD1 and HD22 aptamers with thrombin-ATIII 
complex. The model is constructed with the program 
PyMol by superposing structures of Thrombin-ATIII 
(1TB6) complex and HD1 (4DII) and HD22 (4I7Y) 
aptamers 
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incubated for 30 minutes less the 20% of thrombin is inhibited by 12.5 nM ATIII, with increase of 
the concentration of ATIII, percentage of inhibited thrombin increases. That’s why, injections of 
thrombin with higher ATIII concentration, led to drastic diminution of the signal for all aptamers 
(Fig. 3.20). 
 
This shows that at higher concentration of ATIII all the thrombin in complex with the 
inhibitor and such complex doesn’t interact with either of aptamers. The result is surprising, 
since, as shown on the molecular model (Fig. 3.19), the binding of the ATIII shouldn’t sterically be 
an obstacle for aptamer binding. It can be supposed that binding of ATIII has an allosteric effect 
on thrombin, distorting the topography of exosites for aptamer binding (Parekh et al., 2008). 
Indeed, several studies revealed communication between active site and exosites inducing 
allosteric effects.(Fredenburgh et al., 1997; Petrera et al., 2009) 
With increasing concentrations of ATIII, slight increment of the signal was observed for 
HD22 and NU172, resembling nonspecific interactions with the surface. The injection of 400nM 
ATIII without thrombin was performed as the control to verify if non-specific interactions 
between ATIII and aptamers take place. Control experiment revealed the the presence of 
lightweight non-specific interactions with both aptamers, characterized by fast off rate.   
FIGURE 3.21  Inhibition of thrombin by 12.5, 50, 200 and 800  nM ATIII. (A) Numerical simulation of 12.5 nM 
thrombin inhibition by various concentrations of ATIII. (B) Concentration of inhibited thrombin after 30 
minutes of incubation with different concentrations of ATIII, predicted by numerical simulation.  
(A) (B) 
FIGURE 3.20 Sensograms of interaction of immobilized aptamers HD1 (A), HD22 (B) and NU172 (C) with 12.5 
nM thrombin incubated for 30 minutes with various concentrations of ATIII from 12..5 to 800 nM. 
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3.5.1.2 Interaction of ATIII with aptamer-bound thrombin 
On the other hand, it is also important to evaluate thrombin-ATIII complex formation, in 
the case where thrombin is already bound to an aptamer. For this purpose increasing 
concentrations of ATIII (12.5, 50, 200, 800, 1500 nM) was flowed over preformed thrombin-
aptamer (HD1 and HD22) complex. This experiment was performed at mass transport limited 
mode with high surface density of aptamers (ligand immobilization level corresponding to 500 
RU), in order to keep as much thrombin at surface as possible. At such conditions, bound 
thrombin, as soon as it dissociates from one ligand, rebinds another and therefore instead of 
dissociation, steady signal is observed.  
As shown on FIGURE 3.22 (A), injection of increasing concentrations ATIII, promotes 
dissociation of thrombin from HD1. At low concentration (12.5 and 50 nM) of ATIII, following the 
injection of the inhibitor, slight increase of the signal compared to only thrombin is observed. 
This effect could be interpreted as the formation of ternary complexes of HD1-thrombin-ATIII, 
though this complex shouldn’t be very stable, thrombin-ATIII form so-called loose complex. 
Furthermore, it can be seen at the beginning of the injection of higher concentrations (200-1500 
nM) of ATIII how the signal increases for few seconds and then drops corresponding to binding of 
inhibitor to thrombin and consequent removal of formed complex form the aptamer HD1. This 
result suggests that binding HD1 to exosite 1, doesn’t alter the recognition of thrombin active cleft 
by ATIII (Holland et al., 2000), but once the firm (irreversible) complex between ATIII and 
thrombin is formed (Stone and Hermans, 1995) HD1 cannot rebind dissociated thrombin in 
thrombin-ATIII complex, due to the conformational changes. This interpretation is consistent 
with the results by published by Parekh (Parekh et al., 2008). 
As for HD22 (Fig. 3.22 (B)), no significant interaction (neither association nor dissociation) 
with aptamer-bound thrombin is observed for ATIII concentrations from 12.5 to 200 nM. Starting 
from 800 nM ATIII, minute dissociation of thrombin occurs. We can suppose that for ATIII 
binding to thrombin active site, exosite II has to be accessible. At the same time, ATIII cannot 
displace HD22 aptamer easily. Once the thrombin–HD22 complex is disassociates, only then it is 
possible for ATIII to capture liberated thrombin. However, at lower concentrations of ATIII, time 
needed to diffuse and form the complex with thrombin is longer than needed for thrombin 
FIGURE 3.22 Sensograms of interaction of various concentrations  of ATIII with 12.5 nM thrombin  bound to 
immobilized HD1(A) and HD22 (B) aptamers. First 12.5 nM thrombin was flown over the densely immobilized 
aptamers for 3 minutes and then right away increasing concentrations of ATIII were injected.  
(A) (B) 
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rebinding from one aptamer to another. At higher concentrations, more ATIII is available to 
inhibit thrombin as soon as it dissociates from the HD22 aptamer.  
To summarize, above-described studies show that ATIII-thrombin complex cannot be 
detected by either of aptamers, but ATIII might 
have slight nonspecific interactions with all 
(HD1, H22 and NU172) aptamers. HD22 
interacting with heparin binding site of 
thrombin disturbs docking of ATIII, Whereas 
HD1- thrombin dissociates when ATIII binds 
thrombin.  
 
3.5.2 Heparin cofactor II 
HCII, likewise to ATIII, is the member of 
the serine protease inhibitor superfamily 
(Potempa et al., 1994), responsible for 30%  
anticoagulant activity in plasma. HCII 
irreversibly inhibits active site of thrombin with 
the kon=1.11x10
3 M-1s-1 (Myles et al., 1998). From 
the crystal structure of HCII-thrombin complex 
shown on Figure 3.23 , it is visible that, HCII 
uses exosite I for docking when binding 
thrombin (Baglin et al., 2002).  
3.5.2.1 Interaction of HCII-thrombin complex with HD1 and HD22 
Interaction of HCII-thrombin complex with immobilized thrombin binding aptamers 
HD1, HD22 and NU172 was investigated by injection thrombin-HCII complexes with different 
stoichiometric ratio of the inhibitor over aptamer functionalized surface (Fig. 3.4).  
FIGURE 3.23  Interaction of HD1 and HD22 
aptamers with thrombin-HCII complex.  Superposed 
structures of Thrombin-HCII complex (1JMO) and 
thrombin  aptamersHD1 (4DII)  in the left and HD22 
(4I7Y)  in the right 
FIGURE 3.24 Sensograms of interaction of immobilized aptamers HD1 (A), HD22 (B) and NU172 (C) with 12.5 
nM thrombin incubated for 30 minutes with various concentrations of HCII from 12.5 to 800 nM 
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HD1 and HD22 aptamers showed similar trend of gradual diminution of the signal with 
the increase of the HCII concentration (Fig. 3.24 (A) and (B)). Numerical simulation of 
irreversible inhibition of thrombin by heparin cofactor II shown on figure 3.25 (B) indicates that 
30 minutes of incubation with HCII are not enough to completely inhibit all the thrombin. 
Therefore decrease of response with increase of HCII concentrations means, that signal is due to 
uninhibited thrombin, and once thrombin forms complex with HCII such complex doesn’t 
interact with neither of aptamers. In the case of NU172 we let HCII to incubate longer than 30 
minutes with thrombin and therefore more thrombin was inhibited and thrombin-HCII complex 
didn’t interact with NU172. We deduce that thrombin-HCII complex, once formed, is invisible to 
all thrombin aptamers and especially if glycosaminoglycans (GAGs) are present. GAGs would 
facilitate thrombin inhibition occupying heparin binding exosite II and prevent binding of 
aptamers even more. 
What we can detect, though, is the nonspecific interaction of HCII with the aptamer HD1 
and NU172. Interaction of 400 nM HCII with aptamers yielded the signal equal to 30 % of signal of 
only 12.5 nM thrombin. In real sample of non-coagulating plasma, where concentration of HCII  is 
1.4 μM (Tollefsen et al., 1982), the signal might be comparable to thrombin signal. 
  
(A) 
FIGURE 3.25 Inhibition of thrombin by 12.5, 50, 200 and 800 nM HCII. (A) Numerical simulation of 12.5 nM 
thrombin inhibition by various concentrations of HCII. (B) Concentration of inhibited thrombin after 30 minutes 
of incubation with different concentrations of HCII, predicted by numerical simulation. 
(B) 
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3.5.2.2 Interaction of HCII with aptamer-bound thrombin. 
Similarly to ATIII, interaction of aptamer-bound thrombin with HCII was investigated by 
coinjection of increasing concentrations of inhibitor just after injection of 12.5 nM thrombin over 
densely immobilized aptamer surface. 
Figure 3.26 (A) shows that high concentration of HCII starting from 200nM associate with 
HD1 aptamer-bound thrombin and the complex is rapidly dissociated from the aptamer. This 
effect is expected from the geometry of HCII binding to thrombin exosite I, (Fig. 3.23) that is main 
binding site for HD1 as well. I.e. HCII competes with HD1 and wins binding for thrombin exosite 
I. However it should be noted, the fact that more than 200 nM HCII was required for the 
successful outcome of this challenge, indicates that HD1 binding modulates HCII interaction with 
thrombin exosite I (Holland et al., 2000). 
In the case of HD22 aptamer –bound thrombin no significant effect of HCII presence was 
observed. It is important to acknowledge that HCII didn’t attack thrombin-HD22 complex, that 
can be explained by the fact that exosite II of thrombin, recognized by HD22, doesn’t come 
interact with HCII during the complex formation in the absence of GAG. However, no increase of 
signal indicates that binding of HD22 to thrombin induces changes in thrombin structure that 
HCII is not able to interact with the well exposed exosite I. Again we see the trace of the allosteric 
linkages between the exosites.  
 
To sum up, HCII-thrombin complex is not interacting with none of the aptamers, most 
probably due to the allosteric inactivation of exosite II following the irreversible inhibition of 
exosite I. HCII shows very low affinity towards HD22-thombin complex. HCII competes for HD1 
aptamer-bound thrombin, removing it from the aptamer.  
  
FIGURE 3.26 Sensograms of interaction of various concentrations of HCII with 12.5 nM thrombin -bound to 
immobilized HD1 (A) and HD22 (B) aptamers. First 12.5 nM thrombin was flown over the densely immobilized 
aptamers for 3 minutes and then right away increasing concentrations of HCII were injected 
(B) (A) 
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FIGURE 3.28 Sensograms of interaction of immobilized aptamers HD1 (A), HD22 (B) and NU172 (C) with 12.5 
nM thrombin incubated for 30 minutes with various concentrations of A2M from 12.5 to 800 nM. 
3.5.3 Alpha-2 macroglobulin 
Alpha-2 macroglobulin is a serum protein functioning as the broad range irreversible 
proteinase inhibitor. A2M is a large molecule with a molecular weight of 720 KDa (Arakawa et al., 
1989). It is composed of four identical subunits forming large central cavity where proteases are 
trapped as prey. Proteinases remain active but 
prevented from further contact with high 
molecular weight substrates. Interaction of 
thrombin and A2M is described with 
association rate constant kon=2.5x10
3M-1s-1. 
(Feinman et al., 1985). The structure of A2M-
thrombin complex is not available. FIGURE 
3.27 represents structures of A2M and 
thrombin molecules separately (Marrero et al., 
2012); This image allows to appreciate how 
large A2M is compared to thrombin and to 
imagine how thrombin can be wrapped and 
encapsulated in the scaffold of A2M. It was 
shown that small fluorogenic peptides cans 
still access active cleft of A2M-entrapped 
thrombin (Hemker et al., 2002). However 
there is no evidence about A2M-thrombin complex interaction with thrombin aptamers. 
To answer the question whether surface-immobilized aptamers HD1, HD22 and Nu172 can 
interact with A2M-thrombin complex, similarly to previous experiments with ATIII and HCII, 
thrombin incubated with increasing concentrations of A2M was flowed over sensor surface (Fig. 
3.28).  
According to numerical simulations (Fig. 3.29 (B)), after 30 minutes of incubation with 
12.5 and 50nM A2M, 12.5nM thrombin is only partially inhibited. The signal of interaction of with 
these samples decreases with decrease of free thrombin, suggesting that the response was solely 
from interaction with thrombin and not thrombin-inhibitor complex. We can explain this result 
FIGURE 3.27 Structures of alpha-2-Macroglobulin 
(4ACQ) and thrombin (3U69) 
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by two hypotheses: either the entrapped thrombin is completely wrapped in A2M and aptamers 
cannot squeeze inside the A2M scaffold to bind thrombin; or, alternatively, thrombin might have 
been accessed by aptamers only if they weren’t attached to the surface due to steric repulsion. 
Since there is no structure available for thrombin–A2M complex, it is difficult to say what is true.  
At higher concentrations of A2M thrombin inhibition occurs faster and therefore SPR 
signal should go down to zero. But in the case HD1 and NU172 aptamerss at inhibitor 
concentrations higher than 200 nM, response started to increase again. Injection of 400nM A2M 
revealed that both HD1 and NU172 are engaged in nonspecific interactions with A2M, and with 
increase of concentration response becomes stronger. The conclusion of this set of experiments is 
that, surface bound aptamers do not interact with thrombin entrapped by A2M. But A2M on its 
own shows significant nonspecific interactions with HD1 and NU172 surface. 
3.5.4 Conclusions 
Above studies on interaction of immobilized thrombin aptamers with thrombin-natural 
inhibitor complexes showed that, none of the aptamers are able to interact with complex of 
thrombin with ATIII, HCII or A2M either due to inhibition of binding site, inaccessibility of 
thrombin or inhibitor-induced allosteric changes. For ATIII and HCII binding to thrombin 
induces allosteric changes on thrombin binding sites, since despite of absence of geometric 
constraints for binding aptamers on exposed exosites, no interaction with either of aptamers is 
observed. And in the case of A2M surface-bound aptamers cannot penetrate the scaffold of the 
A2M either because of the size or due to the fact that they are attached to the surface.  
NU172 revealed nonspecific interactions with A2M. In the case of HD1, it tends to interact 
nonspecifically with ATIII, HCII and A2M with several micromolar affinities. Considering the 
normal concentrations of these inhibitors in real samples of blood or plasma, we should expect 
that the signal of HD1 due to these nonspecific interactions will be comparable and even exceed 
the signal from thrombin. 
We conclude that HD22 is the most relevant for real sample characterization.  
FIGURE 3.29 Inhibition of thrombin by 12.5, 50, 200 and 800 nM A2M. (A) Numerical simulation of 12.5 nM 
thrombin inhibition by various concentrations of A2M. (B) Concentration of inhibited thrombin after 30 min of 
incubation with different concentrations of A2M, predicted by numerical simulation. 
(A) (B) 
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3.6 Results of aptamer specificity in native-like environment  
Results obtained from kinetic experiments of thrombin interaction with aptamers inform 
us that aptamers possess low nanomolar range affinity to thrombin. But on the same time we saw 
that ambiguous interactions with aptamers might take place as well. As the ultimate aim of 
building biosensor for thrombin sensing is to be able to detect target protein in its real 
environment, such as plasma or blood, it is important to know how aptamers will behave in such 
complex medium. We need to be sure that sensing elements, and namely aptamers, are specific 
enough to discriminate between thrombin and nonspecific compounds of blood. Unfortunately, 
SPR instrument has its limitation for working in such complex mediums as blood or whole 
plasma, but aptamer specificity was still possible to verify with BSA and diluted plasma.  
3.6.1 Interaction with bovine serum albumin 
Before performing SPR experiments with plasma, interaction of aptamers with the most 
abundant plasma protein serum albumin was investigated (Adkins et al., 2002). Serum albumin is 
present in the concentration of 500-700 μM concentrations in plasma and it possesses 
multifunctional binding properties. One of the main roles of serum albumin is to transport fatty 
acids, hormones, nutrients, drugs etc. Serum albumin is also prone to have nonspecific 
interactions. The presence in high concentration and ability to interact with wide array of 
molecules makes serum albumin a susceptible candidate for nonspecific interactions also with 
aptamers.  
Specificity of aptamers HD1, HD22 and NU172 was verified by injecting various 
concentrations (12.5 nM – 3.2 μM) of bovine serum albumin. The sensograms of interaction of 
immobilized HD1, HD22 and NU172 with BSA are shown on figure 3.30 
At low concentrations (12.5-200 nM) of BSA, none of the aptamers showed any nonspecific 
interactions with BSA. Starting from 800 nM, HD1 and NU172 aptamers, unlike to HD22, revealed 
FIGURE 3.30 Sensograms of immobilized HD1 (A) , HD22 (B) and NU172 (C) aptamer the interaction with 
increasing concentrations of BSA from12.5 nM to 3.2 μM and 800 nM BSA spiked with 12.5 nM Thrombin 
(B) (C) (A) 
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nonspecific binding to BSA (Fig. 3.30 (A) and (C)). Nonspecific signal became significant for 3.2 
μM concentration, suggesting that affinity of BSA to HD1 and NU172 is in micromolar range.  
Since bovine serum albumin and human serum albumin are homologous proteins and 
bear structural similarities, we may assume that the effect observed with BSA might also be true 
for HSA. If we take in account the real concentration of serum albumin in plasma, we can deduce 
that in the observed signal for HD1 and NU172 interaction with real plasma sample, the main 
contribution will be due to the nonspecific interaction with serum albumin. Nonspecific signal for 
serum albumin interaction should be much higher than the signal from thrombin itself.  
The presence of BSA also showed to have slight interfering effect on thrombin association 
with aptamers. Thrombin of 12.5 nM concentration, injected with 800 nM BSA, showed lowered 
response compared to the same concentration of pure thrombin for all aptamers. But this effect 
was more prominent for HD22 (Fig. 3.30 (B)), with the difference in the signals of about 40%. 
3.6.2 Interaction with plasma 
Plasma represents a complex medium, containing 60-80 mg/ml of proteins in addition to 
various small molecules such as salts, lipids, amino acids, and sugars (Adkins et al. 2002). It is 
estimated that up to 10,000 proteins might be commonly present in serum, with varying 
concentrations, the lowest reaching 10 orders of magnitude less than concentration of albumin 
separately (Anderson and Anderson, 2002). Performing SPR measurement within such a rich 
environment, represents limitation for the instrument, therefore experiments were performed 
with diluted plasma. 
 
3.6.2.1 HD1 and HD22 aptamer interaction with 100-fold diluted plasma 
To investigate behavior of aptamers HD1 and HD22 in real like condition we used murine 
plasma. Murine plasma, centrifuged and filtered prior to experiment, was first diluted 100 times in 
PBS running buffer and then injected over the surface modified with HD1 and HD22. Interaction 
results are shown on Fig 3.31.  
Injection of 100-fold diluted plasma in PBS buffer gave significant response, especially for 
HD1. The response of HD1 interaction with plasma was about 4 times higher compared to the 
signal of the same aptamer interaction with 12.5 nM thrombin. The signal of aptamer HD22 
interaction with diluted plasma was slightly higher than that of binding to 12.5 nM thrombin. The 
same diluted plasma spiked with 12.5 and 50 nM thrombin induced response much less than only 
plasma sample or only thrombin, due to the irreversible saturation of the surface. Quality of 
obtained responses didn’t allow calibration. Therefore it is impossible to give any quantitative 
interpretation. Nevertheless, it is important to point out, that the signals shown on figure 3.31 
represent the differences between responses from the flow cells with aptamer and reference 
sequences. This means that aptameric sequences compared to their references had affinity 
towards some proteins in plasma, and notably thrombin.  
  
` 
 
107 3.6.2 Interaction with plasma 
For both aptamers after interaction with plasma sample, it was impossible to regenerate 
the sensing surface and return to the preinjection baseline. With injection of thrombin spiked 
plasma, baseline of HD1, shifted even more, whereas baseline of HD22 remained the same.  We 
suppose that the significant response from plasma sample and shift in baseline are due to several 
factors, the main of which are: (i) specific and non-specific interactions of aptamers (notably HD1) 
with plasma proteins such as endogenous thrombin, prothrombin, serum albumin etc. (the last 
two shown above to interact with HD1) and (ii) non-specific interactions of the surface with 
plasma content.  
The non-specific interactions 
with the surface are the common 
limitation of methods based on 
affinity adsorption. The more 
complex is the surface coverage the 
more is the chance of having non-
specific interactions. Presented 
experiments were performed on the 
SA sensor chip (FIGURE 3.32), the 
surface of which presents gold layers 
covered with a dense forest of 
dextran molecules bearing 
streptavidin molecules covalently 
bound with carboxyl groups for capturing biotinylated ligand. Dextran molecules tend to attach 
non-specifically and irreversibly various biomolecules from plasma, complicating the analysis of 
specific binding interactions and rendering surface unfit for further experiments.  
  
FIGURE 3.32 Surface of the Biacore SA sensor chip. Gold surface 
of the chip is functionalized with dextran molecules bearing 
streptavidin molecules bound with carboxyl functional groups.   
FIGURE 3.31 Sensograms of immobilized HD1 and HD22 aptamer interaction with plasma diluted 100  fold in 
PBS.  
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3.6.2.2 Interaction of HD1 and HD22 aptamers with plasma in the presence of NSB-reducer 
In order to reduce nonspecific binding with surface, for next set of experiments in plasma, 
nonspecific binding reducer (NSBr) buffer was added as suggested by the Biacore manufacturer. 
Carboxymethyl dextran is the main component of NSBr. It has a similar structure to the dextran 
matrix on the sensor surface, thereby reducing non-specific binding of complex sample 
components to the surface via a competition effect.  
Initially, plasma was diluted in 10 mg/ml NSB reducer buffer. 1000 times dilution of 
plasma, induced response of HD1 comparable to the signal of only 12.5 nM thrombin. HD22 
showed only insignificant interaction. Surface regeneration was successful and baseline shift 
wasn’t observed (Fig. 3.33).  
Thereafter plasma was diluted 100 times in 10 mg/ml NSB reducing solution. Response 
signal increased for both aptamers, with HD1 still showing higher interaction than HD22. 
Injection of plasma samples spiked with 12.5, 50 and again 12.5 nM thrombin gave well distinct 
signals between lower and higher concentrations (Fig. 3.34). Although the signals for duplicates 
FIGURE 3.33 Sensograms of immobilized HD1 and HD22 aptamer interaction with plasma diluted 1000 or 100 
times in 10 mg/mL NSB reducer and spiked with 50 nM and duplicate of 12.5 nM thrombin. 
(B) (A) 
FIGURE 3.34  Overlaid sensograms of immobilized HD1 (A) and HD22 (B) aptamer interaction with plasma 
diluted 100 times in 10 mg/mL NSB reducer and spiked with 50 nM and duplicate of 12.5 nM thrombin.  
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weren’t completely identical, aptamers and in particular HD22 (Fig. 3.34 (B)), showed to perform 
well and identify thrombin in these experimental conditions (1% plasma in 10 mg/mL NSB 
reducer). 
When the concentration of the NSB reducer was decreased to 1mg/mL, that is the 
concentration suggested by the manufacturer, nonspecific interaction of plasma with the surface 
became again significant (Fig. 3.35). Both aptamers failed again to show meaningful responses for 
plasma samples spiked with 6.25, 12.5 and 25 nM thrombin. HD1 aptamer instead of giving higher 
response with increase of the thrombin content gave less and less signal (Fig. 3.36 (A)). With each 
injection of sample it was evident how nonspecific interactions both with aptamer HD1 and the 
surface saturated the surface capacity and it became completely impossible to return to initial 
baseline (Fig. 3.35 red curves). In the case of HD22 the shift of the baseline wasn’t observed (Fig. 
3.35 blue curves), but capacity of the surface to bind the thrombin obviously diminished so that it 
could not reflect the increase of the thrombin concentration with each sample (Fig. 3.36 (B)). We 
FIGURE 3.36 Overlaid sensograms of immobilized HD1 (A) and HD22 (B) aptamer interaction with 100 times 
diluted plasma in 1 mg/mL NSB reducer spiked with 6.25, 12.5 and 25 nM thrombin.  
(A) (B) 
FIGURE 3.35 Sensograms of  immobilized HD1 and HD22 aptamer interaction with 100 times diluted 
plasma in 1 mg/mL NSB reducer spiked with 6.25, 12.5 and 25 nM thrombin. 
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can suppose that this effect was due to the simultaneous and comparable saturation of HD22 and 
HD22 reference surfaces by nonspecific bindings.  
Overlaid sensograms represented on FIGURE 3.33 and 3.36 show behavior of aptamers in 
1% plasma in 10 mg/mL and 1 mg/mL NSB reducer. Comparison of these results gives us two main 
results very important for aptamer-based thrombin sensor development: Firstly, in overall HD22 
showed much better performance towards specificity to thrombin than HD1. One of the most 
important factors why HD1 is getting so much interactions could be the ability of HD1 to interact 
with prothrombin which is abundant is the plasma. We can clearly see the advantage of using as a 
recognition element aptamers interacting only with the exosite II1. Secondly, these experiments in 
slightly different environmental conditions highlight how much non-specific interactions affect 
thrombin recognition by aptamers: Environment together with the surface chemistry have 
immense effect on performance of target detection. 
Possible solutions to the encountered problems could be introduction of more competing 
agents or surfactants (SDS) in the sample and selecting optimal surface such as bare gold instead 
of dextran matrix. 
As we see the main limitation of the SPR method in the case of plasma is that we are not 
able to distinguish what gets adsorbed to the surface, is this specific or nonspecific interaction, 
since whatever sticks to the surface changes the refraction index and induces SPR response. This 
shows that in all label free sensing methods (QCM, ring resonator), if optimal chemistry for 
surface modification and environmental conditions aren’t selected, there is a big chance to 
observe nonspecific attachment of the molecules from plasma, saturating the surface and 
obstructing  binding of specific target.  
 
3.6.3 Conclusions 
We studied the behavior of aptamers in the presence of nonspecific but abundant plasma 
protein BSA, which induced nonspecific response in the cases of HD1 and NU172 aptamers. 
Further experiments with diluted plasma showed that nonspecific interaction of plasma proteins 
even in the case of 100 fold dilution is sufficient to irreversibly block the surface of the sensor 
rendering it useless for further experiments. In the presence of nonspecific binding reducer, the 
share of nonspecific interactions with the sensor surface was diminished, and we could make the 
evaluation about the performance of the aptamer HD1 and HD22 in plasma.   
                                                        
1
 Although we haven’t performed experiments in diluted plasma for NU172 but as it also binds exosite 1 of 
thrombin, we can predict to have similar signal as for HD1 in the plasma, due to the undesired interactions with 
prothrombin.   
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3.7 Conclusions  
This study was the first step-by-step investigation of thrombin-aptamer interaction to 
design a functional sensor in plasma. 
Surface plasmon resonance technique was used as the main tool to investigate interaction 
of thrombin binding aptamers with thrombin, prothrombin, thrombin-inhibitor (ATIII, HCII and 
A2M) complexes, nonspecific targets and diluted plasma.  
Binding kinetics of thrombin and prothrombin elucidated complex character of 
interaction with HD1 and NU172, suggesting that both aptamers interact with thrombin not with 
one but two sites with low nanomolar affinities. In the case of prothrombin, HD1 and NU172 
aptamers revealed one order of magnitude less affinity than for thrombin. Aptamer HD22 didn’t 
show any interaction with prothrombin, however inactivation of residual thrombin by argatroban 
was needed to avoid prothrombin auto activation phenomenon.  
We showed that thrombin-inhibitor complexes were completely incapable of binding to 
either of the aptamers, due to possible allosteric changes even though binding sites were still 
exposed for interaction in the case of inhibition by ATIII and HCII. However HD1 and NU172 are 
susceptible in the nonspecific interactions with molecules of ATIII, HCII, A2M and BSA 
HD1 has very characteristic signature of interaction with prothrombin making it 
distinguishable from the binding with thrombin. But in the presence of diluted plasma, where 
there is also endogenous prothrombin and thrombin, it was impossible to say what was 
contributing to the response from HD1. Clearly, interaction with all above seen molecules (ATIII, 
HCII, A2M and BSA) and prothrombin and other plasma molecules resulted in very high 
nonspecific signal for HD1. HD22, on the other hand, proved to be specific enough to deserve 
being used as the sensing element for thrombin detection.  
Interaction with plasma samples highlighted the importance of the careful selection of 
surface, aptamer grafting methods and buffers. Although complex character of plasma medium is 
overwhelming, HD22 with 10 mg/mL NSBr solution allows for thrombin detection at 10 nM range 
in 100-fold diluted plasma.  
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CHAPTER 4. IMMOBILIZATION OF APTAMERS ON SURFACE 
4.1 Introduction 
Surface functionalization is important in many areas, but particularly in chemical and 
biological solid-phase (surface-based) sensors, because of the central role played by the interface 
between sensor and sample. Chemical modification of sensor surfaces is used in two major ways: 
first, to attach selective biorecognition element for recognition of target species in the 
sample and, second, to increase the selectivity of a sensor by reduction of interferences arising 
from non-specific interactions (Taylor and Schultz, 1996). In addition immobilization density of 
sensing element determines regime and time required for biorecognition (Esteban Fernández de 
Ávila et al., 2013). Hence, as the detection of an analyte with biosensors is dramatically influenced 
by the preparation of the biosensing surface including choice of sensing layers and coupling 
methods, from point of view of biosensor development, immobilization of biorecognition element 
on surfaces is one of the most important steps that has to be optimized at an early stage, in order 
to maximize the performance of detection.  
The expectation from surface functionalization, first of all, is to obtain an ordered and 
oriented layer of sensing elements, enabling bio-recognition. However main challenge upon 
functionalization is also to ensure unaffected affinity, high grafting density and flexibility of bio-
receptor and, at the same time, low nonspecific adsorption, low noise to signal ratio (Dugas et al., 
2010). In addition, for reusable sensors, crucial parameter is the stability of the functionalized 
recognition element after regeneration steps. Out of these parameters only flexibility and 
associated degree of freedom can be fine-tuned by incorporating flexible spacers attached close to 
the surface that can lift sensing elements in a ”solution-like” environment, avoid steric hindrances 
and allow optimum binding.  
The other above-mentioned parameters depend on choice of functionalization procedure. 
The choices of surface functionalization strategies depend, on one hand, on available types of 
terminal functional groups linked to sensing elements; and, on the other hand, on choice of solid  
substrate. These determine the type of chemistry that can be used for conjugation (Fig. 4.1).  
For aptamers, adding various functional groups 
doesn’t represent a difficulty, but most commonly 
used  termini modifications  are amine, thiol, carboxyl, 
phosphate or biotin functionalities (Tolle and Mayer, 
2012).  
The choice of substrate is predicated 
predominately by the readout format of the molecular 
association or application area, such as SPR, QCM, 
electrochemical, fluorescence, methods atomic force 
microscopy, capillary electrophoresis, affinity 
chromatography etc. 
FIGURE 4.1 Scheme of decision making for 
functionalization chemistry 
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Thus, different analytical methods require various materials, including, but not limited to, 
gold, glass, silica and silicon surfaces, carbon nanotubes, quantum dots, carbohydrates, polymer 
and bioorganic substrates for probe immobilization (Balamurugan et al., 2008). These substrates 
can be used as a planar support or as nanoparticles to produce monomolecular layer or 
multilayers of controlled thickness (Dugas et al., 2010).  
In this chapter, we explore different surfaces and methods of aptamer immobilization 
techniques. 
4.1.1 Methods of immobilization of aptamers 
Aptamers being oligonucleotides are immobilized with chemical methods previously 
developed for DNA sensors (Wittmann and Marquette, 2006). The most common method for 
DNA attachment to a surface or affinity reactions are physical adsorption, chemisorption, 
covalent linking, bio-coating (Balamurugan et al., 2008; Nimse et al., 2014; Zhou et al., 2011).  
4.1.2 Physical adsorption 
Physical adsorption is the easiest method for attaching nucleic acids to surface as no 
reagents or modifications are required and where no chemical bonds are formed. Electrostatic 
attraction between opposite charges of DNA phosphate backbone and surface is the most 
common mechanism. But adsorption yields a layer of sparsely bound molecules that do not resist 
thorough washing steps that are required to regenerate the surface. Moreover most of the 
immobilized probe lies in a position that is not favorable to interactions (Banica, 2012).  
Despite these inconveniences, aptamer adsorption-desorption has been used in biosensors 
with bare carbon, composite carbon (Banica, 2012), graphene oxide (Song et al., 2014; Wu et al., 
2011), carbon nanotubes (Li et al., 2014) or titanium dioxide (Zhang et al., 2014) surfaces. Typically 
adsorbed aptamer is fluorescently-labeled, but fluorescence is quenched due to close proximity 
with the surface possessing quenching properties. Fluorescence or chemilluminescense signal is 
reemitted following aptamer desorption from the sensor surface and consequently upon 
interaction with target.  
Although, adsorption is considered as a promising immobilization method for mass-
production of disposable screen-printed sensors, for reusable affinity sensors stability of the 
attached aptamer layer is important during binding and regeneration phase. Thus methods of 
immobilization based on physical adsorption of DNA by means of electrostatic interactions are 
not exactly suitable for affinity sensor development. 
4.1.3 Chemisorption 
Chemisorption is a kind of adsorption, which involves, in contrast with physical 
adsorption, a chemical reaction between the surface and the adsorbate, creating new chemical 
bonds on the surface. After chemisorption, compared to physisorption, much less molecules are 
laying on a surface and more are accessible for interaction. In addition, regeneration doesn’t 
induces desorption of grafted molecules (Lalauze, 2012; Nimse et al., 2014). 
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A famous example of chemisorption is interaction of gold surface and sulfur functional 
groups of ligand to form a strong S-Au bond. Sulfur-gold interaction enables a single-point 
attachment of the probe that gives it conformational mobility that in turn results in a relatively 
high reactivity (Bain et al., 1989). This method is widely used to graft thiol-labeled aptamers on 
the gold surface due to its simplicity and because gold layers are often used in various types of 
chemical and biological sensors (electrochemistry, SPR, QCM, gold nanoparticles etc.).  
4.1.4 Covalent attachment 
In the covalent approaches a chemical bond is made between the surface and the attached 
species, which is the irreversible process (Dugas et al., 2010). The nature of this bond and the 
types of modification which can be carried out depend on the particular surface and the chemical 
functional groups present on the surface. Therefore it is often required to form suitable functional 
groups on the support surface prior to crosslinking with the probe. Through covalent attachment 
aptamers can be immobilized on various substrates such as glass, silicon, carbon, gold, polymers 
etc. The three most common groups employed for surface attachment of nucleic acids are 
hydroxyl, amine, and carboxyl (Mascini, 2009).  
Hydroxylated surfaces are first modified with carbonyldiimidazole (CDI) to form a 
reactive intermediate, which forms a stable carbamate bond to an amino-terminated aptamer 
group. 
Amine-terminated surfaces provide several options for aptamer attachment: A surface 
amine group can be modified with glutaraldehyde, which forms an imine bond leaving the other 
aldehyde free for repeating this chemistry with an amino-terminated aptamer group;  
Symmetrical diisothiocyanates have been used as bifunctional linkers for attachment of amine-
functionalized surfaces to either thiol-terminated or amine-terminated aptamers.  
Carboxyl-terminated surfaces can be coupled to with amino modified-aptamers with 
EDC/NHS coupling chemistry.  
Even though, coupling of probes to a solid support may be time consuming, costly and 
less successfully achieved than non-covalent attachment, but it results in a rugged recognition 
layer that is suitable for multiple uses (Banica, 2012).  
4.1.5 Bio coatings 
Bio coating of surface such as avidin or one of its derivatives, have been shown to be 
highly successful for immobilizing biotin-tethered aptamers on various surfaces (e.g., gold, 
silicates, polymers) (Balamurugan et al., 2008). This method is operationally easy, and mainly 
requires incubation of the biotin-tethered aptamer with the avidin-coated substrate at room 
temperature in a buffer solution to give efficient immobilization of biotin to avidin (Mascini, 
2009). In turn avidin and neutravidin are usually linked chemically to the organic layer formed by 
3,3-dithiopropionic acid di(N -succinimidyl ester). Neutravidin is very convenient because it can 
be chemisorbed directly on gold and glass and does not require additional chemical modification 
of the surface (Mascini, 2009). 
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4.1.6 Aim of this study 
As we have seen above various surface and aptamer modifications require specific 
chemical protocols. Some of them are easy to perform but some of them are requiring good hand-
one experience. The quality of obtained layers also differs in terms of grafting density, 
functionality, nonspecific adsorption. Characterization of the immobilized aptamers represents 
also important point.  
The aim of the study discussed in this chapter is to explore aptamer- grafting techniques 
on various surfaces and to evaluate their application for bio-sensing. Supports for 
functionalization were selected from based on their properties as sensing platforms. We intended 
to investigate functionalization of gold and polycarbonate planar substrates and gold and 
polystyrene nanoparticles.  
Gold surface was selected as it is the most utilized surface due to its advantageous 
properties. Gold is air-stable and doesn’t oxidize. It is commercially easily available as a film or as 
nanoparticles. Gold film can be deposited on various substrates which diversifies its application 
and utility. Discontinuous gold films, evaporated on transparent substrates with standard 
microfabrication technologies, show localized surface plasmon extinction in the visible-to-NIR 
range that is highly sensitive to changes in the dielectric properties of the contacting medium, 
thus enabling to monitor the binding of molecular layers to the Au film with high sensitivity 
(Karakouz et al., 2008). Surface plasmon resonance, total internal reflection fluorescence 
spectroscopy, Surface enhanced resonance Raman and resonance Raman scattering methods are 
all based on the optical properties of gold (Anker et al., 2008; McNay et al., 2011) In addition gold 
is good electric conductor and it can be used as the electrode in electrochemical sensors.  
The most prevalent property of gold is the ease of immobilization of thiol-bearing 
molecules, through gold-sulfur bond formation. Formed layer represents monolayer with highly 
ordered nature (Bain et al., 1989). Considering the fact that gold nanoparticles have larger specific 
surface than planar surface, we decided to investigate both surfaces. 
Polycarbonate represents also very interesting material for sensor development 
especially for disposable point-of-care sensors, since it is widely available and cheaper than glass 
(Ahn et al., 2004). It offers advantages of optical transparency for spectroscopic signal recovery 
and do not quench fluorescence signals as is the case for gold (or other metal) substrates. On the 
other hand it has improved optical  and mechanical properties than many types of glasses, is 
resistant to chemical, temperature and high impact and what’s the most important - it is 
moldable. In contrast to gold surface, grafting chemistry is a bit complicated, since first functional 
groups on the surface have to be activated and only then covalent coupling reaction with amino-
labeled DNA can be performed.  
Polystyrene particles where selected due to their fluorescent properties. Commercially 
they can be synthetized with various colors and surface functionalities. Compared to gold 
nanoparticles their density is about 20 times smaller and therefore sedimentation problem 
doesn’t exist even for several µm size particles.  
 
  
` 
 
 
119 4.2.1 Immobilization of aptamers on gold 
4.2 Experimental 
4.2.1 Immobilization of aptamers on gold 
In order to immobilize aptamers on gold we used DNA strands with thiol functional group 
added at the 5’ end (Bain et al., 1989). To increase flexibility of the aptamer we added linker 
composed of 20 thymines between aptameric sequence and thiol group.  Sulfur, present in the 
thiol functional group is known to form moderately stable quasi-covalent (chemoadsorption) 
bond with gold (126-146 kJ/mol)(Nuzzo et al., 1987). This bond is widely used to attach biological 
linkers, functional groups and other molecules to gold surfaces. We functionalized both gold 
films and gold nanoparticles. DNA sample preparation is similar for both cases. 
4.2.1.1 Preparation of the thiol-modified DNA for grafting 
The terminal sulfur atoms of thiolated DNA form dimers in solution, especially in the 
presence of oxygen. Dimerization greatly lowers the efficiency of subsequent coupling reactions 
such as DNA immobilization on gold. Common way to reduce disulfide bonds is to mix thiolated 
molecule with dithiothreitol (DTT) (Cleland, 1964).  
In our experiments thiolated ends of aptamer (4 µM) were activated by cleavage of the 
disulfide bolds using 0.1 M of freshly prepared DTT dissolved in 0.2 mM phosphate buffer over an 
hour period of incubation at room temperature. DTT was then removed by passing DNA–DTT 
mixture through the size-exclusion chromatographic column (NAP-5) that can treat up to 50 μL 
solution retaining small molecules like salt and DTT, but letting larger molecules of DNA to flow 
through. This procedure is called desalting (Fig. 4.2).  During desalting initial concentration of 
DNA is expected to be reduced with 10%.  
4.2.1.2 Functionalization of planar gold surface with thiolated DNA 
Gold coated silicon wafer (with 5 
nm titanium as adhesion layer, between 
silicon and 100 nm gold film) was cut in 
2x2cm chips. Gold-covered chips were 
cleaned with freshly prepared Piranha 
solution for 10 min on a rocker to 
remove any impurities. The wafer was 
then rinsed copious amount of double 
distilled water and dried with N2.  
Sample of freshly desalted ssDNA 
FIGURE 4.3 Schematic illustration of planar gold surface 
functionalization with thiolated DNA  
FIGURE 4.2  Schematic representation of oxidation, deprotection and desalting stages of thiolated DNA 
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was mixed with NaCl and PB to obtain solution with final concentration of 0.7 M and 10 mM, 
respectively. DNA mixture was poured over the gold surface (Fig. 4.3). Treatment with piranha 
renders gold surface hydrophilic, thus DNA solution spread over the surface and covered it 
completely. Surface was left to incubate overnight at room temperature in covered Petri dish in 
the bottom of which was wet tissue paper, in order to maintain high humidity and reduce 
evaporation of liquids from the sample. After the incubation, the wafer was rinsed with plenty of 
water and dried under nitrogen flux.  
4.2.1.3 Functionalization of gold nanoparticles with thiolated DNA 
We used the protocol developed by Mirkin (Mirkin et al., 1996) and further optimized 
(Hurst et al., 2006; Liu and Lu, 2006) for DNA grafting on gold nanoparticles. 
Prior to functionalization, commercial gold nanoparticles, of 20 and 80 nm diameter, were 
sonicated for 2 minutes to resuspend sedimented and aggregated particles. To ensure that colloid 
hasn’t aggregated and to adjust colloid concentration, the next step was to measure the UV 
absorbance of the sample. Since gold nanoparticles possess strong plasmon field, they absorb 
light and, with increasing the size, the characteristic maximum of absorbance increases. So by 
measuring the absorbance of gold colloid, on one hand it is possible to make a quality check - If 
particles have aggregated irreversibly, the color of colloid solution will be more bluish and the 
absorbance maximum will be shifted; and on the other hand, determine the concentration of 
suspended particles using simply Beer-Lambert law (eq. 2.7).  
Absorbance maximum for 20 nm diameter NPs is at 520 nm with extinction coefficient ε 
=8.78 × 108 L/(mol*cm). For 80 nm diameter particles the maximum absorbance is at 550 nm (Fig. 
4.4) and corresponding extinction coefficient is ε=6.85 × 1010 (Haiss et al., 2007; Liu et al., 2007). 
For functionalization we adjusted concentration of particles to be to 1 O.D. that corresponds to  7 
x 1011  and 1.1 x 1011 particles respectively for 20 and 80 nm diameter (BBInterntional solutions 
2014).  
50 μL freshly deprotected thiolated aptamers were added to 950 μL of 1 O.D. NPs and the 
concentration of phosphates was adjusted to 10 mM by incorporating Phosphate buffer 
(NaH2PO4/K2HPO) of pH7.4. To avoid aggregation of the gold nanoparticles Tween 20 with final 
0.01% concentration was also injected. To facilitate aptamer grafting on the gold surface, the 
charge at the surface has to be destabilized by addition of NaCl. But sudden increase of salt 
concentration induces unwanted aggregation of particles. Therefore salt was titrated in small 
FIGURE 4.4 UV absorbance spectra of 80 nm diameter spherical gold nanoparticles 
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beads 
portions every 20 minutes, so that with each step, increment of salt concentration was 0.1 M, until 
final concentration of NaCl became 0.7 M. This procedure is called salt aging (Fig. 4.5). After each 
titration of NaCl, appropriate amount of PB and tween were also added, to maintain constant 
concentration of PB and surfactant, and sample was sonicated for 1 min. This solution was left 
overnight on a microtube-rotator to prevent sedimentation. 
After overnight incubation, to remove 
excess DNA, samples were centrifuged at 14000 
rpm for 20 and 5 minutes respectively for 20 and 80 
nm nanoparticles. The dark pellet of the particles 
appeared on the bottom of the tube and solution 
lost purple color. Supernatant was discarded and 
the pallet was suspended in double distilled water 
after 1 minute sonication. After three-four 
centrifugation and re-suspension step, water 
suspension of DNA-functionalized gold particles 
was stored at 4°C. 
Average size of the gold particles was measured before and after functionalization with 
DLS method. Observed change of about 15 nm indicated successful functionalization step. 
4.2.2 Immobilization of aptamers on the carboxyl-modified polystyrene beads 
To functionalize carboxyl modified polystyrene beads (surface titration value of carboxyl is 
288 µmoles COOH groups/gram beads) we used ssDNA bearing amino group with C6 linker at 5’ 
extremity. As, for all the cases, here also between aptameric sequence and functional group spacer 
of 20 thymines was included. For linking the surface and DNA covalently, we used carbodiimide 
coupling chemistry following the protocol form the manufacturer (TechNote 205 Banglabs).  
100 μL of 0.1 μM carboxylate modified fluorescent polystyrene beads of 20 mg/mL 
concentration were diluted in 900 μL 50 mM MES buffer of pH 4.5. After vortexing for few 
seconds samples were centrifuged for 30 min at 14000 rpm. Supernatant was discarded and pellet 
was resuspended in 1mL 50 mM MES buffer. This step was repeated 2 times in order to wash the 
beads. After last centrifugation, pellet was reconstituted in 500 μL 50 mM MES buffer of pH 6.2, 
containing 10 mM EDAC and 100 mM NHS and let to incubate for 20 minutes mixing (Fig. 4,6). 
DNA was added an incubated for 2-3 hours at room temperature in a microtube rotator. 
FIGURE 4.6 Schematic illustration of functionalization of carboxyl-modified latex nanoparticles with amino-
modified DNA 
FIGURE 4.5 Schematic illustration of gold NP 
functionalization of with thiolated DNA 
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Subsequently mixture was centrifuged for 30 min at 14000 rpm to sediment the particles. The 
supernatant was removed and 250 μL double-distilled water was added, the mixture was vortexed 
and sonicated and again centrifuged for 30 minutes. This step was performed twice for water, 
twice in 10 mM glycine buffer of pH 6, twice with finally particles were resuspended in PBS buffer 
of pH 7.4 and stored in the fridge at 4 °C. 
4.2.3 Immobilization of aptamers on polycarbonate surface 
One cm thick polycarbonate sheet was cut into 1x2 cm size rectangular chips. 
Polycarbonate chips were rinsed with ethanol and dried. To activate i.e. to form polar 
functionalities and mostly reactive COOH (carboxyl) on the surface of polycarbonate, substrate 
was introduced inside PVA Tepla microwave Plasma system for O2 Plasma treatment at power of 
200 W for 30 seconds.  
Over the activated surface 200μL amino-modified DNA sample was immediately poured. 
DNA sample contained 1 μM oligonucleotides mixed with 50 mM MES buffer at pH4.5, 10 mM 1-
Ethyl-3-(3-Dimethylaminopropyl)carbodiimide (EDAC) and 100 mM N-Hydroxysuccinimide 
(NHS). Polycarbonate substrate with DNA sample was incubated overnight in the covered petri 
dish with the wet tissue paper on the bottom to maintain high humidity level. After incubation 
surface was rinsed with distilled water and dried under nitrogen flux. (Tamarit-López et al., 2011) 
4.2.4  Characterization of grafted aptamer functionality by np aggregation 
Aggregation experiments were performed with Zetasizer Nano S (Malvern technologies, 
the principle of the method is described in Chapter 2), that allowed to measure average 
hydrodynamic radius of the aggregate in time-dependent manner. Aptamer- functionalized 
nanoparticles were diluted in PBS buffer to obtain final concentration of particles of 0.1 O.D. This 
concentration of gold nanoparticles corresponds to 1.9 nM aptamers. First the initial size of the 
NP was measured as the control assuring that there was no aggregation without thrombin, and 
only then the protein was introduced. Experiments were performed at room temperature in 
disposable plastic cuvettes for small volume samples.  
Verification of aptamers specificity towards nonspecific protein: Specificity of the 
aptamers towards thrombin was verified by injecting Bovine Serum Albumin of final 
concentration of 100 nM instead of Thrombin.  
  
FIGURE 4.7 Schematic illustration of functionalization of polycarbonate surface with amino-modified DNA 
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4.2.5 Characterization of aptamer grafting density on the surface of gold NPs 
4.2.5.1 Determination of surface density of gold nanoparticle-bound-aptamers 
In order to determine the density of aptamer grafting, we need to know number of 
particles in the sample and the amount of DNA in the sample (Demers et al., 2000; Hurst et al., 
2006).  
For this reason 80 nm gold nanoparticles were functionalized with thiolated HD1 aptamer 
labeled with fluorescent dye Rhodamine G6. After last step of cleaning, pellet of gold 
nanoparticles was resuspended in 200 µL solution containing 0.5 M DTT and 0.2 M PB buffer of 
pH7.4. DTT disrupts gold-sulfur bond and displaces DNA from the particles (Thaxton et al., 
2005).  
Before letting the sample to incubate overnight in the microtube rotator, UV-visible 
spectroscopy measurement was performed to determine the concentration of gold nanoparticles 
in the sample (eq. 2.7).  
After the overnight incubation oligonucleotides were released into solution (Fig. 4.8). 
After centrifugation gold precipitate was removed and fluorescence of the sample was measured. 
To determine oligonucleotide concentration, 80 μL of supernatant was placed in a 96-well plate 
and the fluorescence was compared to a standard curve prepared by 2 fold serial dilution of 200 
nM the same Rhodamine G6 –labeled fluorescent DNA. Because the Rhodamine G6 fluorophore 
is sensitive to pH, the oligonucleotide samples for the standard curve were prepared with the 
same 0.5 M DTT and 0.2 M PB buffer solution. During the fluorescence measurement, the 
fluorophore was excited at 550 nm and the emission was collected at 580 nm, close to the 
characteristic absorbance and emission maximums of Rhodamine G6. The fluorescence signal was 
compared to the signals obtained from standard curve and concentration of the fluorescent DNA 
in the sample was determined.  
 
  
FIGURE 4.8 Illustration of thiolated fluorescent ssDNA displacement after incubation with DTT  
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4.2.5.2 Determination of surface density of functional aptamer  
Not all the DNA after functionalization step will be bound to the surface specifically (will 
be lying on the surface via bonding of the nitrogen lone pairs of the nucleotide bases) or will be 
accessible for interaction. It is important to know what is the functional aptamer density that are 
able for interaction with protein or with complementary strand (Demers et al., 2000).  
In order to determine how much of grafted DNA is in conformation to bind the target we 
performed similar experiment as for determination just DNA density with exception that the 
pellet of 80 nm gold particles functionalized with non-labeled HD1 aptamer, were resuspended in 
100 µL PBS solution of pH7.4 containing 500 nM complementary to HD1 ssDNA labeled with 
Alexa532 fluorophore. To achieve hybridization, sample was incubated for 2 hours at room 
temperature (Fig. 4.9). After hybridization, it was necessary to remove unbound fluorescent DNA. 
For this reason sample was centrifuged and supernatant was discarded. Pellet was reconstituted 
in 200 µL solution of 0.2 M PB and 0.5 M DTT and let to incubate overnight. After incubation, UV 
absorbance measurement and subsequent centrifugation supernatant was collected and 
fluorescence was compared with fluorescence of the standard curve of 20 to 100 nM concentration 
samples. During the fluorescence measurement, the fluorophore was excited at 530 nm and the 
emission was collected at 560 nm.  
  
FIGURE 4.9 Illustration of displacement fluorescent dsDNA after incubation with DTT. First AuNP-bound 
ssDNA was incubated with complementary florescent strand and then both of them were displaced by DTT.  
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4.3 Validation algorithm 
Here we have to mention that we did not intend to carry out in-depth characterization of 
surface with sophisticated methods nor developed new ways or methods for aptamer grafting on 
the surface, but we tried to evaluate what we should expect from the different simple grafting 
methods on important and widely used material surfaces. Using only optical microscopy, dynamic 
light scattering (DLS), Zeta potential, UV-vis and fluorescence spectroscopy we followed the 
validation criteria to characterize aptamer grafting.  
4.3.1 Validation Criteria: 
Qualitative criteria:  
 Show that surface is DNA functionalized observing with microscopy or 
Zetapotential/DLS; 
 Verify whether grafted aptamers are functioning to recognize specific targets 
Quantitative criteria:  
  Characterize (if possible) surface density of grafted aptamers and their 
functional efficiency.  
To assume that aptamer immobilization was successful qualitative criterion needs to be 
fulfilled unconditionally. 
Under verifying functional capabilities of immobilized aptamers we mean indeed 
examining interactions of surface-bound aptamers with thrombin. For nanoparticles this can be 
achieved by mixing aptamer-bound nanoparticles with thrombin and observing the change of 
average diameter by DLS method. But mixing particles with different aptamers recognizing 
distinct epitopes of thrombin in the presence of thrombin, should lead to the interlinking 
particles and lead to aggregation. If functionalization is not successful or thrombin is not 
accessible, no aggregation should be observed. 
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4.4 Results of aptamer immobilization on planar support 
Immobilization of aptamers on the planar support has crucial importance for reusable, 
solid-phase affinity sensors. We decided to investigate aptamer immobilization on two distinct 
planar surfaces; polycarbonate and gold, with different optical and chemical properties and 
requiring distinct chemical procedures, but both of them have very high potential to be used as a 
support for immobilization of sensing element. However we highlight, that the characterization 
used for planar supports is minimal compared to nanoparticles.  
4.4.1 Polycarbonate substrate 
Thus first candidate for the functionalization was polycarbonate substrate. We 
functionalized by O2 plasma activation and subsequently formed carboxyl groups were coupled 
with carbodiimide chemistry to amino-modified DNA. In order to visualize the presence of DNA 
on the surface, we grafted on the surface fluorescently labeled amino-modified DNA bearing 
Alexa 532 fluorophore.  
We tried to observe fluorescence intensity difference between non-functionalized and 
DNA-functionalized PC surface by means of fluorescence microscopy. We were surprised to see 
that both modified and non-modified surface, when illuminated with green light for excitation 
Alexa532, were fluorescent. In fact, whole thickness of the polycarbonate sample was fluorescent. 
This was an effect of autofluoresence. Studies (Hawkins and Yager, 2003; Piruska et al., 2005) 
show that due to some additives or impurities introduced during the manufacturing, PC might 
exhibit strong absorbance and certain level of autofluoresence, that may fade out to a lower 
intensity with the time (several hours) of light exposure, but it can be still limiting factor for high-
sensitivity optical fluorescence detection.  
Different studies have shown successful application of the polycarbonate surface (Ahn et 
al., 2004; Tamarit-López et al., 2011), but it is worth mentioning that quality of the PC varies with 
the differences in processes of manufacturing that will manifest themselves as differences in 
fluorescence. Also important is that the post-production age and handling of material from the 
same vendor can vary.  
Thus, failing the very first validation criteria and learning that PC surface is not always the 
best choice for application in sensing, we didn’t continue any further experiments with 
polycarbonate surface. 
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4.4.2 Gold surface 
Next we investigated aptamer immobilization on gold surface, deposited over the surface 
of silicon wafer. For immobilization we used thiol-terminated aptamers and followed well 
established protocol. In order to verify aptamer grafting through microscope, aptamers where 
fluorescently labeled with Rhodamine G6 dye. (Fig. 4.10) 
The difference in fluorescence intensity 
between functionalized and non-functionalized 
surface was significant. We saw clear brightness of 
the Rhodamine G6 modified gold specimen 
compared to control gold surface. This result gives 
us possibility to get the qualitative information, 
that functionalization step was successful, but  for 
characterization whether immobilization is due to 
physisorption or chemisorption and how 
functional are grafted aptamers require further 
experiments.  
Methods that have been used for surface 
analysis of structure and composition of the 
aptamer monolayers include X-ray photoelectron 
spectroscopy (XPS) and  infrared spectroscopy methods (Opdahl et al., 2007), contact angle 
measurements, quartz crystal microbalance, and electrochemical methods (Castelino et al., 2005; 
Herne and Tarlov, 1997). However these methods require special instruments and expertise. We 
decided to simplify characterization problem by using gold nanoparticles, that are easier to be 
handled than planar surface, but general properties of grafting would be the same. 
  
FIGURE 4.10 Grafting of the DNA on planar gold 
surface. On the left is the non-modified gold 
surface. On the right,  thiolated DNA labeled with 
Rhodamine G6 fluorophore is grafted on the  gold 
surface. 
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4.5  Results of aptamer immobilization on nanoparticles 
On one hand nanoparticle represent nano-scale surfaces, that are easier to handle but, on 
other hand, nanoparticles on their own are important objects with properties unique to nano-
objects (Anker et al., 2008). In addition, nanoparticles offer the advantage of high surface to 
volume ratios and the possibility of combining with bulk characterization techniques. Thus, 
investigating their functionalization for application in bio-sensing is also very interesting subject.  
4.5.1 Gold nanoparticles 
First, gold nanoparticles were functionalized to answer the open question from the 
functionalization of planar gold surface. Since they possess unique properties such as 
colorimetric, conductivity, nonlinear optical properties, easy functionalization with biological 
recognition elements, gold nanoparticles also hold great promise for biosensing together with 
biological and medicinal applications. 
We functionalized gold nanoparticles of 20 or 80 nm size through chemisorption of 
thiolated ssDNA strands. To verify that the particle were well functionalized we performed 
measurement of the average hydrodynamic diameter by dynamic light scattering before and after 
functionalization procedure. Average change in size with 20-25 nm for 20 nm diameter and 15-20 
nm for 80 nm diameter particles confirmed successful grafting of the DNA on the surface of the 
particles. Fig. 4.11 shows the overlaid distributions of size of particles before and after 
functionalization step.  
The onset in hydrodynamic radius is related to the fact that aptamers are polymers with 
intra-chain hydrodynamic interactions (Zimm model), which increases the overall hydrodynamic 
drag of NP plus aptamers. Effect is larger on smaller particles, therefor average change in size 
after functionalization for 20 nm gold nanoparticles is larger than in the case of 80 nm size NPs  
(Diallo et al., 2009; Zimm and Bragg, 1959). 
Measuring Zeta potential of the particles, the effective surface potential at the 
hydrodynamic “shear surface” close to the solid-liquid interface, showed how surface charge of 
gold particles changed after functionalization step. It is assumed that for bear metal particles 
without an oxide layer, surface shouldn’t have inherent change but the negative zeta potential is 
due to preferential adsorption of negative ions to the surface. For coated particles zeta potential 
  
 FIGURE 4.11 Size distribution of non-functionalized and aptamer-functionalized (A) 20 nm and (B) 80 nm 
size  gold nanoparticles measured with DLS 
(A) (B) 
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describes the region at the boundary between the solvent and the coating. (Dougherty et al., 
2008) The initial zeta potential for bear AuNP measured in water was -39 ± 1 mV, after 
functionalization step zeta potential of aptamer-functionalized gold particles became -27± 1 mV, 
this significant change also confirms the successful functionalization.  
After having confirmed that functionalization step was successful, we wanted to verify 
whether the surface-grafted aptamers survived grafting procedure and still maintained their 
aptameric character of binding target.  
4.5.2 Aggregation of aptamer-functionalized Nanoparticles 
To show that aptamers where functioning well we decided induce the aggregation of the 
aptamer-functionalized particles. Since HD1 and HD22 can simultaneously interact with two 
distinct exosites of the same thrombin molecule, thrombin can act as the linker or bridge between 
two NPs functionalized one with HD1 (HD1-AuNP) and the second with HD22 (HD22-AuNP) (Fig. 
4.12).  
Aggregation of particles functionalized with complementary strands, or with strands 
interacting with the common target, has been previously shown in many studies including for 
thrombin and its aptamers (Lin et al., 2009; Mirkin et al., 1996; Pavlov et al., 2004; Zhao et al., 
2008). In most studies aggregation kinetics is followed by eye or UV absorbance technique, where 
they observe the change of characteristic absorbance spectrum (shift of the colloid color form 
Bordeaux to purple and blue with increase of the size) upon aggregation. We instead followed 
course of aggregation with DLS, measuring the instant average size of aggregate with defined time 
intervals.  
We performed aggregation experiment with the mixture of 20 nm size HD1-AuNP and 
HD22-AuNP in the presence of 30 nM thrombin. As we see on the Fig.4.13 (A), the particle 
aggregation induced by thrombin started immediately and aggregate size reached up to 800 nm 
in following 40 minutes. Thus we endorsed the activity of the grafted aptamers.  
 
FIGURE 4.12 Schematic illustration of thrombin-assisted aggregation of nanoparticles functionalized with 
aptamers interacting either with one or another exosite of thrombin. 
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(A) (B)
In order to make sure that this aggregation didn’t occur due to perturbation of the balance 
of colloid system in the presence of any protein leading to aggregation, we decided to perform 
similar aggregation experiment with BSA, the protein that is non-specific to aptamers and is 
present in plasma in high amount. Fig. 4.13 (B) shows that the titration of BSA in the mixture of 
20 nm size HD1-AuNP and HD22-AuNP induced only marginal increase (3-5 nm) of average size 
of the particles and no further increase in averages size, indicating aggregation, was observed. 
This result shows that aggregation in the presence of thrombin indeed happened due to specific 
and simultaneous interaction of HD1- and HD22- modified NPs with appropriate binding sites of 
thrombin.  
In addition, a significant result is that, we can argue that in the case of BSA observed slight 
augmentation of the average size was due to nonspecific interaction with one of the aptamers but 
since there was no simultaneous interaction with both aptamers no aggregation was observed 
and, basically, with this example we demonstrate how targeting two sites at once improves the 
specificity of detection. This lets us to use aggregation not only to characterize functionality of 
grafted aptamers but also to use this approach as the method of sensing. Nevertheless, there is 
still need to characterize the density of grafted aptamers and the density of the aptamers 
functional for interaction that cannot be assessed neither by DLS nor zeta potential.  
4.5.3 Characterization of density of total and functional grafted-DNA 
Now when the two unconditional criteria (successful grafting and functional aptamers) 
are fulfilled and gold nanoparticles show good functionality and specificity after 
functionalization, it is interesting to characterize grafting quantitatively.  
In order to characterize the density of grafted molecule on the surface of the gold nano 
particles we functionalized 80 nm diameter gold particles with thiol modified DNA fluorescently 
labeled with Rhodamine G6. Nanoparticle concentration was determined sing UV-vis 
spectroscopy. Nanoparticle-bound oligonucleotides were liberated into solution by addition of 
DTT, and quantified using fluorescence spectroscopy. The formulas for calculation aptamer 
grafting density are following: 
  
 
FIGURE 4.13 Aggregation kinetics of 20 nm size AuNP functionalized with HD1 or HD22 aptamers in the 
presence of (A) 30 nM Thrombin and (B) 100 nM BSA. First three points represent the average size of AuNP 
before aggregation in the absence of a protein. 
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FIGURE 4.14 Standard curve of dependence of fluorescence intensity on concentration of DNA labeled with 
(A)Rodhamine G6 and (B) Alexa 532. Blue Line corresponds to the concentration of the ssDNA displaced from 
the surface of gold nanoparticles by 200 µL DTT solution. 
(A) (B) 
  
 
The ratio of the fluorescent DNA concentration (𝐶𝐷𝑁𝐴) and AuNP concentration (𝐶𝐴𝑢𝑁𝑃) 
in the sample, give the number (𝑛) of DNA strands per particle. 
𝑛 =
𝐶𝐷𝑁𝐴
𝐶𝐴𝑢𝑁𝑃
 (4.1) 
Assuming that nanoparticles are all spherical with defined diameter (𝑑), the surface area 
of the particle can be calculated. 
𝑆 = 𝜋𝑑2 (4.2) 
Dividing the number of DNA (𝑛) per particle on the surface area (𝑆) of the particle, we 
obtain the surface density of the DNA coverage (𝜌). 
𝜌 =
𝑛
𝑆
=
𝐶𝐷𝑁𝐴
𝐶𝐴𝑢𝑁𝑃
×
1
𝜋𝑑2
 (4.3) 
After calculations we found that 46.1 ±0.5 nM (Fig. 4.14 (A))concentration Rhodamine G6 
– labeled DNA was displaced from 0.035 nM gold NP (Abs(550nm)=2.37 O.D.) in 200 µL DTT+PB 
solution. Meaning that in average 1326 DNA strands were grafted on the surface of each 80 nm 
diameter particle, which corresponds to the 6.6 x 1012 DNA/cm2 surface density.  
On the other hand to verify how many out of grafted DNA were accessible for the 
interaction DNA-functionalized 80 nm gold nanoparticles where incubated with complementary 
strand labeled with Alexa 532 fluorophore. Concentration of gold nanoparticle and double 
stranded DNA liberated after DTT treatment was determined similarly as described above. 
Hybridization of the nanoparticle-bound ssDNA with its complementary strand labeled 
with Alexa532 fluorophore revealed that the concentration of DNA available for hybridization, 
corresponding to 0.049 nM gold NP (Abs(550nm)=3.34 O.D.), was 22.5 ±0.5 nM (Fig.4.14(B)). That 
gives us about 460 functional DNA per particle of 80 nm diameter i.e. surface density of 
functional DNA is 2.3 x 1012 DNA/cm2. The ratio between   functional DNA density and DNA 
grafting density, we get that about only 35% of grafted DNA is accessible for interaction.  
Obtained results are in good conformity with the results reported by earlier studies (Hurst 
et al., 2006), where they investigated effect of spacer, experimental conditions and size of the 
particles on the density of DNA grafting. Smaller particles where showed to have higher DNA 
coverage than larger. In addition, taking in account that surface area to volume ratio of particles 
increases with the decrease of the particle diameter, we can imagine that small particles represent 
very strong platforms for bio-sensing.  
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Overall carried out experiments showed how easily can be gold nanoparticles 
functionalized and characterized. Also the aggregation assay, used to demonstrate aptamer 
functionality offers opportunities to investigate different points in low cost, which we will discuss 
later on in this chapter.  
4.5.4  Polystyrene nanoparticles direct and indirect assembly 
Seeing that gold nanoparticles where so easy to handle and functionalize we decides to 
investigate other aptamer grafting methods with different chemistry also on the nanoparticles. 
For this reason, we choose to try functionalization of polystyrene nanoparticles bearing 
carboxylate moieties on the surface. This choice was made because polystyrene particles offer 
some interesting properties that are not available for gold particles such as: low density (1,05 
g/cm³, compared to gold density  19.30 g/cm3),making them  less prone to sedimentation; 
fluoresce, allowing observing interaction (aggregation ) with fluorescence methods; possibility of 
incorporation of magnetic cores  and various surface modification.  
We used 100 nm size fluorescent polystyrene nanoparticles with carboxyl groups to 
explore the amino coupling reaction with amino modified aptamers.   
Measurement of the hydrodynamic diameter of the particles with DLS before and after 
functionalization steps showed increase of average size with 15 nm, indicating successful grafting 
of the DNA. However results of zeta potential measurement were ambiguous. No significant 
change was observed between the potentials of particles before and after functionalization,-48±2 
and -45±1 mV respectively.  
To verify DNA grafting quality 
and functionality, here also we applied 
aggregation approach. We let the 
mixture of polystyrene particles 
functionalized with HD1 and HD22 
aptamers to interact with thrombin and 
consequently form the aggregates. 
However, contrary to functionalized 
gold particles, polystyrene particles 
didn’t show any aggregation tendency. 
The reasons of failing aggregation test 
can be either unsuccessful 
functionalization step or alterations of 
the aptamers folding after the chemical 
procedure.  
To find the underlying causes, 
we performed experiment of direct aggregation of polystyrene particles functionalized with 
complementary strands. As it’s shown on the fig. 4.15 assembly through the hybridization of 
complementary strands was successful. These results lead us to think that the surface charge of 
carboxyl groups on this particular type of particles is perturbing aptamer folding and 
consequently distract recognition and binding of thrombin. 
FIGURE 4.15 Aggregation of 100 nm size polystyrene particles 
functionalized either with complementary ssDNA strands 
(green) or with HD1 and HD22 aptamers in the presence of 50 
nM Thrombin (yellow). First four points correspond to average 
size of AuNP before introducing particles with complementary 
strands (green) or in the absence of thrombin (yellow) 
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(A) 
FIGURE 4.16 Illustration of assembly of carboxyl-modified 100 nm size functionalized with amino-terminated 
(A) aptamers in the presence of thrombin and (B) complementary strands. (A) Presence of thrombin didn’t lead 
to aggregation of aptamer-covered particles. (B) mixing particles functionalized with complementary strands led 
to hybridization and aggregation. 
(B) 
 
It would have been interesting to investigate what would be the outcome of the amino 
coupling reaction if the DNA had carboxyl modification and polystyrene particles had amino 
terminations. But, having performed functionalization of carboxyl-modified polystyrene with 
amino-terminated aptamers using various modifications of protocols and still getting 
unsuccessful conditions for aptamers, no further investigation of polymer functionalization was 
conducted.   
Surfaces that have been chemically functionalized to provide–NH2 or COOH groups for 
covalent attachment still offer a rather large surface area for adsorption. Hence, unless serious 
control methods are used, molecules covalently immobilized on such surfaces may represent a 
minority; hydrophobically adsorbed molecules may comprise the majority. Some studies have 
shown that  immobilization process can significantly alter the biological activity of the reactant; 
most adsorbed proteins on polystyrene or silicone are partially or largely denatured (Butler, 
2000). 
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4.6 Conclusions 
In this chapter we attempted aptamer immobilization on planar surface of gold and 
polycarbonate and on gold and polystyrene nanoparticles. We used simple characterization tools 
to investigate successfulness of surface functionalization in different cases.  
From point of view of the easiness of functionalization, in both cases, for polycarbonate as 
well as for gold planar surfaces, aptamer immobilization procedures were one-step and easy to 
carry out. But qualitative characterization of aptamer grafting with fluorescence microscopy being 
successful and sufficient for gold surface, was absolutely impossible for polycarbonate surface due 
to inherent internal fluorescence, existence of which depend from the origin.  
Exploring aptamer grafting methods on nanoparticles we investigated thiolated aptamer 
immobilization on the surface of gold nanoparticles and amino-terminated aptamer 
immobilization through amino coupling reaction on the carboxyl modified surface of polystyrene 
particles. Functionalization of gold particles is achieved easily after stepwise titration of salt in the 
thiolated DNA and AuNP mixture. Surface density of total immobilized and functional 
immobilized DNA was determined using simple methods as UV-vis spectrometry, Fluorescence 
spectrometry and DLS. In the case of polystyrene particles, even though measurements of average 
size confirmed successful grafting of the aptamers on the surface, absence of aggregation in the 
presence of thrombin indicated that grafted aptamers were not functional. Thus, comparing 
above discussed two methods, gold nanoparticles show clear advantage over carboxyl modified 
polystyrene particles, in terms of easiness of functionalization, characterization and the quality of 
resulting surface.  
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CHAPTER 5. SELF-ASSEMBLY OF APTAMER-FUNCTIONALIZED 
GOLD NANOPARTICLES ON PLANAR SURFACES  
5.1 Introduction  
In previous chapter we discussed several surface functionalization methods for their 
application in bio-sensing. We showed, that gold nanoparticles being, on one hand, simple and 
effective to functionalize and, on the other hand, easy to manipulate and characterize, represent 
perfect objects for sensing. We also demonstrated the application of aptamer-functionalized gold 
nanoparticles for thrombin sensing in liquid phase. But what if instead of using functionalized 
gold particles in volume we arranged them on surface? This would allow us creating well-
characterized gold nanoparticle interface for solid state detection devices. In addition, the 
arrangement of nanoparticles on the surface also grants us possibility to exploit all those 
interesting properties that appear only in well order particle arrangements thus facilitating the 
detection scheme.  
Organized colloidal layers and arrays exhibit unique properties that open up new and 
exciting opportunities in the field of nanotechnology. For example, collective optical, magnetic, 
electric or transport properties enable novel optical devices, narrow-band optical filters, 
waveguides, anti-reflecting and self-cleaning coatings, energy storage devices, information 
carriers,  catalysts, highly sensitive  chemical, biological,  gas and humidity sensors (Edel et al., 
2013; Malaquin et al., 2007; Shipway et al., 2000; Velev and Gupta, 2009; Yang et al., 2002).  
In our case, using arranged nanoparticles as immobilizers for bio-molecules and electron 
transfer enhancers would have important added value for the development of a biosensor. 
Namely, for electrochemical (Orozco et al., 2012) and optical sensing using effects like localized 
surface plasmon resonance (LSPR) (Sannomiya et al., 2009; Shao et al., 2010), surface-enhanced 
Raman scattering (SERS) (Cho et al., 2008). Therefore in this chapter, we would like to explore 
the possibility of arrangement of the aptamer-functionalized gold nanoparticles on solid 
substrates for integration of reusable biosensors.  
5.1.1 Overview of nanoparticle self-assembly on surfaces 
Integration of the nanoparticles on the surfaces represents one of the main challenges in 
the development of the next-generation electronic devices and sensors. The critical step is the 
capability to direct and control the assembly of nanoparticles (NPs) into distinct patterns and 
arrays on a variety of substrates. Conventional top-down fabrication methods could be time-
consuming and unsuitable for direct handling of nanoparticles. Bottom-up assembly techniques 
which take advantage of self-assembly processes occurring in fluidic environments to organize 
particles along desired patterns have been vaunted as promising technologies (Grzelczak et al., 
2010). 
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Self-assembly of nano/micro objects into ordered arrangements on the surface is driven by 
the interaction forces such as Van der Waals, hydrophobic, electrostatic, capillary, and 
hydrodynamic forces acting between colloidal particles and/or particles and surface (Whitesides 
and Grzybowski, 2002).  A number of studies have been conducted in order to achieve the control 
over one or several of these influencing forces and thus drive the “bottom-up” assembly of the 
colloidal objects on the surface (Mastrangeli et al., 2009). Immobilization of the particles on the 
surface can be achieved either by chemical or physical attachment (Handbook of nanofabrication 
2010).  
Chemical approach of particle self-assembly is a powerful approach to obtain a high-
quality monolayer or structure of organized layers relying on covalent and non-covalent 
interactions of linkers covering the surface either of solid support or assembled objects.  Different 
approaches such as, electrostatic self-assembly of molecular layers (SAMs) or functionalization of 
the object and/or surface with functional groups of alcohol, thiol, amine, acid and azid, can be 
applied  to achieve highly ordered arrangement of particles (Chung et al., 2005; Crespo-Biel et al., 
2006; Fendler, 2001; Guo et al., 2005; Liu et al., 2004). The main inconvenience of this approach is 
that the interaction between ligands is so affine and often irreversible, that the control of particle 
assembly into regular structures represents a challenge (Mahalingam et al., 2004). However, 
advanced surface patterning techniques such as nanolithography (dip-pen) and micro contact 
printing enable attachment of objects on desired areas of desired substrate using the indirect 
chemical binding forces (Gilles et al., 2011; Grzelczak et al., 2010; O’Brien and Thomas, 2013).  
Physical approach of particle self-assembly is driven by physical forces and therefore 
includes rich selection of methods. It is used to obtain multilayer of particles or thin films.  For 
example under influence of magnetic or electric fields particles can be aligned not only as a 
monolayer with very strong symmetry but also in the various 1D, 2D or 3D structures. Application 
of alternating or constant electric field allows manipulation of the assembly through electro-
osmotic or electro–chemic effects on various shaped surface (Boccaccini et al., 2010; Hermanson 
et al., 2001; Krommenhoek and Tracy, 2013; McMullan and Wagner, 2010; Neirinck et al., 2013). 
The limitation of this method is that it is limited to charged or magnetic particles.  
Other efficient techniques for preparing highly ordered, closely packed particle 
monolayers include the spin-coating method (Ko et al., 2011; Wang and Möhwald, 2004), dip-
coating (Ye and Qi 2011), ink-jet (Park and Moon, 2006) etc. which rely on the meniscus force 
action induced by solvent evaporation.   
Another promising set of approaches, exploiting capillary and convective forces in the 
three-phase contact line of the evaporating colloidal drop, are convective and capillary assembly. 
These methods are particularly well-suited for the assembly of micro- and nano- particles with 
good resolution (Malaquin et al., 2007; Velev and Gupta, 2009).  
Since at LAAS, we have in possession an instrument for performing convective or capillary 
assembly, we decided to investigate assembly of DNA-functionalized gold nanoparticles as a 
monolayer on various substrates through convective assembly. For this reason we discuss the 
convective assembly in more details below.  
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5.1.2 Convective assembly of the particles  
Self-assembly of colloidal particles driven by convective, capillary and colloidal forces 
(mostly electrostatic, which being relatively weak in the solution become significant when the 
solvent is slowly evaporated) leads to uncontrolled or controlled accumulation of the particles on 
the surface of various characters depending on chosen strategy.  
One of the first observed and investigated way to organize particles by capillarity and 
convection is to spread a thin layer of the particle suspension onto substrate and leave the 
suspension to dry (Denkov et al., 1992, 1993). Just like in the case of coffee stain which forms ring-
like arrays of coffee particles on the border of the drop (Deegan et al., 1997). This is simplest but 
uncontrolled way to texture a solid surface by particles, in which the choice of a solvent, a size of 
particles and thermodynamic state could produce different morphologies of NP coverage over 
large surface. 
In further study, increased control on 2D assembly of particles through capillary forces 
was achieved by dipping the clean wettable surface into the particle suspension and then carefully 
withdrawing the substrate, similar to Langmuir Blodgett method for thin film formation  
(Dimitrov and Nagayama, 1996). Withdrawing the substrate created areas of thin films of spread 
colloids with increased evaporation leading to controlled formation of mono or multilayers of 
particles. This approach is called convective assembly. 
FIGURE 5.1 Assembly mechanisms based on particle confinement at the contact line of a droplet.  Convective 
assembly is obtained on wetting substrates for contact angle values below 20°, where convective flow of solvent 
induced by evaporation at the contact line of the droplet, leads to the formation of (A) continuous 2D layers of 
packed particles on flat surfaces or to (C) 2D discontinuous arrangements on patterned surfaces. Capillary 
assembly takes place for contact angles greater than 20°. While no deposition occurs on flat surfaces (B), the 
combined effect of geometrical confinement and capillary forces created on patterned substrate can be used to 
deposit only one or a few particles in organized manner (D). 
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In later studies, instead of dipping and retracting the substrate, a droplet colloid was 
spread by a glass spatula (glass slide) over the substrate moving in opposite direction to 
assembled layer with defined speed (Prevo and Velev 2004; Ormonde et al. 2004; Malaquin et al. 
2007). In this way, monolayers of controlled coverage and structure can be produced with the rate 
regulated by particle concentration or by the implementation of forced convection.  
The underlying mechanism of convective assembly (Fig. 5.1 (A)) is following: on the 
wettable surface of substrate the profile of the liquid meniscus close to the contact line of three 
phases (air, substrate, colloidal drop) leads to a vertical confinement of the suspended particles 
into a thin film of solvent. The surface contact angle below 20° gives ideal confinement creating 
the zone of strong evaporation. When the solvent (water) evaporates from the contact-line area, a 
continuous flux of solvent from the thicker part of the layer is induced to compensate it. This 
convective flow drives the suspended particles toward the contact line.  
The assembly process starts when the thickness of the solvent layer becomes equal to the 
particle diameter. The combined effects of convective flow and attractive capillary forces, that 
arise when the top of the particles protrudes from the solvent layer, lead to the formation of 
extended layers or multilayers of closely packed particles (Fig.5.1 (A)). As the layer of particles 
grows, the substrate has to be withdrawn together with the already formed layer.  
For hydrophobic surfaces the contact angle doesn’t allow for particle assembly (Fig. 5.1 
(B)) unless capillary forces are enhanced by introducing local distortions i.e. patterns. This 
assembly is called capillary assembly. Capillary assembly employing hydrophobic patterned 
surfaces is relevant to the particle assembly on patterned area (Fig.5.1 (D)) and thus allows 
creation of 1D, 2D or 3D structures (He et al., 2011; Malaquin et al., 2007). 
5.1.3 Important parameters for successful convective assembly 
In order to achieve our goal of deposition of DNA-functionalized gold nanoparticles on 
the surface of substrate as an ordered monolayer, we have to take in account all the parameters 
influencing the assembly. For the steady-state assembly of 2D lattice, Dimitrov and Nagayama 
proposed a simple equation that describes the solvent flux and the accumulation of the particles 
in the drying region (Dimitrov and Nagayama, 1996).  
𝑣𝑐 =
𝛽𝑗𝑒𝑙𝜑
ℎ(1 − 𝜖)(1 − 𝜑)
 
 (5.1) 
 
 This equation establishes a relation between the growth velocities (𝑣𝑐) of the NP layer, 
porosity (ε), the height of the assembled layer (ℎ) or particle diameter, the volume fraction ratio 
of the particles in the suspension (𝜑), a coefficient that relates the solvent velocity to the particle 
velocity (β) and the evaporation rate of pure water Je. l represents the ratio of the averaged 
evaporation rate (Jevap) and evaporation rate at any point of the drying region.   
This equation identifies three major process parameters that can be used to control the 
thickness and structure of the assembled layer: the particle volume fraction (𝜑) the solvent 
evaporation rate (Jevap) and the substrate displacement velocity(𝑣𝑠). The substrate displacement 
velocity is experimental parameter is not related to eq. 5.1, however directly influences the 
morphology of assembled layer. To obtain uniform monolayer at fixed evaporation rate and 
volume fraction, layer growth velocity 𝑣𝑐 has to be equal to substrate displacement velocity  𝑣𝑠 so 
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that the particle consumption due to the layer growth will be exactly compensated by the influx.  
Increasing the substrate velocity above the natural assembly speeds for a monolayer or, 
equivalently, decreasing the volume fraction of the suspension will lead to formation of an 
incomplete layer. Contrary, decreasing the substrate velocity or increasing the volume fraction 
will result in the formation of multiple layers. But these parameters on their own depend on other 
parameters. Table 5.1 shows various influencing parameters during experiments, which need to be 
fine-tuned to obtain desired quality particle layers, summarized in the three groups: (i) External 
and internal parameters of the experimental platform; (ii) internal parameters of colloid solution; 
(iii) parameters of the solid support. 
In our study we investigate majority of these parameters in more details and therefore 
their roles will be discussed later. However below we want to highlight the importance of the 
choice of particle size and density. 
5.1.3.1 Choice of the particle size  
In order to obtain an ordered NP layer, the size of the self-assembling particles has to be 
selected carefully, considering the chemical composition of the particle, since the density 
influences the process of the assembly. Studies performed by Qihao HE (He, 2012) on particles of 
various nature and size (gold, latex, magnetic particle) suggested that in order to obtain ordered 
assembly there has to be particular correlation of the size of the particles with the density. Large 
and dense particles tend to sediment on the surface in a random manner before getting deposited 
by convective (capillary) assembly. On the other hand, small and light particles float and due to 
Brownian motion diffuse around, that also disturbs controlled assembly.  
 The dimensionless Peclet (Pe) number establishes the relation (eq. 5.2) between 
convective (gravitational) forces governing sedimentation and thermal diffusion acting on colloid 
of radius R.  
 
 
Here 𝑣 is velocity of sedimentation, D is the constant of thermal diffusion, Δρ is the 
buoyant density (density difference between colloid and solvent), g is the gravitational 
acceleration, kBT is thermal energy.  The Peclet number is seen to be the effective gravitational 
Table 5.1 Parameters influencing convective assembly of particles 
External and internal 
parameters of the 
experimental platform 
Internal parameters of  
colloid solution 
Parameters of the solid 
support 
- Substrate withdrawal 
velocity  
- Evaporation rate 
- Temperature of the 
support 
- Humidity 
- Size and density of the 
Particles  
- Concentration of the 
particles 
- Solution composition  
 
- Substrate nature 
- Surface roughness  
- Surface 
hydrophobicity 
 
𝑃𝑒 =
𝑣𝑅
𝐷
=
4𝜋𝑅4𝛥𝜌𝑔
3𝑘𝐵𝑇
 
( 5.2) 
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potential energy difference across a height equal to the particle size, scaled by the temperature 
(Ramaswamy, 2001; Whitmer and Luijten, 2011). 
 If for a particle Pe is larger than one, this means that gravitational force is predominant 
and particles will sediment rapidly. So desired condition for the controlled assembly would be 
Pe=1, at which sedimentation is contra-balanced by diffusion. For gold np-s, with the density 19.32 
g/cm3, 80 nm particle diameter corresponds to Pe=1. If Pe is smaller than 1, then diffusion will 
dictate the distribution of particles and in this regime convective assembly is still possible but to 
certain limits. Convective assembly technique hardly works for the assembly of tiny nanoparticles 
smaller than 10 nm into monolayered arrays. The limitation is related to the evaporation and 
convections occurring at a much larger volume than nanoparticle size. As a result, multilayered 
nanoparticle arrays are usually created (Qian et al., 2012). 
5.1.4 Objective of the study: 
The aim of the study is to investigate feasibility of a monolayer of aptamer-functionalized 
gold nanoparticles for biosensing interface. For this purpose we explore convective assembly of 
DNA-capped gold nanoparticles on various substrates and investigate different influencing 
parameters. 
5.2 Experimental 
5.2.1 Colloid solution 
For the reasons discussed above (Peclet number), the size of the  gold nanoparticles for 
assembly was selected to be about 80 nm, so that Brownian motion of the gold NP  and their 
gravitational force balance each other and let  homogenous assembly of NP on the surface. 
The functionalization of AuNPs was performed according to classical protocol described 
in the chapter 4. After functionalization, nanoparticles were resuspended in small amount (50-100 
µL) of double-distilled water, to obtain highly concentrated colloidal stock solution. The 
concentration of the AuNP stock was quantified through absorbance measurement at 550 nm 
taking in account following relation:  
𝐶 (
𝑛𝑝
𝑚𝐿
) =
𝐴550(𝑂. 𝐷. )
𝜖550
𝑁𝐴  ,            𝜖550 = 6.65 × 10
10 𝐿        
(5.3) 
 
Further in this chapter, concentration of the gold nanoparticles will be expressed by 
means of corresponding absorbance at 550 nm. 
Before the experiment stock solution with concentration corresponding to absorbance  
𝐴550 = 10-15 O.D. was diluted down to desired experimental concentration in water-surfactant 
mix. Surfactant tween 20 in various concentrations (0.1, 0.01 and 0.005 %) was used in order to 
maintain stability of an individual nanoparticle and also alter the surface tension of the colloidal 
drop. 
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5.2.2 Parameters of the experimental platform 
The experiments of convective assembly of DNA-functionalized nanoparticles were 
performed on the platform developed at LAAS-CNRS by Mike Genevieve during his PhD work 
(Geneviève, 2009). The schematic illustration of the setup and description of its working principle 
are given in the chapter 2. Below we describe important parameters of the assembly experiments. 
5.2.2.1 Substrate withdrawal rate  
The substrate withdrawal rate is the one of the crucial parameters during the assembly. In 
order to obtain homogeneous and compact 2D layer of nanoparticles the substrate withdrawal 
rate has to be equal to the rate of layer formation.  The experimental platform limits us to move a 
substrate with the minimum velocity of 100 nm/s and therefore the majority of the experiments 
were performed at this substrate withdrawal rate.  
5.2.2.2 Liquid evaporation rate 
Evaporation rate is another important parameter, which on its own depends on the 
temperature and the humidity of the experimental environment. The platform doesn’t allow 
to control and regulate these parameters automatically; therefore external environmental factors 
have to be always controlled by an experimenter if possible. For example if the humidity is higher 
than 45%, it is better not to perform experiment. Also the microscope light is better to be off 
unless necessary, in order to avoid undesired local heating of support that is inducing changes in 
various thermodynamic parameters of the assembling system. The substrate temperature 
compared to external environmental conditions has an even higher impact on evaporation. It 
importantly influences how compact and homogeneous is the NP deposit. We could see the clear 
difference in the deposition at temperatures of 15, 18 and 22 °C.  
5.2.2.3 Glass slide 
The edge of a glass slide, used to spread the colloid drop on the substrate, was aligned 
perfectly parallel to the surface of the substrate so that the distance between them is in the range 
of 1 mm. In all cases, right after the injection of the solution, formed meniscus drags the glass 
slide towards support to achieve the optimal distance less than 1 µm in heights. The glass 
slide is tilted relative to the support plane at about 20 degrees. Although this parameter isn’t 
directly influencing the front of convective assembly, however it plays role on the other side of 
the glass slide, where the drop of colloid solution is: larger angle exposes larger area of the drop in 
contact with the air and therefore facilitate unwanted evaporation of the solvent and consequent 
increase of particle concentration; smaller angel  will spread the drop on larger area of the 
support surface, that might enhance uncontrolled deposition of the nanoparticle due to the 
sedimentation. For each experiment, glass slide with dimensions of 1 x 1.5 x 0.1 cm was used. To 
avoid presence of contamination (mostly organic), just before the experiment, glass slides were 
cleaned with RT2 solution, rinsed with copious amount of distilled water and dried under flux of 
compressed nitrogen.   
  
 
146 Chapter 5.Self-assembly of aptamer-functionalized gold nanoparticles on planar surfaces 
 
5.2.3 Substrate parameters 
The nature and the treatment of the surface are important parameters that we can 
adjust. The state of surface charge, roughness, hydrophobicity/hydrophilicity and the behavior of 
the colloid solution on the liquid-solid interface depend greatly on the nature of the surface. For 
this reason we used various types of materials and surface-treatment approaches. The 
hydrophobicity of surface in all cases was assessed by measuring the contact angle between a drop 
of water and the surface. To show the effect of the surface nature, we also used surface of silica 
treated with Piranha, Chromic acid and HDMS, surface of oxidized Aluminum and PDMS.  
5.2.3.1  Silicon surface 
At first we worked with silicon wafer, which is generally very hydrophilic once oxidized. 
Further, we used oxidized silica wafers obtained either through dry oxidation, allowing obtaining 
surface with the contact angles of < 3°, or through wet oxidation. There are few protocols of wet 
oxidation to obtain highly hydrophilic and well sanitized silicon oxide surfaces: 
 
Treatment of silicon surface with Piranha-HF-Piranha: this treatment represents a 
chemical attack of the surface with the 
mix of H2O2 and H2SO4 in equal volumes. 
The layer of the oxidized silicon formed 
after this attack encapsulates all the 
organic contaminations and impurities 
on the surface. As the next step the wafer 
is incubated for 30 minutes in the bath of 
5% HF in order to remove oxide layer. At 
last, the silicon surface is again placed in 
the Piranha solution to recreate new silica 
layer. After this treatment the contact 
angle is about 4° (Fig. 5.2).  
 
Treatment of silicon surface with chromic acid:  this treatment represents successive 
cycles of growth and removal of the oxide layer from the wafer surface by means of chromic acid. 
After this step the contact angle is about 5.3°.  
After comparing the results of the treatments with Piranha and chromic acid (Fig.5.2), we 
saw that piranha yields lower contact angle, which is maintained for longer period than in the 
case of chromic acid treatment. In addition, piranha treatment allows better control of created 
oxide layer and is less dangerous. Thus we used the silica substrate treated with Piranha not later 
than 5 days after the treatment.  
 
Treatment of Silicon with HDMS:  for this treatment silicon wafer surface is at first well 
dehydrated. Then liquid hexamethyldisilazane (HDMS) is dispensed on the wafer using a syringe 
while the wafer is attached to a vacuum chuck on the spin coater. This treatment makes silicon 
surface silated, leaving it non-polar and thus hydrophobic. 
FIGURE 5.2  Dependence of the contact angle of silicon 
oxide surface on aging after treatment with Piranha (blue 
squares) and Chromic acid (red dimes) 
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5.2.3.2 PDMS Surface 
Polydimethylsiloxane (PDMS) is formed by mixing elastomer base and the curing agent 
(mass ratio 10:1). To remove bubbles created during the mixing, PDMS mix is either degased 
under vacuum for 30 min or degased through several-minute-long centrifugation.  Highly viscous 
but still liquid PDMS is pored over the plane silicon surface placed in the aluminum fold 
container in order to obtain desired thickness (3-4 millimeters). Then PDMS is cured in the oven 
at 80 °C for 1 hour. Cured PDMS is carefully peeled off from the substrate with tweezers.  PDMS 
surface unless treated with oxygen Plasma, is highly hydrophobic (contact angle ~ 110°). No 
additional treatments were conducted for our experiments. 
5.2.3.3 Aluminum oxide 
Surface of Aluminum oxide was 
obtained by sputtering of 100 nm aluminum 
layer on the standard silica wafer. Sputtering is 
a deposition method, that involves ejecting 
molecules from source metal by bombarding it 
with the plasma of an inert gas, and depositing  
them on to a substrate surface. After surface 
modification the angle of contact changes from 
hydrophilic (~5°) to hydrophobic (~ 70 °) in just 
4 days (Fig 5.3). Hence, we used additional 
treatment to make the Aluminum oxide surface 
less hydrophobic and more stable. The optimal procedure was the UV-Ozone treatment of the 
surface for 20 min that reduced the contact angle down to 11°, followed by 24 hours aging under 
Nitrogen gas. The last step resulted in the contact angle of about 34° stable for 5 days following 
the treatment.  
5.2.4 Characterization of self-assembled AuNPs 
In order to analyses the information of assembled particles on the surface we used 
scanning electron microscopy as the characterization method. Since this method is allowing us to 
access simultaneously information about the shape, structure, arrangement and distribution of 
the particles on the surface on several scales (from several mm to several nm).  
  
FIGURE 5.3 Dependence of the contact angle of 
aluminum oxide surface on aging in the case of no 
treatment (blue squares) and UV-Ozone treatment 
(red dimes) after sputtering 
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5.3 Results 
5.3.1 Optimization of the support displacement velocity 
The very first convective assembly experiment was conducted with gold nanoparticles 
suspended in PBS buffer, but the presence of the high concentration of the salt led to the 
formation of the salt crystals on the surface and the deposit was hence irregular. In the next 
experiment we used a suspension of 80 nm size DNA-functionalized gold particles in pure 
distilled water with the concentration corresponding absorbance of 𝐴550=6.3 O.D. The assembly 
was performed at 21 °C of substrate temperature first with 100 nm/s and then with 300 nm/s 
substrate displacement velocity. Fig.5.4 shows the SEM image of the assembled layer. 
Obviously the deposition in this condition 
didn’t have the homogeneous and compact 
character. But the assembly at 100 nm/s rate clearly 
gave better (more dense) coverage of the surface 
than with 300 nm/s rate. After this, in all further 
experiments we used support displacement velocity 
of 100 nm/s. 100 nm/s is the minimum rate allowed 
by the experimental platform, therefore, in order to 
diminish the difference between the support 
displacement and layer formation rate of the 
particles and thus facilitate homogenous and 
compact assembly, we had to optimize evaporation 
and convection parameters.  
 
5.3.2 Optimization of the surfactant concentration 
Surface tension of the liquid has the impact on the convection and capillary properties of 
the colloid and therefore on evaporation rate. Presence of the surfactant reduces free energy of 
the confining interface, i.e. it diminishes the contact angle between liquid and solid support and 
helps surface wetting. For this reason we decided to add surfactant Tween 20 in water solution of 
gold nanoparticles. Tween 20 is a non-ionic detergent, molecules of which have zero total charge.  
In addition, Tween 20 is also known to facilitate stability of the particles in the solution and 
prevent their undesired aggregation (Niño and Patino, 1998). We tried several concentration of 
the Tween 20 namely 0.1, 0.01 and o.oo5% water solutions. Obtained results are shown in the Fig. 
5.5. 
FIGURE 5.4 SEM image of the deposit of 80 nm 
size DNA-functionalized gold nanoparticles, 
assembled through convective assembly on the 
silica oxide surface first with a substrate 
displacement rate of 0.1 µm/s and then with 0.3 
µm/s.   
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A) 0.1% TWEEN 20   B) 0.01% TWEEN 20 C) 0.005% TWEEN 20 
FIGURE 5.5 SEM image of  80 nm diameter DNA-functionalized gold  particles with concentration 
corresponding A550=5.4 O.D. self-assembled through convective assembly on the silicon surface in presence of   
(A ) 0.1,  (B) 0.01 and (C)o.oo5% water solution of TWEEN 20. 
 
The best particle adsorption to the support was observed at 0.01% concentration of the 
Tween 20 (Fig. 5.5 (B)).  At the higher concentration, namely at 0.1% we observed deposition of 
the AuNP-s in gel-like matrixes (Fig. 5.5 (A)). We could suggest that,  since the concentration of 
the surfactant was higher than the critical micelle concentrations (CMC)1 of Tween 20 (0.0074%  
(Kim and Hsieh, 2001)), micelles of Tween 20 molecules  could have formed encapsulating a 
number of gold nps. Thus, 0.01% of Tween 20 was selected for the further experiments.  
5.3.3 Optimization of the substrate temperature 
The next important parameter for optimization was the substrate temperature. We 
conducted experiments with the support temperature of 15, 18 and 21 °C.   
A) Tsub= 21°C B) Tsub= 18 °C 
FIGURE 5.6 SEM image of  80 nm diameter DNA-functionalized gold  particles with concentration 
corresponding A550=10.4 O.D. self-assembled through convective assembly on the silica surface with  
temperature of  (A ) 21 °C  or   (B)  18 °C. 
With increased concentrations (A550=10.4 O.D) compared to previous experiments for all 
temperatures of substrate surface coverage was much more dense. But the density of assembled 
layer was decreasing with increase of support temperature. Our observations confirm that the 
higher is a substrate temperature, the larger is the solvent evaporation rate and thus less particles 
have chance to get recruited at the front line of assembly. At 21 °C the arrangement of the 
nanoparticles (Fig 5.6 (A)) was less compact than at 18 °C (Fig 5.6 (B)), but further lowering of the 
support temperature down to 15 °C, led to formation of the multilayer of the particles. In order to 
                                                        
1
 The critical micelle concentration is the concentration of surfactants in bulk above which the micelles start 
forming. 
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achieve better control over evaporation rate further convective assembly experiments were 
performed mostly at 18 °C or at 21 °C.  
5.3.4 Optimization of the concentration of Gold NPs 
 An appropriate nanoparticle concentration was also a crucial factor in this approach, thus 
requiring optimization. In previous experiments with various concentrations of gold NPs we saw 
that better assembly was observed for highly concentrated samples (𝐴550  ≥ 7 𝑂. 𝐷. ). So we 
performed assemblies at 18 °C and 21 °C temperature for several different concentrations of gold 
NPs. The results of these experiments are shown on the Fig.5.7.  
 
(A) A550=5.25 O.D. (B)  A550=9.5 O.D. 
Tsub= 21°C 
(C) A550=8.5 O.D. (D) A550=19.6 O.D. 
Tsub= 18°C 
FIGURE 5.7 SEM image of various concentrations of 80 nm Gold deposited on silica surface of (A-B) 21 
°C or (C-D)18 °C Temperature through convective assembly.  
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Results suggest that the higher the temperature, the larger concentration is needed to 
have compact layer of NPs. For example, at 21 °C compact layer is achieved at particle 
concentrations higher than 9 O.D. With lowering the temperature a compact layer can be 
obtained even for concentrations corresponding 8 O.D. absorbance at 550 nm. Concentrations 
larger than 12 O.D. yield multilayer coverage on the support.  Thus when working at support 
displacement rate of 100 nm/s and support temperature 18-21 °C optimal results are obtained for 
the particle concentration in range of 8-11 O.D. 
 
5.3.5 Optimization of the substrate contact angle 
Above we saw that the convective assembly on the oxidized silicon surface, were the 
contact angle of the colloid solution with surface about 5° was more or less successful. We 
decided also to explore the effect of different surface treatment and nature of support on the 
assembly. For this reason, we conducted experiments also: on the surface of aged silica oxide with 
high angle of contact (22°); Aluminum oxide surface treated with UV-Ozone (contact angle 34° ); 
silicon oxide surface salinized with HMDS (75°)and PDMS  surface (contact angle ~ 110°).  The 
results obtained on surfaces with different nature and contact angle are shown on the Fig.5.8 
 
Successful and homogeneous adsorption of the AuNPs on all scales was observed for all 
surfaces except for the surfaces of HMDS-treated silica oxide and PDMS (Fig.5.8 (E,F)). In fact, for 
PDMS no adsorption of nps was observed what so ever. Whereas on HDMS-treated surface 
particles were distributed non-homogeneously at all levels and particles were assembled 
randomly into unorganized multilayers. For aluminum oxide (Fig.5.8 (D)) despite the 
homogeneity, we couldn’t achieve compact organization, suggesting necessity of increasing the 
(A) SiO2≤3°                                   (B) SiO2=5°                              (C) SiO2=22°                    
(D) Al2O3=35°                             (E) HMDS=75°                          (F) PDMS=110° 
FIGURE 5.8 SEM image of 80 nm gold nanoparticles (Abs550=9.6 O.D.) deposited on various substrates  at 18°C 
substrate temperature.  
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concentration of NPs, which was sufficient for homogeneous and compact assembly in the case of 
low-contact-angle silicon oxide. In the case of aged silica oxide surface, contamination of the 
surface led to the dense but uncontrolled assembly of the particles into one or several layers 
(Fig.5.8 (C)). The best results were obtained for the silica oxide surface with contact angle less 
than 3° (Fig.5.8 (A,B)).  
 
5.3.6 Optimal experimental conditions 
After having searched for optimal conditions for monolayer assembly, we performed 
experiment of  A550 =10 O.D. gold nanoparticle deposition on silica surface with temperature of 18 
°C,  and displacement speed of 100 nm/s..  
Even though, at larger scale residual areas showed lower density of adsorbed particles, 
overall assembled layer represented homogeneous and compact monolayer. Defect-free surfaces 
of more than 200 μm2 can always be identified.  
 
5.3.7 Effect of the second layer 
It was interesting to see whether performing the second assembly experiment over the 
already deposited surface would result into homogeneous second layer. The SEM images of the 
NP deposit after the first and the second experiments are shown on the Fig 5.10. 
FIGURE 5.9 SEM image of 80 nm gold nanoparticle monolayer assembled on silica surface (θ ≤ 3° ) at optimized 
conditions. Substrate displacement rate 100 nm/s, Substrate temperature 18  °C, colloid concentration A550 =10 
O.D.  i.e.  9x1010  np/mL 
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(A) first layer  (B)  second layer 
FIGURE 5.10 SEM image of  80 nm gold nanoparticles (A550=9.2 O.D.) deposited on  (A) silica substrate at 
18°C substrate temperature  or  (B) over the already existing gold nanoparticle layer.  
 
The second try didn’t appear to leave the surface as homogeneous as it was after the first 
assembly.  We could suggest two main underlying reasons to explain obtained results: either the 
first layer was destabilized due to wetting upon deposition of second layer; or the presence of the 
first gold layer changed the regime (conditions) of convective assembly for the second layer. 
Nevertheless it seems rather complicated to optimize the growth of the multilayer by layer–by- 
layer convective assembly method.  
 
5.3.8 Effect of the wetting on the assembled layers 
Investigation whether wetting of the surface can initiate destabilization of the 
homogeneously packed NP layer is of crucial importance, not only for the second layer assembly 
but for main purpose – application of the assembled monolayer as the sensing element platform 
in biosensor with microfluidics system. Thus we tried to tackle this question by wetting the 
assembled layer with the drop of water for 5 minutes. SEM pictures showing the surface before 
and after are showed below.  
(A) Before wetting (B) After wetting 
FIGURE 5.11 SEM  image of  80 nm gold nanoparticle layer deposited on silica substrate  (A) before and  (B) 
after wetting with water  
 
No obvious changes were observed, no irregular multilayer formation. The measurement 
of absorbance of the water drop, collected form the surface, didn’t give the absorbance signal at 
the characteristic wavelength for Au colloid, which would be stronger than the error of the 
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instrument even after concentrating it. Therefore it is difficult to quantify desorption and evaluate 
the processes ongoing during the wetting with a drop. Further studies of deposit behavior under 
the flux of liquid (for example in the microfluidic channel), would most probably give a better 
insight into this phenomena.  
 
5.4 Conclusions  
In this study we investigated assembly of the DNA-functionalized gold NPs on the solid 
substrate through convective assembly, representing a simple and promising self-assembly 
method. The physics underlying the mechanism of assembly required highly hydrophilic 
substrate with contact angle less than 20°, and therefore the best results were achieved for silica 
surface oxidized either by dry or chemical methods (contact angles 3° and 5° respectively). We 
optimized internal and external experimental parameters such as substrate displacement rate, 
substrate temperature, concentration of nanoparticles and composition of the solvent to obtain 
compactly arranged homogeneous monolayer of the assembled gold particles.  
The best results for silica substrate moving with the minimal possible 100 nm/s rate were 
obtained at substrate temperature 18 °C, particle concentrations corresponding absorbance of 10 
O.D. at 550 nm in the 0.01% Tween 20 water solution. Assembled gold NP layer was homogeneous 
in a large area with small defects. Deposited particles didn’t show any destabilization and 
desorption from the surface after wetting it with drop of water.  
To summarize, convective assembly of gold nanoparticles is simple and cheap self-
assembly strategy, allowing creation of homogeneous nanoparticle monolayer. First results 
obtained are promising but require further investigation to consider this method for integration 
of aptamer-functionalized gold nanoparticles in biosensors. Evaluation of stability of the 
monolayer under the flux of solutions of various compositions would further complement this 
study. Relative slowness of the process could be speeded up by using suspensions of volatile 
organic solvents or further increase of volume fraction. Better focus will be required to solve 
issues of scalability, control, and precision.  
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CHAPTER 6. GOLD NANOPARTICLE AGGREGATION ASSAY 
6.1 Introduction 
In the chapter 4, we have demonstrated successful immobilization of aptamers on the 
surface of gold nanoparticles by monitoring their aggregation, which occurs whenever thrombin 
mediates the formation of bonds between two functionalized AuNPs. As aggregation requires 
simultaneous recognition of distinct binding sites of the same molecule, those experiments 
demonstrated that, gold nanoparticle aggregation not only helped to characterize functionality of 
the grafted aptamers, but also proved to be specific to the target. Therefore we assume that the 
observing the kinetics of aggregation we should be able to detect and quantify thrombin. Indeed,  
different studies based on aggregation of bare or aptamer-capped gold nanoparticles in presence 
of thrombin, have successfully demonstrated thrombin detection in various concentration ranges 
(Aaryasomayajula et al.; Chen et al., 2014; Pandana et al., 2008; Pavlov et al., 2004; Peng et al., 
2013; Wei et al., 2007; Xia et al., 2010; Zhengping and Zhuo, 2009), (detailed review is made in 
chapter 1). But we believe that our approach has potential to give more information in low cost. It 
may be used not only as an assay for detection and quantification of thrombin, but also for  
understanding the mechanisms of interaction between HD1, HD22 and NU172 aptamers and 
thrombin or inhibited thrombin as well.  
Thus in this chapter we intent to explore the capabilities of the aggregation assay and 
gather the evidence in support of our beliefs.  
6.2 Experimental 
6.2.1 Aggregation assay: 
Aggregation experiments were performed with Zetasizer Nano S (Malvern technologies, 
the principle of the method is described in Chapter 2), that allowed to measure average 
hydrodynamic radius of the aggregate in time-dependent manner. In a typical aggregation assay, 
aptamer- functionalized gold nanoparticles diluted in PBS buffer to obtain final concentration of 
particles of 0.1 O.D. corresponding to 1.9 nM concentration aptamers in 100 μL. First the initial 
size of the NP was measured as the control assuring that there was no aggregation without a 
protein, and then was introduced a protein (Thrombin, Thrombin-ATIII, Thrombin-HCII, diluted 
plasma). We used protein stock solutions about 50 to 100 times more concentrated than the final 
experimental concentration, in order to avoid dilution effect in cuvette. All experiments were 
performed at room temperature unless indicated.  
Aggregation with the range of Thrombin concentration: In order to observe 
dependence of the aggregation kinetics and maximal average size of the aggregates on the 
thrombin concentration 4, 8, 16, 32, 64, 128 256 nM Thrombin was titrated into the solution of 
aptamer-functionalized 20 nm diameter gold nanoparticles. 
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FIGURE 6.1 Aggregation kinetics of 20 nm gold nanoparticles functionalized with HD1 and HD22 in the 
presence of various concentrations of thrombin 
(A) (B) 
Interaction of aptamers with thrombin-inhibitor complexes: 50 nM Thrombin was 
incubated either with ATIII or HCII of 100 nM concentration for 30 minutes at room temperature 
in order to reach binding equilibrium of thrombin-inhibitor complexes. Thrombin-inhibitor 
solution was titrated into 80 nm size gold particles. To evaluate whether each of the aptamers 
could interact with thrombin-inhibitor complex, aggregation experiment was carried out not only 
with both aptamer mixture but also with each of aptamers separately. 
Mechanisms of aptamer-thrombin interactions: In order to understand interaction 
between aptamers and thrombin we have performed aggregation assay in the presence of only 
one type of gold particles bearing aptamer (either HD1, HD22 or NU172) and 50 nM thrombin, or 
50 nM thrombin preincubated with excess (>1 µM) free HD22 strand. Aggregation of HD22 in the 
presence of 10-fold diluted, filtered murine plasma in PBS was also performed. 
6.3 Results of aggregation assay  
6.3.1 Concentration range 
First of all, we were interested to investigate possibility of using gold nanoparticle 
aggregation as a bio sensing assay. For this purpose, we performed aggregation of mixture of 20 
nm size HD1-AuNP and HD22-AuNP in the presence of various thrombin concentrations starting 
from 1 nM up to 1000 nM. Aggregation kinetics was monitored by DLS measuring average 
hydrodynamic radius of aggregate in time dependent manners. The results are shown on figure 
6.1.  
Aggregation was observed starting from 5-8 nM thrombin concentration, thus being lower 
limit of detection (Fig. 6.1 (B)). With increase of thrombin concentration aggregation speed and 
the maximum size of aggregate increased and time to reach the signal saturation decreased. 
Nevertheless, after 256 nM thrombin concentration the size of the maximum aggregate and shape 
of kinetics didn’t change (Fig. 6.2 (A)) and the experiments where automatically stopped by the 
instrument. It was due to insufficient counts/events, meaning that upon aggregation, aggregates, 
starting from certain critical size, were sedimenting and leaving suspended only smaller size 
aggregates in low concentration. Thus the upper limit of this approach was due to sedimentation. 
Two possibilities can be proposed to overcome this limitation. First, by fine-tuning of initial 
concentration of gold nanoparticles, namely by decreasing the initial concentration, it will 
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become possible to push upper limit, but in that case time to reach the signal saturation will 
increase and effect of natural sedimentation of particles will also become evident. The second 
option might be the replacement of gold nanoparticles with less dense polymer particles.   
Nevertheless we have successfully demonstrated that aggregation assay has a potential to 
be used for bio-detection. This assay without any optimization already allows measurement of 
thrombin in the concentration range from 5 to 250 nM, which is relevant to thrombin 
concentration range in blood. We believe that optimization can further push the detection limits 
and sensitivity. Furthermore, this assay can be used for other bivalent targets.  
6.3.2 Characterization of thermal stability of aptamers 
Next, we used aggregation assay to investigate thermal stability of the aggregate and thus 
thermal stability of each component of aggregation system, namely aptamers and thrombin. 
Figure 6.2 demonstrates results of thermal denaturation of aggregating system. 
We started normal experiment of aggregation of HD1- and HD22-capped 20 nm diameter 
gold nanoparticles in the presence of 30 nM thrombin, at room temperature (22 °C). After 
aggregate size reached about 450 nm, we heated up the system up to 70 °C. At this temperature 
secondary and tertiary structure of aptamers unfolds and thrombin as well undergoes 
denaturation. Hence, aggregates fall apart. Indeed, the size of the system measured using DLS, 
decreased back to initial value, indicating disassembly of aggregates due to thermal denaturation 
of aptamers and linking protein.  
After cooling down, back to room temperature, average size was maintained the same as 
during denaturation. No aggregation was observed, meaning that after thermal denaturation, 
either thrombin or aptamers didn’t return to initial structure (renaturate). It is known that G-
quadruplex and duplexes are more stable than double strand but after thermal denaturation they 
also need more time to return to initial folding, but the folding is always reversible. Keeping this 
in mind, we measured size of the system, on next day after incubation for 18 hours at room 
temperature. The size of the system remained unchanged. Since by this time, aptamers should 
FIGURE 6.2 Effect of themperature on the components of aggregating system. Aggregation  of  20 nm HD1-
AuNP  and HD22-AuNP in the presence of 30 nM thrombin proggressing normally at room themperature, is 
reversed and aggregates are disassambled following the thermal denaturation of aptamers and thrombin  at 70 
°C. Cooling down back to room temperature allows refolding of aptamers but not thrombin. Aggregation restarts 
only after injection fresh thrombin. 
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FIGURE 6.3 Measurement of  an average hydrodynamic diameter of 80 nm size gold particles functionalized  
with either HD1, HD22 or NU172 aptamers in the presence of thrombin , thrombin-HD22 complex, thrombin 
and HD1’. (A)Presence of thrombin induces aggregation with almost similar kinetics in the mixture of HD1-
AuNP and HD22-AuNP, Nu172-AuNP and HD22-AuNP, or only HD1-AuNP and only NU172-AuNP but not 
for only HD22-AuNP. (B) Thrombin complexed with ssHD22, didn’t allow binding of neither HD1 nor NU172 
to thrombin exositeII and thus didn’t lead to particle aggregation. Presence of thrombin doesn’t induce the 
aggregation of HD1-AuNPs hybridized with complementary HD1’.  
(A) (B) 
have already adopted normal aptameric folding, we deduced that reason of failing aggregation 
process was in thrombin, that after the heating process was irreversibly denaturized and unable to 
link the aptamers. Titration of fresh 30 nM concentration thrombin, instantaneously induced 
aggregation with the similar rate as it happened in the begging of the experiment.  
Thus, showing that thrombin undergoes irreversible conformational change upon the 
thermal denaturation contrary to aptamers, which return to their aptameric folding, we propose 
that thermal denaturation may be considered as the one of the options for surface regeneration in 
sensor. The advantages, offered by thermal denaturation as surface regeneration method are: no 
change in buffering condition, less harsh influence on aptamers and the surface, no need of 
extensive rinsing to remove the cleaning agents. But the time of aptamer refolding after thermal 
denaturation, representing important point, needs further evaluation and determination.  
6.3.3 Mechanisms of aptamer interaction with thrombin 
One of the first crystal structures of thrombin and HD1, suggested that HD1 can weakly 
interact also with exosite II of thrombin (Padmanabhan and Tulinsky, 1996). Other studies as well 
showed that stoichiometry of thrombin-HD1 interaction is not always one-to-one and therefore 
HD1 is interacting not only with one site of thrombin (Pagano et al., 2008; Pavlov et al., 2004). 
Thus, if HD1 can interact with more than one site of thrombin, we should expect to see 
aggregation of HD1-AuNP in the presence of thrombin without need of HD221.  
To verify our assumption we performed aggregation assay for 80 nm size gold particles 
functionalize with HD1 in the presence of 50 nM Thrombin. Results shown on Fig. 6.3 (A) 
demonstrate that particle aggregation, comparable with aggregation in standard experiment with 
                                                        
1
 The first experimental evidence of HD1 interaction with several sites of thrombin was demonstrated also 
through aggregation assay by Pavlov (Pavlov et al., 2004). In their study aggregation of HD1-functionalized gold 
nanoparticles in the presence of thrombin was monitored with UV-spectroscopy. 
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FIGURE 6.4 Aggregarion of 
HD1-capped gold 
nanaoparticles in the presence 
of thrombin, due  to HD1 
interaction with both binding 
sites of thrombin 
FIGURE 6.5 Interaction of  HD1-
capped gold nanaoparticles in the 
presence of thrombin-HD22 
complex.  HD1 interacts only 
with thrombin exposite I since 
exosite II is already occuped by 
stronger  aptamer HD22.  
HD1-AuNP and HD22-AuNP, occurred even in the absence of HD22-AuNP, confirming that HD1 
has more than one binding site on thrombin (Fig.6.4). Similar experiment for only HD22-capped 
particles didn’t show any evidence of aggregation. Slight change of average hydrodynamic 
diameter of HD22-AuNP with 3±0.5 nm, only indicated the normal 1:1 binding of HD22 with 
exosite II of thrombin (Fig.6.3).  
Further complementing experiments were conducted to clarify whether the second 
binding site for HD1 was indeed exosite II. We reasoned that the specificity of HD22 binding to 
thrombin exosite II could be used to block the access to this site by pre-incubation of thrombin 
with an excess of HD22 for 20 min. This HD22-thrombin complex was then injected into the HD1-
AuNP solution, and aggregation did not take place (Fig. 6.3 (B)). Rather the average diameter 
increased by 15±2 nm, in agreement with the formation of ternary complex between HD1-AuNP, 
thrombin and HD22 (Fig. 6.5).  
From these results we can draw out main conclusion that HD1 has two binding sites with 
thrombin, one is widely known exosite I and another is exosite II. The arguments are following: 
Since thrombin having HD22 bound exosite II didn’t lead to aggregation of HD1-AuNP, reason 
can be that covered exosite II was the second site of HD1 binding and only alternative to exosite I; 
 
 
 
FIGURE 6.6 Interaction of gold 
nanoparticles bearing HD1 
aptamer hybridized to its 
complementary strand with 
thrombin. Thrombin exositeI 
displaces complementray strand 
and binds HD1 but  exositeII  
being  energetically less 
favorable for binding than 
complemenatry strand, remains 
unbound.  
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Affinity of HD1 towards exosite II has to be much more lower than that of HD22, since HD1 
couldn’t compete and replace HD22 from thrombin-bound state. Therefore we can assume, that 
in all aggregation experiments with HD1 and HD2-AuNP, aggregation occurs due to HD1 binding 
only to exosite I and only HD22 interacting with binding exosite II (as it binds stronger), however 
in the absence of HD22, HD1 can easily access exosite II  as well and initiate aggregation. These 
results were used in Chapter 3 to justify the use of heterogeneous analyte model for HD1.  
For estimation the range of the binding energy of HD1 to the exosite I and exosite II of 
thrombin, we made two experiments. In both experiments HD1-AuNP was incubated with excess 
of single-stranded DNA complementary (ssHD1’) to HD1 to induce hybridization. In one case 
HD22-AuNP and thrombin was injected and in another case, only thrombin. 
In first experiment, with thrombin and HD22-AuNP, the aggregation occurred normally 
(data not shown), meaning that thrombin competed for binding to HD1-AuNP with ssHD1’ and 
successfully replaced it. From this, it follows, that binding of HD1 to thrombin exosite I is stronger 
than binding energy to its complementary strand. Indeed the binding energy (free energy) 
calculated for energy of the HD1 and its complementary HD1’ is -29.35 kcal/mol (OligoAnalyzer 
IDT), whereas the binding energy for HD1 to thrombin exosite I calculated with MD simulations 
is ranges from -66.73 to -47.03 kcal/mol (Trapaidze et al., 2015).  
The second experiment, with only thrombin injected in sample of HD1-AuNP and HD1’, 
no aggregation was observed (Fig. 6.3 (B)), meaning that if thrombin managed to displace HD1’ 
for binding HD1 to exosite I, it didn’t succeed in competition with HD1’ for binding HD1 to exosite 
II (Fig.6.6). Thus HD1 binds exosite II with lower energy than -29.35 kcal/mol. 
Experiments similar to those for HD1-AuNP, were also performed for 80 nm size particles 
functionalized with NU172 aptamer, primarily known to bind exosite I of thrombin. Aggregation 
assay for NU172-AuNP and HD22-AuNP was performed first, that led to formation of aggregates 
as predicted. Even though there was no implication, for NU172-capped gold particles as well we 
injected only thrombin, but to our great surprise, similarly to HD1, aggregation did occur (Fig. 6.3 
(A)). Suggesting that NU 172 also have also more than one binding sites. Injection of thrombin 
incubated with ssHD22 similarly to HD1 didn’t lead to aggregation revealing that here also exosite 
II was the second binding site for NU172 (Fig. 6.3. (B)). Experiments with complementary strands 
weren’t performed for NU172. 
Globally if we compare normal aggregation, i.e. aggregation in the presence of two 
aptamers binding different sites of thrombin, with each other and with aggregation in the absence 
of second aptamer (Fig. 6.3 (A)) we will notice that aggregation kinetics in all cases are almost 
identical, despite the association constants being different. This justifies that in current 
experimental conditions aggregation kinetics depends on the diffusion of nanoparticles and not 
on reaction rates i.e. aggregation is diffusion limited.  
The increase of gold nanoparticle concentration, leading to increase of concentration of 
aptamers in solution could shift aggregation more towards reaction-limited state, but then due to 
very strong affinity of aptamers to thrombin would lead to very rapid aggregation and consequent 
sedimentation and we wouldn’t be able to see the beginning of the aggregation of slope due to the 
limitation of instrument requiring up to 3 minutes for one measurement. Contrary, decrease of 
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concentration of gold nanoparticles would still leave us in the diffusion-limited conditions and in 
addition full aggregation kinetics would have taken much longer time.  
6.3.4 Natural inhibitor-thrombin complex 
As we discussed already, thrombin as free protein exists rarely and only for few minutes in 
plasma. Main natural inhibitors ATIII and HCII present in high concentrations in plasma attack 
thrombin and deactivate it irreversibly. To verify which impact such complexes can have on 
aggregation of aptamer-modified gold nanoparticles we performed aggregation assays with 80 nm 
AuNP capped with HD1 and HD22 and thrombin incubated in excess of either inhibitor. Figure. 
6.7  shows the kinetics of interactions.  
Knowing that upon binding with inhibitors thrombin undergoes allosteric change and 
becomes inaccessible for interactions, we didn’t expect to have as strong aggregation as just for 
free thrombin. Indeed, change of the average size of the particles was about 25 nm for both cases 
when thrombin-ATIII and thrombin-HCII where injected into the mixture of HD1 and HD22 
particles. This slight change can be associated either to remnant free thrombin (though, 
concentration should be very low), to interactions with free inhibitors (existing in excess 
concentration) or directly to thrombin-ATIII and thrombin-HCII complexes. In addition, it is 
important to know, which of the aptamer was involved in interactions. 
To find out interacting couple, we inject thrombin-ATIII or thrombin-HCII complexes 
with only one type of aptamers and observed the aggregation kinetics. 
In the case of HD1 aptamer injection of thr-ATIII complex induced slow but significant 
aggregation trend, whereas with injection thr-HCII initial size of HD1-capped gold particle 
remained unchanged.  
For HD22-functionalized particles, contrary to HD1, no size change was observed after 
injecting thrombin-ATIII complex. Interaction of HD22 with thrombin-HCII complex however 
had almost identical aggregation trend as it was observed for HD22 and HD1 mixture. 
These results elucidate the reason of observed size change in the HD1 and HD22 mixture. 
In the case of thrombin–ATIII complex it was HD1 interacting with complex and with thrombin-
 
 
 FIGURE 6.7 Kinetics of aggregation of  80 nm size gold particles in the presence of (A)  thrombin-ATIII 
complex or  (B) thrombin-HCII complex.  Aggregation was performed for mixture containing (red) either type 
of particles bearing HD1 or HD22, (green) only  particles with HD1aptamers, (violet) only  particles ith HD22.  
(A) (B) 
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HCII interacted HD22. These results seem logical, knowing that ATIII and HCII bind thrombin at 
its active site, need for docking interaction with thrombin exosites. For docking ATIII partially 
covers exosite II (Baglin et al., 2002; Li et al., 2004) and HCII occupies exosite I, thus disturbing 
binding of appropriate aptamers (Holland et al., 2000) Exosite II, partially occupied by ATIII, is 
not accessible for the specific to this site HD22 but we can presume that  smaller HD1 can still 
bind it with weak nonspecific interaction and this is why the aggregation was observed.  
However, our explanation contradicts with the results obtained by SPR (see Chapter 3.), 
where we saw how did inhibitor deactivate thrombin allosterically upon binding, making binding 
sites inaccessible for interaction with aptamers. But on the other hand, in the case of SPR 
experiments, where ligand-receptor interactions occur within a reaction volume close to the 
solution/solid phase interface, aptamers are not flexible enough, because of being attached to the 
large surface, there steric interactions (repulsive forces) with other aptamers restrict the 
interaction with target instead of helping. Whereas in the case of nanoparticles, curvature of bead 
may help grafted aptamer to stand out and find its interaction site easier with less obstacles. 
Therefore reaction kinetics, reaction volumes, functional versus actual aptamer concentration and 
their molecular configuration on planar surface differ significantly that occur in solution or on 
surface of colloids (Butler, 2000). 
To obtain full image it would be interesting also to see the interaction of NPs with ATIII 
and HCII without complex with thrombin, as in SPR experiments some nonspecific interactions 
with thrombin aptamers was also revealed.  
6.3.5 Plasma 
The natural environment for thrombin is plasma. Therefore detection of thrombin must 
happen in whole or diluted plasma. Of course, interesting would be to investigate behavior of 
particles in the presence of diluted plasma. For this 
purpose we injected certain amount of plasma, to 
achieve 10 times dilution, into the mixture of HD22-
AuNP of 80 nm size. We selected HD22, as it 
interacts with only one site of thrombin and thus 
cannot aggregate in the presence of thrombin and 
also because it is less prone to nonspecific 
interactions compared to HD1 or NU172. Plasma 
sample was centrifuged and supernatant was passed 
through the filter to remove all suspended cells and 
aggregates that could give artefacts in size 
measurement with DLS method. 
Despite the fact that in buffer no aggregation of HD22-AuNP takes place in the presence 
of thrombin, in 10% plasma (without injection additional thrombin) particles aggregation was 
initiated. Apparently some plasma proteins managed to interconnect particles and induce 
aggregation through nonspecific interactions. These results don’t give favorable answer for 
application aggregation assay for thrombin detection in real plasma.  
  
FIGURE 6.8 Aggregation  of  80 nm size HD22-
AuNPs in the presence of 10 times diluted 
murine plasma 
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6.4  Conclusions  
Aggregation assay allowed investigating not only possibility of thrombin detection in the 
physiological concentration range of thrombin, but also let us research stability of the thrombin – 
aptamer structure and mechanisms of interaction of  thrombin with aptamers and thrombin 
inhibitors. HD1 and NU172 showed interaction with thrombin exosite I and weaker interaction 
with exosite II as well, whereas HD22 showed strong and faithful interaction with exosite II. 
However in diluted plasma without adding thrombin, even HD22 started aggregation. Thus, we 
developed assay which gives possibility to observe kinetics of interaction between aptamers and 
their target protein and to extract information about specificity and selectivity at low cost. Results 
of conducted experiments once again prove that targeting two sites simultaneously, increases 
specificity of detection. This assay can readily be used to detect and perform studies on other 
targets having two interaction sites 
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CHAPTER 7. DIMERIZATION OF THROMBIN APTAMERS 
7.1 Introduction 
Detection of thrombin as a clinical marker of hemostatic state requires performing 
biorecognition in the blood or plasma medium, which represent highly complex biological 
mixtures. Cationic and other aptamer-binding components present in real samples can affect the 
performance of aptamers. Although thrombin aptamers are characterized with very high affinity 
towards thrombin, the initial purpose of their selection was their therapeutic application as 
anticoagulant drug and therefore, for most of thrombin aptamers, the question of selectivity in a 
complex environment remains unanswered or neglected.   
The results of our investigations presented in the third chapter have shown that HD1 or 
NU172 tend to interact with various nonspecific component of the plasma, compromising specific 
detection of thrombin. However, high nonspecific background encountered in the case of single-
site interaction diagnostic assays, can be efficiently diminished by changing the detection format 
with double-site interaction. Targeting two sites of thrombin simultaneously, requiring two 
separate concurrent binding events for signal generation, can provide greater stringency for assay 
specificity and selectivity.  
7.1.1 Simultaneous targeting of non-overlapping sites on the thrombin 
Thrombin detection through double-site binding, other than sandwich assays described in 
the introductory chapter of this thesis, can be achieved as well in two other formats, both 
requiring simultaneous binding of aptamers on non-overlapping sites of the same thrombin 
molecules: (i) assembly of DNA motifs triggered by the dual-binding event; or (ii) bivalent 
aptamer structures (aptadimer).  
The first approach typically involves two DNA probes, each bearing aptameric sequence 
for target binding at distinct sites and special DNA sequences, which hybridize or self-assemble 
into a DNA motif, exclusively after both aptamers simultaneously recognize the same target. 
Upon assembly, DNA motif generates a signal, detected as an indirect measure of the target (Fig. 
7.1). 
 One of the first reports with two aptamers recognizing different epitopes was reported in 
2002 (Fredriksson et al., 2002). Aptamer probes contained also specific sequences which, upon 
dual-recognition of thrombin, were located in close proximity, enabling complementary 
connector oligonucleotide to hybridize and link two aptamers. Then the 5’ terminus of one 
aptamer and 3’ terminus of another, located next to each other, were ligated with DNA ligase. 
Ligated sequence was finally detected by real-time PCR (Fig. 7.1 (A)). This strategy allowed 
detection of picomolar concentration of thrombin. Later a dual-recognition assay that did not 
require the ligation step was reported (Heyduk and Heyduk, 2005). HD22 aptamer was labeled 
with fluorescein as the fluorescence donor and HD1 aptamer was labeled with dabcyl as the 
fluorescence acceptor to form the FRET couple.  Simultaneous binding of the two aptamers to the 
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same thrombin molecule induced FRET effect of between closely located donor-acceptor (Fig. 7.1 
(C)). The quantification of the fluorescence signal permitted detection of as low as 50 pM 
thrombin. More complex, DNA engineering-based approach was proposed by Guisto and 
colleagues. Rolling circle amplification was used to achieve 30 pM  thrombin detection limit 
(Giusto et al., 2005). For this purpose HD22 aptamer was incorporated into a circular DNA 
sequence so-called “captamers”, whereas HD1 aptamer was connected to the short primer 
sequence, able to hybridize with the circular DNA. Binding of both aptamers to a thrombin 
molecule brought the primer to the close proximity with the circular DNA template, promoting 
hybridization and hence forming a primer for polymerase-mediated extension by the rolling circle 
amplification reaction (Fig. 7.1 (B)). The products of the amplification reaction were either labeled 
with intercalating fluorescent dye and fluorescence was measured; or electrochemically labelled 
nucleoside vinyl-Fc-dUTP was incorporated during the amplification and electrochemical signal 
was collected from the hybridization with complementary stand on array electrode. One aptamer 
contained silver nanocluster nucleation sequence and the second a guanine-rich sequence (Li et 
al., 2012). Aptamers could hybridize through short complementary linker, which would form 
following the simultaneous recognition of thrombin by two different aptamers (Fig. 7.1 (D)). The 
formation of DNA duplex structure ensured the proximity of AgNCs with the G-rich sequence, 
which induced 500-fold enhancement of the red fluorescence of AgNCs and hence allowed 
thrombin quantification.  
While the above reported detection limits prove the high sensitivity, they function only 
when both aptamer probes are brought together upon binding to the same target molecule, i.e. 
when tertiary complex aptamer1-thrombin-aptamer2 is formed. This happens when aptamer1-
thrombin complex encounters free aptamer2 or vice versa but tertiary complex will not form if 
aptamer1-thrombin and aptamer2-thrombin complexes meet. To increase the chance of tertiary 
complex formation thus high concentrations of aptamer probes and long incubation time is 
needed. Thus, this format offers good selectivity but doesn’t enhance the sensitivity of detection 
and requires time.  
Improved sensitivity and less reaction time together with the enhanced specificity is, 
however, offered by the second approach - aptamer dimer (aptadimer) format, in which 
distinct aptamers are conjugated (Fig. 7.2 (A)) with an optimal linker (Hasegawa et al., 2008; 
FIGURE 7.1  Detection of thrombin by assembly of DNA motifs triggered by the dual-binding event 
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Müller et al., 2007) or co-hybridized or co-printed on the sensor surface (Fig. 7.2 (B)) with an 
optimal density (Hianik et al., 2009; Lao et al., 2009). Similar to antibodies bivalent aptamers 
show enhanced functional affinity so-called avidity1 effect against thrombin after dimerization.  
Thrombin binding to one aptamer from dimer increases the likelihood of the interaction with 
another aptamer due to the local concentration and proximity. Hence sensitivity increases, time 
to form the complex decreases and captured thrombin remains longer within the complex. 
Depending on the length, design and the chemical composition of the linker 5 to 200 fold 
enhancement of functional affinity of various dimers against thrombin have been reported 
(Ahmad et al., 2012; Hasegawa et al., 2008; Müller et al., 2008; Rakhmetova et al., 2010; Rinker et 
al., 2008; Tian and Heyduk, 2009).   
Improved thrombin detection through binding with immobilized aptadimer (Fig. 7.2 (A)), 
was successfully demonstrated by conventional label-free methods such as electrochemistry, 
QCM (Hianik et al., 2009), SPR (Hasegawa et al., 2008; Müller et al., 2008; Rakhmetova et al., 
2010), AFM (Neundlinger et al., 2011).  Although aptamer dimerization has a capacity to allow 
detection in real samples, thrombin detection assays based on aptadimer haven’t been largely 
investigated. In fact, only two groups have tried to use the aptadimer in the assay for thrombin 
detection in diluted plasma or serum. First, Lao and colleagues  co-printed thrombin aptamers on 
the surface of microarrays to detect fluorescently labeled thrombin (Fig. 7.2 (B)) in the range of 
0.01-10 nM concentration in 10% serum (Lao et al., 2009). Later, Muller and colleagues used 
aptadimer, immobilized on the surface of the microtiter, to capture thrombin from plasma 
sample of the real patients (Müller et al., 2011). Captured thrombin was then let to hydrolyze 
thrombin-specific fluorogenic peptide (Fig. 7.2 (C)). The rate of substrate hydrolysis by captured 
thrombin was compared to those of standard thrombin concentrations. This approach allowed 
detection as low as 1 pM concentration of thrombin. Yet the time needed to extract the 
information about thrombin concentration makes this assay incompatible with the requirements 
of real-time protein detection.  
  
                                                        
1
 Avidity, commonly referred to as functional affinity is the accumulated strength of multiple affinities of an 
individual non-covalent binding interaction, representing combined effect of all affinities participating in the 
bimolecular interaction, rather than sum of affinities. 
FIGURE 7.2 Thrombin detection with bivalent aptamer 
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FIGURE 7.3 Illustration of (A) the structure and working principle of the aptadimer; (B) “mix and read” 
thrombin detection format with aptadimer in liquid phase; and (C) Dual detection  of thrombin with 
fluorescence and a coupled method  by the immobilized aptadimer on the surface of electrode, waveguide or 
quartz crystal.   
7.1.2 Aim of present project 
In the present study we aim to take advantage of enhanced interaction specificity, offered 
by aptamer dimerization, to propose a sensitive and time-efficient strategy to detect thrombin in 
complex medium. For this purpose, we decided to investigate the possibility of engineering an 
aptadimer of HD1 and HD22 thrombin aptamers in such a way that binding to target could 
directly lead to the generation of optically detectable signal. Namely, our approach involves 
triggering the fluorescence emission through “turn-on” mechanism upon aptamer-thrombin 
interaction. We intend to use the FRET effect for turning on and off the fluorescence, which is 
modulated by the proximity of fluorophore and quencher coule, incorporated within the 20-45 
bases long linker (Fig. 7.3 (A)). The linker conformation in the absence of a target represents a 
rigid DNA hairpin composed of a loop and double-helical stem, which keeps FRET couple close to 
each other. Thus the fluorescence of fluorophore is expected to be quenched very efficiently. 
Following the capture of the target by aptadimer, complementary stands of the stem dehybridize 
to allow effective docking of aptamers at corresponding sites of thrombin. As the result, the 
distance between fluorophore and quencher increases and fluorescence escapes quenching. Such 
dimer construct theoretically promises a rapid detection both in the liquid phase and at the 
surface of the solid support. In bulk it can be compatible with mix and read mode, whereas when 
immobilized on the surface, fluorescence signal generation can be also conjugated with other 
detection methods such as surface plasmon resonance spectroscopy or imaging, QCM or 
impedance. Since the linker can be custom-engineered for any aptamer this approach is 
potentially generic. 
(A)
 
(B)
 
(C) 
 
The implementation of our vision comprises several stages. The first and very crucial step 
is the engineering the optimal linker i.e. determination of the optimal chemical type, 
composition, stability, compatibility and length of the linker and positioning of FRET couple (sec. 
7.2). The second stage is experimental validation of the action principle, involving the 
endorsement of successful folding of aptadimer linker into hairpin and stability of the structure 
(sec 7.4.1). The following step is confirmation of thrombin sensing, finding optimal condition for 
the experiment (sec 7.4.2-3). The fourth stage concerns specificity of the dimer with non-specific 
proteins and diluted plasma (sec 7.4.4).  
  
  
 
173 7.1.2 Aim of present project 
7.2 Dimer construction 
Construction of bivalent aptamer dimer, first of all, requires careful selection/design of the 
linker, especially if the generation of a biorecognition signal is directly dependent on it. The main 
requirement from the linker is that its presence shouldn’t affect aptameric conformation of 
component aptamers. This question depends on the chemical composition of the linker, which 
can be either an oligonucleotide or a polymer. Chemical composition also defines whether or not 
the linker will be flexible; influence (up- or down-regulate) interaction of dimer with target; allow 
incorporation of functional groups. The length of the linker is also one of the important 
parameters. It should allow interconnected aptamers reach their optimal positions and 
orientations for docking and wrapping around their common target easily and effectively.  
In the first attempt to create a thrombin aptamer dimer, HD1 and HD22 aptamers were 
simply interconnected with 15-nucleotide long poly-adenine linker, which demonstrated 3-fold 
improvement in the affinity over the original monovalent precursors (Müller et al., 2008). Almost 
simultaneously bivalent thrombin aptamers with 0, 5, 10, 15 and 20 poly-thymine linkers were 
shown to improve about ten times the apparent affinity (Hasegawa et al., 2008).  Subsequently, 
complex construct of rigid DNA scaffold was used to create multivalent aptamer DNA tiles, with 
up to 50 fold increase of affinity compared to monovalent aptamers (Rinker et al., 2008). PEG-
based 12 and 24 nm length flexible linkers were used to construct bivalent thrombin aptamer 
allowing 100-fold improvement of initial affinities (Tian and Heyduk, 2009). Based on the 
assumptions that not only flexibility but also rigidity can influence the enhancement of dimer 
affinity, instead of designing the linkers Ahmad and colleges selected the optimal scaffold-
forming linker from the library of dimers containing HD1 and HD22 aptamers interconnected 
through 30 bases long combinatorial linker (Ahmad et al., 2012). This way almost 200-fold 
enhancement of affinity was achieved. 
Although selection from combinatorial library of linkers has shown its advantage over 
design, but the functionality that we want to get from a linker in our case, requires complex 
designing approach. Other than the concerns about chemical composition and length, the 
placement of the FRET couple and functioning “on-off” mechanism are also of essential 
importance. Therefore, we need to design a DNA linker, which contains sufficient number of 
complementary bases to form a stable stem to keep the construct in closed conformation. But, at 
the same time, the bonding between the complementary regions should get easily disrupted upon 
target binding. For this reason we decided to design a linker for our aptadimer, following the set 
of rules described in next paragraph.  
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7.2.1 Aptadimer construction rules 
The main requirement for any bivalent aptamer is the absence of internal conflict between 
the linker and the aptamers; however design of an aptadimer also requires fulfillment of few more 
specific rules: 
(I) The length of the linker has to be sufficiently long to allow aptadimer 
wrapping around thrombin. 
(II) The stem of the linker has to be composed of complementary regions with 
desired melting temperature. 
(III) Quencher and fluorophore are embedded within the complementary strands of 
the stem opposite to each other. 
(IV) Only Thymine can be internally modified with a quencher and a fluorophore  
(V) Loop of the linker has to be stable and limited to 5-to 10 bases 
(VI) Linker should have no complementarities with either of aptamer sequences.  
(VII) For flexibility linker should contain more thymine bases  
 
Each point will be discussed in following paragraphs. 
7.2.2 The linker length 
In order to estimate the optimal length of the linker we had to evaluate the distance 
between two aptamers when docked on the non-overlapping sites on the thrombin surface. For 
this reason we reconstructed molecular structures of HD1 (4DII pdb) and HD22 (4I7Y pdb) 
aptamers bound to thrombin using PyMol software (Fig.7.4).  
Assuming that in our dimer the sequence 
of HD1 was interconnected by linker with the 
sequence of HD22, i.e. the aptadimer had 
following sequence - 5’-HD1 -3’-5’ -linker -3’-5’-
HD22-3’, we measured the distance between 3’ 
terminus of HD1 and 5’ terminus of HD22. The 
measured linear distance between the extremities 
of the aptamers was about 7.3 nm. Taking in 
account the curvature of the thrombin molecule, 
diameter of which is about 4.2 nm, we estimated 
that linker length should be longer than 9-10 nm.  
If we consider that one nucleotide size or 
length, measured between phosphors of neighboring nucleotides, is approximately 0.67 nm, then 
for 10 nm long linker, at least 15 nucleotides are needed. However, the complexity (functionality) 
of the stem might require larger number of nucleotides.  
 
 
 
 
FIGURE 7.4 The measurement of linear distance 
between 3’ and 5’ extremities of thrombin–bound 
HD1 and HD22 aptamers respectively. 
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7.2.3 Stem of the linker 
The stem represents the central player in functionality of the aptadimer. It has to 
guarantee specific and reversible signal generation upon aptadimer interaction with thrombin. 
This responsible function is based on dehybridization of complementary regions, bearing 
fluorophore and quencher, upon binding to target. Thus the complementary regions have to be 
designed in such way, that in the absence of the target they remain in stable double-strand 
conformation, which gets easily disrupted upon biorecognition. 
 One of the characteristic parameters of the double-stranded DNA is the melting 
temperature, at which thermal agitation overtakes the bonding energy between DNA strands and 
they denaturate. The higher is the melting temperature of the double-stranded region, the 
stronger is the bonding. In order to be able to work not only at room temperature but also at 
body temperature conditions, we decided to seek for the complementary sequences with the 
melting temperature in the region of 43-48 °C.  
First we decided to estimate the number of base pairs needed to form a hairpin with the 
desired melting temperature. To accomplish this we used the software Oligoanalyzer 3.1 which 
predicts folding of the secondary structure of given sequence and based on the nearest neighbor 
method (SantaLucia, 1998) calculates melting temperature of proposed structure. Inputting 
random complementary sequences of different length containing all types on natural nucleotides, 
we estimated that complementary sequences of desired melting temperature were about 5 to 7 
complementary pairs long. Optimization of stem sequences requires knowledge where exactly the 
fluorophores will be located and what would be the sequence of the interconnecting loop.  
7.2.4 Placement of the fluorophore 
In order to realize signal 
generation the way we had 
imagined, it is necessary to 
incorporate fluorophore and 
quencher within the stem of the 
linker. But this is only possible if we 
introduce fluorophore or quencher 
bearing nucleotide. However not all 
the FRET couples can be appended 
to nucleotides within the sequence1, 
and with exception of Thymine 
other nucleotides cannot be 
internally functionalized2. 
                                                        
1
 In common FRET formats fluorophores and quencher are located at the extremities of the sequence, which 
is not difficult to synthetize. 
2
 It should be highlighted that chemical synthesis of oligonucleotides containing two internally modified 
nucleotides has very low yield. Out of material needed for synthesis of 1000 nmol non-modified sequence only 5 
nmol of FRET pair-modified sequence was synthetized. 
FIGURE 7.5 Illustration of fluorophore ATTO532 and Black Hole 
Quencher 1 molecules connected to thymine at the 5th position  
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Thus out of few options as fluorophore ATTO 532 and the corresponding quencher Black 
Hole Quencher 1 (BHQ1) were selected. These dyes might be incorporated into the DNA by 
internal modification of thymine at the 5th position (Fig. 7.5).  
Although the size of the each dye relative to thymine is several times larger, we neglected 
this fact and assumed that presence of these dyes wouldn’t affect base-pairing of neither the 
internally modified thymine nor the neighboring nucleotides.  
Thus to incorporate FRET couple in the stem 
we need to have at least one thymine at each 
complementary region. Moreover thymines have to 
be located close to each other within the stem to 
assure the effective quenching of the fluorophore 
emission.  
For example if modified thymines are located 
opposite to each other paired to each other’s 
neighboring adenine, then the distance between the 
5th positions is about 0.8 nm (Fig.7.6). 
 
 
7.2.5 Design of the Loop 
Loop region of the linker has not only the function of interconnecting the complementary 
parts of the stem, but it also defines the stability of the stem. If the loop is less than 4 nucleotides 
long then bending of the DNA stand would be difficult. On the other hand long loop introduces 
additional entropic and enthalpy contributions which might affect the folding of the stem. 
Therefore we considered a loop with 4 to 10 bases to have the optimal length. Although it is 
difficult to estimate how the flexibility of the loop and stability of the stem depend on the 
sequence of the loop, but loop shouldn’t have any complementarities neither with aptamers nor 
with the stem.  
7.2.6 Manual design of the linker 
After having set the rules, first we started designing the linker manually. Based on our 
rules, we created initial 25 nucleotides long linker structure containing 7 bps in the stem, 5 
nucleotides in loop, and, for 2 and 4 thymines between the rigid stem and HD1 and HD22 
aptameric structures respectively for flexible spacing. We run the oligoanalizer software to 
generate the secondary structure of the aptadimer construct. We checked for the possible internal 
interference between the stem, the loop, and aptameric sequences and verified the melting 
temperature of the dimer. According to the results of oligoanalizer, we made alterations in the 
loop and stem sequences and again generated the secondary structure. We verified again the 
presence of interfering sequences and folding energy.  
FIGURE 7.6  Visualization of the linear 
distance between two thymines located in 
opposite to each other complementary strands 
and paired with neighboring adenines.   
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Thus we made several iteration steps until stable structure of desired melting temperature 
was obtained. The resulting sequence of the aptadimer and folding of its linker in the secondary 
structure are shown on the Fig. 7.7. The internally modified thymine bearing Black Hole 
Quencher was positioned at the 20th position and whereas ATTO 532 appended to the thymine 
with the 33th position.  
7.2.7 Dimer construction by software 
Manual selection of the custom spacer, requiring conception of the preliminary structure 
and then iteration-optimization steps, is relatively time-consuming and subjective process. 
Therefore to be able to screen the larger variety of possible spacer sequences special software was 
developed in our group. The algorithm of the software obeys the selection rules described above 
to help the selection of the optimal spacer. In addition it also evaluates the thermodynamic 
parameters of each fitting sequence.  
The user-friendly, interactive software upon inputting the sequences of the first and 
second aptamers, the number of complementary bases in stem, the number of nucleotides in the 
FIGURE 7.8 The software for computational selection of a spacer for given sequences of aptamers. 
FIGURE 7.7 Primary and secondary structure of manually designed aptadimer S1. Table shows predicted 
melting temperature and thermodynamic parameters of the spacer and complete structure S1 
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loop and the number of thymines for each aptamer spacers, generates the possible sequences and 
arranges them either by the melting temperature or by the free energy change (Fig. 7.8).  
The spacer sequence of desired melting temperature was selected and manually evaluated 
again by Oligoanalyzer. Indeed, no interference between selected spacers and aptameric 
sequences was revealed (Fig. 7.9).  
We came up with the 85 nucleotides long aptadimer sequence with a 41 nucleotides long 
linker. Linker contained 8 thymine spacers at each extremity, 7 base pairs in stem, and 15 poly-dT 
loop. Quencher and fluorophore are embedded at the 26th and 47th positions, respectively. 
 
We should highlight that development of the software took in total 6 months of 
laborious work of two master students. Hence the computationally designed aptadimer 
was created much latter than manually designed one. For this reason and due to time 
constrains most experiments presented in this study are carried out with manually 
designed aptamer dimer.  
  
FIGURE 7.9 Primary and secondary structure of computationally designed aptadimer S2. Table shows 
predicted melting temperature and thermodynamic parameters of the spacer and complete structure S2 
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7.3 Experimental  
7.3.1 Structure of the dimers 
The linkers between HD1 and HD22 aptamers were selected based on compatibility rules 
and melting temperatures either manually (S1) of by using the software (S2), specially developed 
for this purpose in our lab. Sequences and specific characterizations are given in the table 7.1. 
Table 7.1 Sequences of manually and computationally selected aptadimers 
S
S1 
5’ -
GGTTGGTGTGGTTGGTTTT*T*ATTCGCGAAGAA*T*AAATTTTAGTCCGTGGTAGGGCAGGTTGGGGTGACT -
3’ 
69 bases, linker length 25 bases, 7 complementary bp, loop 5 bases, BHQ1 - dT(20), ATTO532 - dT(33) 
S
S2 
5’- GGTTGGTGTGGTTGG 
TTTTTTTTCA*T*AAGATTTTTTTTTTTTTTTTC*T*TATGTTTTTTTTAGTCCGTGGTAGGGCAGGTTGGGGTGA
CT-3’ 
89 bases, linker length 45 bases, 7 complementary bp, loop 15 bases, BHQ1- dT(26), ATTO532 –dT(47) 
7.3.2 Fluorescence measurements 
As FRET pair the fluorophore ATTO532 and the quencher BHQ1 were selected, since they 
can be internally appended to dT. The maxima for excitation and emission spectrum of ATTO532 
are located at 532 and 546 nm, respectively (Fig. 7.10). In our typical experiment, fluorophore was 
excited at 510 nm and emission range from 520 to 650 was scanned. Integration time was 0.1 s and 
step was equal to 1 nm. 
Fluorescence measurements were made in quartz cuvette. Experiments were typically 
conducted in the PBS of pH 7.4, containing 10 mM PB (Na2HPO4/ KH2PO4), 145 mM NaCl, 5 mM 
KCL, 1 mM CaCl2 and 1 mM MgCl2. Dimer structures were kept in 5 μM concentration water 
solution in the freezer.  
Buffer-diluted samples of desired concentrations were prepared in advance or just freshly 
prior to experiment. In the first case, sample was diluted in PBS buffer, heated in boiling bath and 
allowed to cool down overnight in adiabatic conditions. In the latter case, the stock water-
solution was heated in boiling water-bath then it was freeze-cooled and kept on ice; just before 
FIGURE 7.10 Excitation and emission spectrum of ATTO532 fluorophore 
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the measurement the appropriate amount of dimer sample was injected into 5 °C PBS buffer. An 
appropriate concentration of protein was added after 1 min stabilization. 
7.3.3 Endorsement of the structure folding 
For the endorsement of successful folding of the linker into double-helix stem 
configuration, 100 μL of 100 nM concentration S1 structure in PBS was thermally dehybridized and 
re-hybridized.  The system was heated up from room temperature to 60 °C and allowed to cool 
down with step of approximatively 5 °C.  
Chemical denaturation of the stem was accomplished with the stepwise titration of the 
detergent Triton X-100 with final volumetric concentration from 2 to 8%.  
Effect of chemical and thermal denaturation was obtained by heating up and cooling the 
dimer sample containing 8% detergent.  
Folding of S2 structure was verified only by thermal denaturation. 
At each point, before taking the absorbance spectra, the system was stabilized for 3 
minutes.  
7.3.4 Tuning experimental conditions 
Interaction of 100 nM S1 construct with equimolar or excess thrombin was performed at 
room temperature (22 °C), with two different sample preparations. Sample with S1 structure was 
either prepared in advance (a) or was prepared freshly (f) just before experiment. Absorbance 
spectra were taken right after thrombin injection, and then after 1 and 3 minutes. 
7.3.5 Aptadimer interaction with thrombin 
Equimolar and excess thrombin interaction with freshly prepared 300 μL 75 and 10 nM S1 
or 50 nM S2 was investigated by temperature scanning mode.  
7.3.6 Investigation of aptadimer interaction with the specific and nonspecific targets 
Interaction of 300 μL of 50 nM concentration freshly prepared S1 structure with thrombin, 
prothrombin, excess BSA, and 10% and 1% plasma was examined by measuring the fluorescence in 
scanning temperature mode. For this reason freshly prepared S1 sample with a titrated protein 
was heated from 5 °C to 60 °C, with increment of 5 °. After each heating step, the system was 
allowed to stabilize for 3 min and then the fluorescence was measured.  
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7.4 Results 
7.4.1 Endorsement of aptadimer linker folding into hairpin 
As the first step, the folding of the stem of the aptadimer was examined. To verify whether 
complementary regions have successfully engaged, we decided to induce the dehybridization of 
stem. If the stem has folded as predicted, then the fluorescence emission of the fluorophore 
quenched in the double-strand conformation due to the proximity with the quencher, is expected 
to increase upon dehybridization and subsequent increase in distance between FRET pair.  
7.4.1.1 Folding of manually selected linker 
First we examined the folding of the manually selected 25 nucleotides long linker of S1 
aptadimer. The central part of the linker is the hairpin with 7 bps long double-strand forming 
region interconnected with 5 nts loop. 3 Thymines at each side of the hairpin serve as flexible 
spacers between aptameric sequences and the hairpin. Dehybridization of the stem, first, was 
accomplished thermally, by heating 100 nM concentration S1 structure in PBS from room 
temperature till 60 °C and then cooling back to ambient conditions. Thermal de- and re-
hybridization of structure was followed by the measurement of the fluorescence emission at 550 
nm wavelength. As expected, with the increase of the temperature, intensity of fluorescence 
emission built up (Fig. 7.11 (A, D)). The drastic increase of the fluorescence intensity was seen 
starting form 42-45 °C, the melting temperature1 of the double-stranded stem was located in the 
temperature region of 45-50 °C as predicted by the software (Fig.7.7). At 60 °C, the fluorescence 
intensity was increased with about 2.3 fold compared to the fluorescence of the same structure 
just before denaturation at room temperature. The fluorescence of the sample started to decrease 
and reached the same level upon cooling the sample down to room temperature, proving that 
Watson-Crick base pairing again took over the thermal agitation at low temperature and favored 
re-hybridization of complementary regions of the stem.  
After thermal modulation of the stability of the stem region, aptadimer structure was 
denaturized chemically in presence of nonionic surfactant Triton X-100. Chemical denaturation 
also induced separation of complementary regions. Titration of increasing concentrations of 
detergent in sample at room temperature induced the similar effect to thermal denaturation - the 
intensity of the fluorescence emission augmented drastically (Fig. 7.11 (B, E)). As a result, in 
presence 0.6% (volume fraction) detergent, increase of fluorescence of about 200% was observed, 
which didn’t increase further at 0.8 % Triton X-100. Thus the detergent effect gave a fluorescence 
intensity change comparable to that of observed at the maximum of thermal dehybridization. 
Both pathways of dehybridization lead to the separation of the quencher and the fluorophore 
with the same degree.  
Interestingly, when the sample with the 0.8% Triton X-100, was heated up to 60 °C and 
cooled back to room temperature, we observed an additional onset in fluorescence emission (Fig. 
7.11 (C, F)). Fluorescence intensity at 60 °C was more than 1000% higher compared to the 
fluorescence of the same sample at room temperature in the absence of detergent. 
                                                        
1
 Melting temperature is the temperature at which half of the DNA is in random coil.  
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This superposed effect of thermal and chemical denaturation was reversible and cooling 
the sample made the fluorescence emission decrease to the initial level (Fig. 7.11 (G)). 
The possible explanation of this reversible extra enhancement might lie in the change of 
properties of environment upon heating, which influence FRET efficiency. Since FRET efficiency 
depends not only on distance but also on the orientation of the dipolar moments of FRET donor 
and acceptor pair and optical density of the medium. The presence of surfactant, on one hand, 
separates complementary strands increasing the distance between FRET pair and stabilizes 
fluorophore and quencher orientation enveloping them in micelles; and, on the other hand, it 
changes the local optical index of the medium. Namely when the temperature of nonionic 
surfactant increases, the surfactant (especially with the concentration higher than the critical 
micelle concentration) undergoes phase separation. This point, called cloud point, for Triton X-
100 is achieved at 63-69 °C in water (Ruiz et al., 2001). In the presence of a salt, repulsive steric 
interactions between the surfactant micelles decrease and attractive van der Waals interactions 
increase, leading to decrease of the cloud point temperature. When phase separation occurs small 
DNA fragments tend to stay in the surfactant phase.  Since the concentration of Triton X-100 in 
our experiments is much larger than its’ critical micelle concentration and the salt concentration 
is about 150 mM, we can suggest that, our sample reaches cloud point at lower temperature than 
(A)  (B) (C) 
(D) (E) (F) 
(G) 
FIGURE 7.11 Fluorescence intensity of 100 nM S1 
aptadimer excited at 510 nM. Fluorescence spectrum in 
range of 520-650 nm during (A) thermal denaturation 
from 22 to 60 °C and back; (B) chemical denaturation 
with Triton X-100; and (C) thermal denaturation in 
presence of detergent. Fluorescence intensity at 550 nm 
for respective cases (D-F). Summarized comparison of 
fluorescence emission intensity at 550 nM.(G). The 
percentage is calculated relative to fluorescence 
intensity of S1 structure in buffer at room temperature.  
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60 °C. If it is so, the aptadimer would appear within the detergent phase, where the optical index 
is different and the orientation of the FRET dipoles is rigidly fixed so that quenching efficiency 
decreases and therefore fluorescence emission is enhanced.  
7.4.1.2 Folding of computationally selected linker 
After validating folding of manually selected linker of S1, we examined folding of stem of 
S2 structure linker of which was selected by software. Similar to S1 structure, S2 also had 7 bps 
long complementary stem region, but loop contained 14 thymines, and hairpin was flanked at 
each sides by 8 thymines, making total length of 
linker equal to 44 nucleotides long. In this case 
folding of stem in double-strand was endorsed 
only through thermal denaturation (Fig. 7.12).  
75 nM concentration of S2 aptadimer in 
PBS buffer was heated from 5 to 60 °C. Increase 
of fluorescence emission intensity was observed 
starting from 25-30 °C and reached the maximum 
already at 50 °C, in agreement with the 
expectation that the melting temperature of S2 
structure is 40 °C.  This melting temperature is 
slightly lower than that of S1, which can be explained by the fact that the S1 has shorter and more 
stable loop that has less entropic and enthalpic influence on the double-strand of the stem than 
in the case of flexible poly dT loop of S2 aptadimer. In other words, it is slightly easier to 
destabilize the stem interconnected with longer loop than with shorted less flexible loop.  
Another interesting observation was the intensity of the fluorescence emission in the state 
of complete denaturation of the stem. Namely the fluorescence signal was increased to more than 
650% compared to initial signal. This corresponds to about 3 fold more intensity than with S1 
structure at 60 °C. The reason of such a huge difference between maximum fluorescence signals 
lies in the position of the fluorophore and quencher. In case of S1, the distance between FRET pair 
in the linear linker is equal to 12 separating nucleotides i.e. about 8 nm. Whereas in S2 linker 
quencher-fluorophore are separated with 21 nucleotides, making the linear distance equal to 
about 14 nm. As it is known the efficiency of the FRET depends on the distance with the inverse 
6th power, meaning that quenching efficiency of S1 is about 29 times stronger than that of S2 (See 
chapter 2). Thus in S1, shorter distance between quencher and fluorophore, doesn’t allow release 
of maximum fluorescence emission whereas in S2 thermal denaturation separates FRET pair on 
the distance where the quenching effect is diminished. Hence, when examining stability of S1 and 
S2 aptadimers we found that both structures have well folded stem. S1 has more stable stem than 
S2, however S2 is able to generate way larger fluorescence emission.   
FIGURE 7.12 Thermal denaturation profiles of 75 
nM concentration S1 (blue circles) and S2 (red 
squares) aptadimers in PBS buffer 
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FIGURE 7.13 Effect equimolar, 2 and 3 fold thrombin presence on fluorescence intensity of 100 nM 
S1 structure prepared (A) by overnight adiabatic incubation or (B) freshly prior to experiment.   
7.4.2 Interaction of dimer with Thrombin 
After successful endorsement of linker stem folding, the next point of interest was the 
validation of the working principle of signal transmission upon thrombin-dimer interaction. For 
this purpose we decided to allow various concentrations of thrombin to interact with aptadimer 
at room temperature.  
First 100 nM concentration S1 structure in PBS buffer was examined. The stock solution of 
dimer was prepared in PBS buffer day before the experiment; it was first heated up till 90 °C and 
then cooled down adiabatically to room temperature overnight. Sample was diluted to desired 
concentration prior to experiment  
(A) Adiabatically cooled overnight in buffer (B)Freshly diluted in buffer before experiment 
 
 
 
Surprisingly, expected enhancement of the fluorescence intensity was not observed upon 
titration equimolar or excess thrombin for adiabatically cooled samples (Fig. 7.13 (A)). Obtained 
result didn’t give a hint whether thrombin was interacting with the dimer or not. In fact, 
thrombin could interact with dimer but without having disrupted the stem conformation, in case 
of interaction with only one of the aptamers. Thus, the reasons for not having an effect of 
thrombin presence on stem dehybridization could be following: either thrombin was interacting 
with only one of the aptamers and therefore didn’t affect the stability of the stem; or thrombin 
couldn’t open the stem to position itself between the two aptamer for simultaneous docking to 
form tertiary complex. 
In order to elucidate whether the strength of stem folding was causing the problem for 
simultaneous interaction of both aptamers with thrombin, we decided to affect the stability of the 
dimer by changing the protocol of sample preparation. Namely, instead of overnight incubation of 
the dimer in buffered environment, the stock of dimer was prepared in water, which prior to 
experiment was heated up till 90 °C to destroy all the bonding and was subsequently cooled by 
placing it on ice. As soon as 100 nM concentration sample was prepared in PBS buffer various (50, 
100 and 150 nM) concentrations of thrombin was titrated and fluorescence was measured, leaving 
very short time for forming the stable double-helical stem. 
Interestingly, the change in fluorescence signal obtained (Fig. 7.13 (B)) in these conditions 
was sufficient to associate it with specific interaction between thrombin and dimer. Obviously, it 
was stem rigidity objecting the generation of the fluorescence signal and in this conditions 
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thrombin took advantage over the weaker stem folding to insert itself within dimer. The 
fluorescence intensity after addition equimolar concentration of thrombin increased with 5% and 
upon doubling the concentration the increment was about 18% compared to initial fluorescence 
level. Although the change in fluorescence intensity upon thrombin addition was much smaller 
compared to the signal observed during thermal denaturation. We suggest, that when dimer 
wraps around thrombin, diameter of thrombin of 4-5 nm might be insufficient to increase the 
distance between fluorophore and quencher, so that they remain still in quenching distance and 
FRET quenching efficiency is still significant.  
The stability of the dimer stem depends on 
the folding of the structure, which in turn depends 
on the environmental condition, the presence of the 
salt. In order to show that freshly made sample had 
weakly stabilized stem than buffer-incubated we 
performed the thermal denaturation experiment of 
both samples. For this purpose we scanned the 
temperature from 5 to 40 °C measuring the 
fluorescence intensity at 550 nM after each increase 
of the temperature with a 5 °C step. The result 
presented in Fig. 7.14 shows that the behavior of 
thermal profiles of the two structures differs in the region of 5-20 °C. At 5 °C, fluorescence 
intensity of the freshly prepared sample is significantly larger compared to the incubated sample. 
However upon increase of the temperature the signal of the fresh sample decreases, finally 
reaching at 20 °C the similar fluorescence level as the incubated sample.  
This difference in the thermal profiles elucidates the stem folding-associated question. 
When dimer structure has the salty environment, the overnight incubation favors formation of 
base-pairing intra- and inter-dimer1. Whereas dilution of water stock solution of dimer into the 
buffer just prior to the experiment (directly low concentration) and low temperature favors 
formation only the self-folded dimers. Thus the decrease in the fluorescence for freshly prepared 
samples corresponds to hybridization of complementary regions, which in the absence of salt 
were not associated, separating quencher and fluorophore from each other. Upon hybridization 
quencher and fluorophore were set closer to each other. Hence the FRET quenching of 
fluorescence took place. So we can assume that at 20 °C fresh and incubated samples have formed 
stems2. Thus, in order to detect the interaction between thrombin and the dimer it is better to 
observe the fluorescence signal of thrombin and freshly prepared aptadimer sample.  However, 
we believe that thrombin can not only insert itself on weaker stem, but it also can affect the 
global stability of the structure and induce the change in thermal denaturation profile.  
                                                        
1
 The complementary regions of the dimer can form double helix by interacting either with each other (intra), 
or with complementary regions of another dimer molecule (inter). The chance of forming complex structure with 
another dimer molecule is low at nanomolar concentration of DNA but increases with the increase of the 
concentration, for example in stock solution.  
2
 For freshly prepared sample we can assume that complementary regions hybridize exclusively with each 
other, whereas in incubated samples there is higher chance to have inter-molecular dimers with similar fluorescence 
quenching level, but stronger binding energy.  
FIGURE 7.14 Thermal profile of fluorescence of 
100 nM concentration dimer adiabatically cooled 
overnight in PBS (red square) of freshly diluted 
in buffer (blue circle). 
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FIGURE 7.15 Thermal denaturation profiles of (A)75 nM S1, (B) 10 nM S1 and (C) 50 nM S2 aptadimers in 
the presence of various thrombin concentrations. Dependence of fluorescence intensity change of (D) 75 nM S1, 
(E) 10 nM S1 and (F) 50 nM S2 dimers on the thrombin concentrations at 30 °C. Labels indicate the increment 
of fluorescence intensity relative to the fluorescence emission of bare dimer structure in the same conditions. 
7.4.3 Interaction of aptadimer with various concentration of thrombin 
After showing that thrombin can interact with dimer (both aptamers simultaneously) only 
if the dimer stem is destabilized, and taking in account that destabilization of the stem folding is 
dependent on the temperature, we decided to optimize fluorescence signal generation by tuning 
the temperature. However instead of finding the optimal temperature, we decided to carry out 
thrombin-aptadimer interaction experiments in thermal scanning regime.  
First, the thermal scanning experiments in the presence of freshly prepared 75 nM S1 
aptadimer and 75, 150 and 187 nM concentration of thrombin were performed (Fig. 7.15 (A)). The 
temperature was scanned in the range of 5-55 °C with the increment of 5 °C. Thrombin injected in 
aptadimer sample just before starting the thermal scanning, already manifested itself in the 
beginning of the measurement. Namely, instead of decrease of fluorescence intensity in the 
region of 5-20 °C, which is characteristic to freshly made aptadimer without thrombin, the 
increase of fluorescence intensity was already observed starting from 10 °C when the thrombin 
was present. Starting from 20 °C it became already evident that the stem destabilization effect 
upon thrombin–aptadimer interaction was dependent on thrombin concentration. The slope of 
the stem dehybridization curve became steeper with the increase of thrombin concentration. The 
comparison of the fluorescence emission intensity of aptadimer in the presence of various 
concentrations of thrombin at 30 °C shows already significant differences in the signals. The more 
thrombin is titrated, the more is the melting curve affected i.e. the stronger is the destabilization 
effect. 
(A) 75 nM S1  (B) 10 nM S1 (C) 50 nM S2 
(D) 
 
(E) (F) 
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The sensitivity of the fluorimeter machine allowed decreasing of the concentration of 
fluorescently labeled aptadimer further down. Hence, the second set of experiments now was 
performed for 10 nM concentration of freshly prepared dimer sample in the presence of 5, 10, 20 
and 30 nM concentration of thrombin (Fig. 7.15 (B)). Similarly to the previous experiments, in this 
case as well, was shown that the shape of the thermal denaturation curve of the stem depends on 
the concentration of the thrombin. The strength of the fluorescence signal indicated that with the 
same instrument it is possible to investigate the samples with even lower dimer concentration.  
At last we also investigated interaction of freshly prepared 50 nM S2 aptadimer with 
various concentrations of thrombin (Fig. 7.15 (C)). Although when superposed, it was difficult at 
first glance to see the difference between the thermal denaturation profiles, however this is only 
because the change in fluorescence intensifies between closed stem and denatured stem is of 
larger scale than in the case of S1 structure. If we zoom to only one temperature point, we will be 
able to see the significant differences between fluorescence intensities of the same structure in 
the presence of various concentrations of thrombin.  
We compared thrombin concentration-dependent changes of the fluorescence to the 
fluorescence of the bare dimer at 30 °C (Fig. 7.15 (D-F)). This temperature was selected because at 
this point the stem is still double-stranded for both S1 and S2 structure, the thrombin 
concentration dependent changes in fluorescence are already significant and the thrombin 
structure is not denatured. Results reveal that fluorescence signals of the both dimers are 
sensitive to thrombin, even when thrombin concentration is below than aptadimer concentration. 
For both aptadimers, interaction with equimolar concentration of thrombin results in 22-30% 
increase of fluorescence intensity. Furthermore doubling the thrombin concentration leads to 
increase of fluorescence signal with 45-55% relative to only dimer. Thus, fluorescence response 
increases linearly with increase of thrombin concentration and it doesn’t tend to deviate from the 
trend even when thrombin exceeds the concentration of aptadimer three times. This fact 
indicates that, in our experimental conditions1 the dimer is not getting saturated2 in the presence 
of equimolar concentration of thrombin. Complete dimer saturation would require excess 
thrombin with several fold larger concentration than that of the dimer. 
Thus, examining the thermal denaturation profile gave better sensitivity and signal 
definition than just observation of the fluorescence change at the fixed temperature. We believe 
that this effect is due to thrombin coordination by the dimer and therefore specific only to 
thrombin. In order to verify the specificity of the aptadimer we will continue to use the same 
approach.  
  
                                                        
1
 10, 50 or 75 nM concentration of dimer is in the same range of dissociation constants of thrombin aptamers 
and therefore to affinity of the dimer. The closer the concentration of dimer to the dissociation constant the less 
thrombin – aptamer pair will be formed at equimolar thrombin concentration. 
2
 Under saturation we consider the state of the dimer sample when all the dimers are paired with thrombin. 
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FIGURE 7.16 Thermal denaturation profiles of 50 nM S1 structure in the presence of 
(A) equimolar prothrombin and excess of BSA; or (B) 100 and 10 fold diluted plasma. (C) 
Summarized comparison of fluorescence emission intensity at 550 nm and 30 °C. The 
percentage is calculated relative to fluorescence intensity of only S1 structure in buffer 
at 30 °C.  
7.4.4 Interaction of aptadimer with nonspecific proteins 
To show that change in fluorescence intensity upon destabilization of the stem is only 
characteristic of thrombin presence and depends on specific interaction of thrombin and 
thrombin-sensing regions of aptadimer, we decided to investigate the behavior of the 50 nM S1 
aptadimer melting in the presence of prothrombin, serum albumin and diluted plasma.  
 
(A) (B) 
(C) 
 
Titration of equimolar concentration of prothrombin or excess of BSA didn’t induce 
significant changes in the shape of the stem melting curve and the fluorescence emission 
intensity at 30 °C was almost identical to that of only dimer. The same result was obtained for the 
sample with 100 fold diluted murine plasma. Observed results suggested that indeed change of 
the dimer conformation is specifically dependent on thrombin (Fig 7.16).  
However, when the 100 fold diluted murine plasma was spiked with thrombin in 
equimolar to dimer concentration, observed change in the shape of the curve and the subsequent 
change in the florescence intensity was comparable of the of 100 nM Thrombin, i.e. the effect was 
double-enhanced. The enhancement of the fluorescence intensity with more than 120% was 
observed at 30 °C when 10 fold diluted plasma was introduced in aptadimer sample, indicating 
that despite the specificity of thrombin-aptadimer interaction, nonspecific interactions still take 
place with aptamers, affecting the stability of the stem in the similar way as thrombin. 
Although the specificity of thrombin detection by means of aptadimer in plasma still 
remains problematic, preliminary results are promising and further improvement in the dimer 
structure and assay design give a hope to succeed on this path.  
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7.4.5 Open questions and encountered problems 
This work represents the first attempt to generate smart aptamer dimer for thrombin 
detection purposes. Being still in the phase of conception, together with the validation of the 
detection principle, we also faced some problems and open questions that need to be solved and 
thought on at the following stages of development of the aptadimer-based biosensing. Since the 
identification of all possible bottle-necks of our approach represents a great and even an essential 
importance for improving the performance of the dimer, therefore here we intend to highlight 
open questions, observations, concerns:  
1. Interaction of thrombin with dimer i.e. how exactly does thrombin interact with 
dimer:  
a. Can thrombin insert itself within the aptadimer without triggering the 
fluorescence emission, i.e. without disturbing folding of the stem or changing 
the distance between the fluorophores? What would be the possible the 
solution?  
b. How many thrombin molecules can interact with one aptadimer? Can two 
thrombin molecules simultaneously interact with each of the aptamers of the 
same dimer? If it is so, what happens with fluorescence signal?  
c. What can be done to assure 1-to-1 interaction between thrombin and 
aptadimer?  
2. Folding of the dimer: 
a.  What is the chance of having higher-order complex molecules such as dimer 
of aptadimers, interconnected with complementary regions? How would this 
affect interaction with thrombin, the signal generation and the quantification 
of thrombin concentration? Which approaches could help to examine these 
questions? 
3. The strength of fluorescence signal: We performed thrombin-dimer interaction 
experiments on several instruments. We observed that success of the readout depends 
on the sensitivity of the fluorimeter. Some instruments allowed sensitive fluorescence 
measure at 10 nM and even lower concentrations of dimer but required large volume 
of the sample and we could measure fluorescence signal of only one sample. Whereas 
other instrument like real time PCR machine, allowed fluorescence detection of 
several smaller-volume samples (70-100 µL) but required high concentration of the 
dimer and protein. This point has to be considered when multiplexing the detection. 
4. Which additional rules do we need to apply during the design process of the linker in 
order to get responsive but stable dimers? Should the larger, scaffold-forming 
sequences be considered as well?   
5. It is expensive, time-consuming and difficult to synthetize sufficient concentration of 
the aptadimer sample with two internally modified nucleotide, would be better to 
think about approaches like click-chemistry to assemble the dimers with less 
expensive parts rather than synthetize. 
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7.5 Conclusions and outlook 
In this study we presented our first attempt to design aptamer dimer for recognition and 
quantification of thrombin. For this purpose, we proposed an integrated approach to design 
aptadimer structures, which involves the development of new software to predict custom linker 
sequences obeying defined rules focused on the preservation of aptamer structure and stability. 
We endorsed dimer folding and confirmed the functionality of aptadimers measuring 
fluorescence with scanning temperature mode in the presence of specific and nonspecific targets 
and diluted plasma. The detected specific changes in the fluorescence in presence of thrombin 
indicated the existence of specific interactions with aptadimer construct.  
We believe that this technology is a step forward for developing aptamer-dimer-based 
sensors, not only for thrombin but also for other targets. This work provides a starting point for 
merging the principles of DNA nanotechnology with aptameric functions in order to develop 
specific, performant aptamer-based fluosensors, both for the surface and the volume 
measurements.  
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OVERALL CONCLUSIONS  
 
The present work was dedicated to investigation of thrombin aptamers and to 
development of innovative technological bricks which together would drive future advancement 
in the field of point-of-care devices for continuous monitoring of thrombin in plasma. Real-time 
detection of free thrombin concentration in blood, has a vital importance for tailoring individual 
hemostatic or anticoagulant therapy in patients with the risk of developing thromboembolic or 
hemorrhagic complications 
In frame of this Ph.D work, we first tackled fundamental questions of molecular 
interactions of thrombin aptamers with thrombin, specify towards thrombin in the presence of 
interfering molecular species such as thrombin precursor prothrombin, thrombin complexes with 
natural inhibitors ATIII, HCII and A2M, nonspecific molecule serum albumin and complex 
environment as diluted plasma. Rigorous investigation with surface plasmon resonance revealed 
that HD1 and NU172 aptamers are interacting not only with exosite I of thrombin, as it was 
thought before, but also with exosite II and the affinities for both aptamers for both sites are in 
nanomolar range. These aptamers also demonstrated high affinity towards prothormbin. HD22, 
on the other hand, showed low nanomolar dissociation constant to thrombin exosite II and no 
affinity at all to prothrombin. Interestingly none of the aptamers recognized inhibited thrombin, 
indicating that irreversible binding to its natural inhibitors rendered thrombin exosites 
inaccessible and allosterically deactivated for interaction with aptamers. Moreover we found out 
that HD1 is involved in nonspecific interactions with serum albumin. HD1 is unable to identify 
thrombin in diluted plasma sample, as it gets irreversibly oversaturated by nonspecific 
interactions even in the presence of nonspecific binding reducing reagent. HD22, on the other 
hand, didn’t show significant interaction patterns neither with BSA nor with diluted plasma in the 
presence of NSBr. Thus, HD22 proved to be indeed highly affine and specific sensing element for 
thrombin and showed its advantage over HD1 and NU172 aptamers. These results will have 
positive impact not only on the field of design of aptasensor for thrombin detection but also on 
the advancement of basic science. 
We also focused our efforts to explore various aptamer immobilization approaches on 
planar and nanoparticle surfaces of gold and polymer materials. We found that, out of 
investigated methods, immobilization of thiolated aptamers on gold surface was the easiest and 
the most efficient functionalization strategies. Immobilized thiolated aptamers were fully 
functional and the grafting density was optimal for solid state biosensing. Furthermore to achieve 
nanoscale control of functional aptamer density, we showed advantage of ordered immobilization 
of DNA-capped nanoparticles on the desired solid support through convective assembly. We 
investigated the main influencing experimental parameters in order to obtain highly ordered 
monolayer of aptamer-functionalized 80 nm gold nanoparticles on silica surface for its further 
application as the part of biorecognition signal transducing element.  
Aptamer-modified gold NP-s were also used in aggregation assay, which was first 
performed to verify functionality of nanoparticle-grafted aptamers. Aggregation of gold 
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nanoparticles was triggered by simultaneous recognition of the same thrombin molecule by 
particle-grafted two distinct aptamers. With this assay, we managed not only to detect different 
concentrations of thrombin (5-500 nM) with good precision, but also to study the thermal 
stability of the aptamers and their complex with thrombin; and specificity of aptamers towards 
inhibited thrombin in buffer. In diluted plasma, however aggregation of nanoparticles occurred 
even in the absence of thrombin, suggesting the presence of nonspecific interactions with 
aptamers that cannot be controlled or neglected in aggregation assay. Interestingly, results of 
aggregation assay, showing aggregation of HD1- or NU172-capped gold nanoparticle in the 
presence of only thrombin helped us to elucidate the real mechanism of HD1 and NU172 
interaction with thrombin. These results helped us to apply appropriate fitting model to surface 
plasmon resonance data and correctly interpret association and dissociation constants of 
thrombin interaction with HD1 or NU 172. Not only was this assay informative for investigation 
thrombin-aptamer interactions, but also it promises to be an easy and low-cost tool for detection 
and characterization any other bivalent target.  
Finally we proposed innovative approach of engineering a smart aptadimer of HD1 and 
HD22 aptamers, allowing detection of thrombin with increased specificity and sensitivity. 
Aptadimer represents two aptamers interconnected with a nucleic acid spacer, that forms a 
hairpin with 7 bps. Fluorophore and quencher couple is embedded within this hairpin. In the 
absence of target, the fluorophore remains quenched, whereas upon capturing the target, 
fluorescent signal is triggered. Since this strategy requires simultaneous targeting of both 
binding-sites, it provides an efficient solution for improved thrombin detection, by increasing 
specificity, selectivity and affinity, and decreasing non-specific interactions. Preliminary tests gave 
promising results in specific detection of thrombin in 10 times diluted plasma and opened new 
perspectives for development specific aptamer-based fluosensor both for the surface and the 
volume measurements. Although further research and development is necessary, this aptadimer 
technology already offers novel, more powerful approach in detection. 
To conclude, the aim of this Ph.D project was achieved. We indeed made big progress in 
understanding thrombin-aptamer detection problematics and created tools which in near 
perspective will lead to a successful integration of an aptamer-based thrombin sensor. 
 
